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Platelets in haemostasis and thrombosis 
Blood platelets play a crucial role in haemostasis and thrombosis. Following 
vascular injury, the haemostatic response is considered to be driven by platelet 
activation, which leads to aggregation of the cells and plug formation. Impairment in 
platelet function can give rise to excessive blood loss. On the other hand, undesired 
platelet activation upon rupture of an atherosclerotic plaque can trigger a thrombotic 
response, which impedes blood flow through the diseased artery and can even 
completely occlude the vessel
1
. Depending on the location of the blood vessel, this 
atherothrombotic reaction may lead to stroke or myocardial infarction. These diseases 
are among the most common causes of death in the Western world. 
It is clear that not only platelets are involved in haemostasis and thrombosis. 
Complementary to platelet activation acts the process of blood coagulation or clotting, 
resulting in the generation of thrombin and the formation of haemostatic fibrin clots. 
Since thrombin is also a main platelet activator, there is increasing interest in the 
interactions between platelet activation and coagulation
2,3
. 
Thrombosis is normally classified as venous thrombosis (e.g., in deep veins) or 
arterial thrombosis (as in myocardial infarction and ischemic stroke). It is generally 
accepted that activated platelets and the coagulation system contribute in different ways 
to the thrombotic process in veins and arteries. Venous thrombosis is commonly 
associated with high coagulation activity, responsible for unwanted fibrin clot formation. 
On the other hand, arterial thrombosis is often linked to high platelet activation, which 
leads to formation of platelet-rich thrombi
4,5
. Nowadays, there are good examples of 
favourable combination therapy with anticoagulant and antiplatelet drugs. However, 
anticoagulants are still preferred in reducing venous thromboembolism, while antiplatelet 
agents are mostly used in the prevention of arterial thrombosis. This is in apparent 
paradox with the fact that thrombin is one of the most potent platelet agonists
6
. 
Furthermore, at least in vitro, antiplatelet drugs inhibit coagulation as well
7
.Together, this 
urges for better knowledge of the functions of platelets in relation to coagulation. 
To provide a general background for the activation mechanisms of platelets and 
the coagulation system, in this chapter, an overview will be given of: key signaling 
processes implicated in platelet activation; the proposed roles of platelets in thrombin 
and thrombus formation; and finally, of the differences among individual platelets. 
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Platelet signaling to calcium mobilisation and beyond 
Most physiological platelet agonists evoke a sudden increase in the cytosolic 
free Ca
2+
 concentration. This holds for primary agonists such as collagen (exposed at a 
damaged vessel wall) and thrombin (the most reactive coagulation product); but also for 
the secondary agonists ADP and thromboxane A2 (TxA2), which are so-called autocoids 
that are produced by activated platelets themselves and enhance the platelet activation 
process. Elevated Ca
2+
 is implicated in almost all platelet responses, such as shape 
change, secretion, aggregation, development of procoagulant activity and clot 
retraction
8
. As illustrated in Figure 1, the key effector enzymes in the Ca
2+
 rise are 
members of the family of phosphoinositide-specific phospholipase C (PLC) isozymes, 
PLC-β and PLC-γ. 
Platelets become activated in response to collagen via the immunoreceptor 
family member, glycoprotein VI (GPVI). Collagen binding results in the phosphorylation 
of two tyrosines in the the Fc receptor γ-chain of the GPVI co-receptor
9,10
. The Fc 
receptor γ-chain contains an immunoreceptor tyrosine-based activation motif (ITAM), 
which includes two conserved tyrosine residues. Initial receptor phosphorylation is 
accomplished by the Src family kinases, Fyn and Lyn, which associate with proline-rich 
regions of GPVI
11,12
. Once phosphorylated, the Fc receptor γ-chain binds the tyrosine 
kinase Syk via its ITAM, which then becomes phosphorylated by Src kinases and also by 
itself
13
. The activated Syk phosphorylates multiple signaling proteins, including the 
transmembrane adaptor LAT (linker for activation of T cells). Once phosphorylated, LAT 
serves as a docking site for proteins such as Gads, Grb2, phosphoinositide 3-kinase 
(PI3K) and PLC-γ2
14
. Activation of PLCγ2 causes a prolonged increase in cytosolic Ca
2+
 
concentration
15
. 
Human platelets express two receptors for thrombin, PAR1 and PAR4
16,17
. 
Cleavage of these receptors by the protease thrombin exposes a short auto-activating 
peptide ligand, known as a tethered ligand
18
. Both activated receptors couple to the G 
proteins, Gq and G13, of which the former is a strong activator of PLC-β isoforms, 
mediating increases in cytosolic Ca
2+
 concentration
19
. The ability of thrombin to interact 
with PAR1 and PAR4 is facilitated by its ability to also bind to platelet GPIb-IX-V
20,21
. 
Secondary mediators, of which ADP and TxA2 are the most important, are 
released by activated platelets, and act as paracrine agents that reinforce the platelet 
activation process. ADP is released by exocytosis of dense granules stored in the 
platelets. The key receptors for ADP are P2Y1 and P2Y12
22
. The first, P2Y1, also couples 
to Gq
19
, which again stimulates PLC-β and causes Ca
2+
 mobilisation
22,23
.  
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On the other hand, P2Y12 couples to Gi, which G protein inhibits adenylate 
cyclase and thus reduces the cyclic AMP level
24
. 
Calcium-dependent activation of cytosolic phospholipase A2 cleaves 
arachidonic acid from membrane phospholipids. The shortly living autocoid TxA2 is 
synthesised from arachidonic acid by the enzymes cyclooxygenase and TxA2 
synthase
25
. After diffusion across the plasma membrane, TxA2 binds to the TPα 
receptors on the same or adjacent platelets. TPα also couples to Gq and thus activates 
PLC-β
26
. 
 
Figure 1 Overview of intracellular platelet signaling via phospholipase C (PLC) isoforms and 
Ca
2+
 signaling. The ADP receptor P2Y12 activates the G-protein Gi, which couples to and inhibits 
adenylate cyclase. This results in reduced cAMP level and inactivated protein kinase A (PKA), 
relieving the PKA-mediated suppression of IP3 receptors (IP3-R). The ADP receptor P2Y1, the 
thrombin receptors PAR1 and PAR4, and the TxA2 receptor TPα all activate Gq, which couples to 
PLCβ.  Collagen activation of GPVI, via tyrosine phosphorylation of the Fc receptor γ-chain (FcRγ) 
triggers a cascade of phosphorylation reactions via Src and Syk kinases. The phosphorylated 
adaptor protein LAT mediates activation of PLCγ2. Both PLC isoforms cleave PIP2 into IP3 and 
DAG. The former second messenger opens IP3 receptor channels which releases Ca
2+
 from 
intracellular stores, while the latter activates protein kinase C (PKC), involved in secretion. Ca
2+
 
release is followed by store-regulated Ca
2+
 influx, likely involving TPRC channels and the adaptor 
protein STIM1. Elevated Ca
2+
 can lead to phospholipase A2 (cPLA2) activation, arachidonate 
release and TxA2 formation; further to PS exposure at the platelet surface; and to secretion. 
Mechanisms of Ca
2+
 lowering are not indicated. For further explanations, see text. 
General introduction 
 
 
13 
Both PLC-γ and PLC-β isoforms cleave membrane-bound phosphatidyl inositol-
4,5-biphosphate to form the second messengers inositol-1,4,5-triphosphate (IP3) and 
1,2-diacylglycerol
27
. Once released from the membrane, the hydrophilic IP3 binds to IP3-
operated Ca
2+
 channels in the endoplasmic reticulum membrane, surrounding 
intracellular Ca
2+
 stores. These mediate rapid release of Ca
2+ 
into the cytosol, in a 
typically Ca
2+
-enhanced way
28,29
. Phosphorylation of the IP3 receptors by cyclic AMP-
dependent protein kinase down-regulates their Ca
2+
 channel activity, and thereby 
suppresses Ca
2+
 mobilisation
30,31
. The second PLC product, 1,2-diacylglycerol, remains 
membrane-associated and activates the serine-threonine protein kinase C, which is 
implicated in secretion. 
A direct effect of depletion of the Ca
2+
 stores is triggering of the process of 
store-regulated Ca
2+
 entry, by which Ca
2+
 from the extracellular medium enters into the 
cell. In platelets, this leads to substantial amplification of the Ca
2+
 signal
8,32
. The ion 
channels mediating Ca
2+
 entry and implicated in the linkage mechanism between store 
 
Figure 2 Overview of the roles of phosphoinositide 3-kinase (PI3K) in platelet activation. The 
ADP receptor P2Y12, the thrombin receptors PAR1 and PAR4, and the collagen receptor GPVI 
activate PI3K, which converts PIP2 to the second messenger PIP3. PI3K activated downstream of 
GPVI stimulation plays a role in recruiting PLCγ to the plasma membrane. As shown in Figure 1, 
elevated Ca
2+
 following PLCγ2 activation, leads to PS exposure at the platelet surface and to 
secretion. Platelet secretion products reinforce the activation process through positive feedback 
mechanisms. Separately, P2Y12 and PAR1/4 stimulation activates the PI3K, Akt and RapIb 
pathway, which leads to integrin αIIbβ3 activation and subsequent platelet aggregation. 
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depletion and Ca
2+
 entry likely include the TRPC channels, as these can interact with 
platelet IP3 receptors
28,33
. Adaptor proteins in the endoplasmic reticulum membrane like 
STIM 1 are identified as putative reticular Ca
2+ 
sensors that regulate the Ca
2+
 entry
34
. In 
particular, Ca
2+
 entry is required to achieve the prolonged, high cytosolic Ca
2+
 
concentration for exposure of procoagulant phosphatidylserine (PS) at the platelet 
surface
35
. 
The PI3K enzyme plays a role in signaling from the major classes of surface 
receptors, including ADP, thrombin and collagen receptors. PI3K converts PIP2 to the 
phospholipid derivative phosphatidylinositol 3,4,5-trisphosphate (PIP3) (Figure 2). The Gi 
and Gq protein-coupled pathways starting from P2Y12 and PAR1/4 lead to activation of 
PI3K, which is involved in the activation of integrin αIIbβ3 via the GTP-binding protein, 
RapIb
36
. In addition, PI3K is also activated following GPVI stimulation, and plays a role in 
recruiting PLCγ2 to the plasma membrane and, hence, in mediating Ca
2+
 mobilisation
37
. 
P2Y12 plays a critical role in supporting platelet activation, because it serves as 
the major receptor for the secondary feedback agonist ADP, and also because it signals 
in a distinct way to other receptors. It is the ability of the P2Y12 receptor to activate 
Rap1b towards αIIbβ3 activation, that underlies its ability to act in synergy with other 
receptors. Although there are still missing links in this pathway, it is clear that a reduction 
in cyclic AMP is not required
38-40
. Important components in the signaling pathway to 
integrin activation are PI3K isoforms and the downstream mediator, Akt/PKB. 
It has been reported that platelets contain various PI3K isoforms, i.e. the class 
IA isoforms PI3Kα, β and δ, and the class IB isoform PI3Kγ
41
. Both class IA and IB forms 
consist of a catalytic and regulatory subunit. In platelets, class IA PI3K forms comprise to 
date three p110 catalytic subunits (α, β and δ) and three regulatory subunits (85α, 85β, 
and 55γ). In addition, the p85α protein possesses two alternatively spliced variants, p55α 
and p50α. Of the various regulatory subunits, p85α is the most abundantly expressed, 
and it interacts with the phosphorylated adaptor protein, LAT. The class IA regulatory 
subunits are characterized by the presence of SH2 and SH3 domains, by which the 
protein can interact with growth factor-like receptor complexes, such as the GPVI 
signaling complex. 
The class IB PI3Kγ comprises a complex of a p110γ catalytic subunit and a 
unique p101 regulatory subunit. Thus, the p101 protein specifically binds to the N-
terminal domain of p110γ
42
. The regulatory subunit lacks SH2 and SH3 domains and is, 
in general, considered to interact with the β/γ subunits of heterotrimeric G proteins
42
. 
Whether this is also the case for platelets, has not yet been investigated. It is also not 
General introduction 
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completely sure which regulatory subunit can bind to which catalytic subunit. As far as 
known, the inter-SH2 domains of p85α, p55α, p50α, p85β and p55γ constitutively 
interact with the N-terminal domain of p110α, β and δ. Binding of the dual SH2 domains 
to tyrosine-phosphorylated adaptor proteins activates the kinase function of the p110 
subunits. The precise signaling and functions of the various isoforms in platelets are 
unclear. 
Platelets and coagulation 
That platelets have an active role in the coagulation process appears from 
thrombin generation experiments in platelet-rich plasma. Here, thrombin generation 
strongly relies on the presence of activated platelets, as inhibition with several platelet 
antagonists has an anticoagulant effect by slowing down the formation of thrombin and 
fibrin
2,7,43
. Indeed, binding of several coagulation factors to the platelet surface has been 
reported
38,44
. The recognition that platelet activation and coagulation are mutually 
interacting processes has stimulated the research to find ‘receptors’ or binding 
components for coagulation factors on the platelet surface. Current evidence shows that 
these binding components comprise both surface phospholipids and glycoproteins 
(Table 1). 
For long, it is known that resting platelets have an outer membrane 
phospholipid surface that is not active in coagulation
45
. Due to the activity of an 
aminophospholipid translocase, platelets and other cells sequester the 
aminophospholipids PS and phosphatidylethanolamine at the inner membrane 
leaflet
46,47
. In most cell types, ABC transporters or P4-ATPases are found to be 
responsible for the translocation reaction
48
. For platelets, Ca
2+
 ionophores and potent 
Ca
2+
-mobilizing agonists (collagen plus thrombin) are capable to evoke surface exposure 
of PS due to the so-called scramblase reaction
35,45
. However, the molecular identity of 
this scramblase has remained unclear
48,49
.  
Activated platelets that expose PS bind vitamin K-dependent coagulation 
factors (prothrombin and factors VII, IX and X) as well as vitamin K-dependent 
anticoagulation factors (protein C and S) via their Gla residues. Most of the blood 
coagulation enzymes belong to the serine protease family. They are primarily 
synthesized in the liver and require post-ribosomal modifications for proper functioning. 
The γ-carboxylation of N-terminal glutamic acid residues to γ-carboxyglutamic acid (Gla) 
under the influence of a vitamin K-dependent carboxylase is considered of key 
importance for adequate function in coagulation.  
Chapter 1 
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The N-terminal Gla modules of the coagulation factors prothrombin, VII, IX, X, 
protein C and protein S contain between 9 and 11 Gla residues that are pivotal for Ca
2+
 
ion binding. The Ca
2+
-bound conformation of Gla modules is essential for binding of 
these coagulation proteins to negatively charged PS-containing (platelet) surfaces, and 
thus for initiation and propagation of blood coagulation. Accordingly, the PS-exposing 
membranes, by acting as assembly sites for the tenase and prothrombinase complexes, 
strongly accelerate the process of thrombin generation and, hence, clotting. In the 
tenase reaction, the protease factor IXa, assisted by factor VIIIa, together with its 
cofactor factor Va, cleaves factor X into its active form, factor Xa
50
. In the 
prothrombinase reaction, factor Xa catalyzes the cleavage of prothrombin into thrombin. 
Of relevance for this thesis, procoagulant (platelet) phospholipids (PS) stimulate these 
two reactions by several orders of magnitude
51
. 
Abnormal regulation of platelet phospholipid asymmetry is incidentally seen in 
patients. In the rare Scott syndrome, impairment of phospholipid scrambling is 
accompanied by an increased bleeding tendency. Activated platelets from such patients 
are strongly impaired in their ability to support prothrombin and factor X activation
52
. In 
addition, Scott platelets produce less microparticles
53,54
, which normally also propagate 
the coagulation process. Important for this thesis, it has been proposed that the store-
regulated Ca
2+
 entry is defective in the Scott syndrome
55
. An alternative view is that 
Table 1 Procoagulant entities at the platelet surface 
 
Surface component Factor(s) bound Function Refs. 
Aminophospholipids 
(PS, PE) 
vitamin K-dependent 
prothrombin, factors 
VII(a), IX(a), X(a) 
assembly of tenase and 
prothrombinase complex 
45 
Tissue factor or 
another receptor 
factor VII(a) initiation of coagulation 
58,59 
GPIb-V-IX thrombin 
factor XI 
 
factor XII 
facilitates thrombin activity 
facilitates factor XI 
activation 
factor XI activation 
79 
63 
64 
Integrin αIIbβ3 fibrin(ogen) 
prothrombin 
platelet aggregation 
facilitates prothrombin 
activation 
114,115 
65 
Serotonin groups fibrinogen, factor Va, 
thrombospondin 
formation of coated 
platelets 
111,116 
Elusive EPR1 factor Xa prothrombin activation 
EPR1 is non-existent 
67-70 
Unknown receptor factor V(a) 
 
factor XIIIa 
facilitates prothrombin 
activation 
cross-linking of fibrin 
38 
72 
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platelets from Scott patients lack a Ca
2+
-dependent phospholipid scramblase activity, but 
no missing proteins have been found in these patients
56
. 
It has been recognized that PS exposure is required, but not sufficient to explain 
the stimulation of coagulation by platelets
35,57
. In recent years, evidence has been 
presented that (activated) platelets can also bind several coagulation factors via protein 
interactions (Table 1). Platelets interact with factor VIIa, which is a serine protease 
initiating the coagulation process
58
. Some authors have reported that (activated) platelets 
contain tissue factor, which is the common cellular receptor for factor VIIa
59
. However, 
others have challenged the significance of this finding, because platelets store large 
amounts of tissue factor pathway inhibitor
60,61
. 
The GPIb-V-IX complex not only acts as a shear-dependent receptor for von 
Willebrand factor (vWF), but also provides binding sites for coagulation factors. For 
instance, GPIb-V-IX binds two thrombin molecules. Furthermore, this complex 
immobilises factor XI which, once activated by thrombin, converts factor IX to factor IXa 
which subsequently cleaves factor X to factor Xa, thus providing a pathway of thrombin 
generation independently of tissue factor
62,63
. Others have demonstrated that biotinylated 
factor XII binds to GPIbα in a Zn
2+
-dependent fashion
64
. 
Clearly, integrin αIIbβ3 is the major fibrin(ogen)-binding protein on activated 
platelets. However, this integrin also binds prothrombin even on non-stimulated platelets, 
thus providing a local pool for thrombin generation under coagulant conditions
65
. 
Coagulation factor binding can also be achieved by serotonin residues on the platelet 
surface. Dale and co-workers show that stimulation of platelets with collagen and 
thrombin, but also with Ca
2+
 ionophores, results in so-called COAT (collagen- and 
thrombin) stimulated platelets, currently also indicated as coated platelets
66
. These 
platelets can expose serotonin-conjugated proteins that interact with serotonin binding 
sites on fibrinogen and thrombospondin. The same platelets may also bind fibronectin 
and vWF, as well as granule-derived factor Va, which is involved in coagulation. It is 
suggested that the coated platelets also express surface PS and support prothrombinase 
activity
66
. 
Some authors have suggested that platelets bind factor Xa via a receptor 
consisting of anionic phospholipids, factor Va and effector cell protease receptor-1 
(EPR1)
67
. Preliminary support for involvement of EPR1 came from studies that compared 
the binding characteristics of factor Xa onto phospholipid vesicles and thrombin-activated 
platelets
68,69
. Others, however, were unable to demonstrate involvement of an EPR1-like 
protein in the assembly of the prothrombinase complex at the surface of activated 
platelets
70
. The EPR1 work came into a new perspective with the finding that the so-
Chapter 1 
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called ‘EPR1’ gene actually encodes for a protein regulating apoptosis, and that the 
elusive factor Xa receptor protein is not transcribed in cells
71
. The transglutaminase 
factor XIIIa may also bind to platelets, and functions to mediate the cross-linking of 
coagulation factors with αIIbβ3 and associated proteins
72
. 
Of all platelet receptors, especially GPVI has been linked to PS exposure and 
procoagulant activity
73,74
. However, at the start of the investigations of this thesis, only 
very little was known of the signaling pathways used by GPVI to evoke this response, 
nor of the consequences of platelet GPVI stimulation for coagulation factor binding. 
Thrombin also stimulates procoagulant activity, although its effect is less profound than 
that of GPVI, but synergizes with the collagen-induced procoagulant response
75
. In the 
literature it has extensively been discussed which thrombin receptor is responsible for 
the procoagulant activity. The receptors, PAR1
76,77
, PAR4
76
, and GPIb-IX-V
78-80
, have all 
been proposed as potential mediators of this thrombin response. Recent results, using 
selective inhibitors of the various receptors, show that the synergistic effect of thrombin 
in collagen-induced platelet procoagulant activity is mediated not through GPIb-IX-V or 
PAR4, but through PAR1
20
. 
Platelets and coagulation in thrombus formation 
So far, the initial events leading to collagen-induced platelet aggregation and 
thrombus formation under shear have mainly been studied by in vitro flow studies using 
anticoagulated human and murine blood (Figure 3). Under conditions of high, arterial 
shear rates, platelets initially adhere to immobilized vWF via GPIb-V-IX, and 
subsequently via integrin αIIbβ3
81,82
. These interactions cause limited platelet 
activation
83
. Since vWF binds with a high affinity to collagen, the vWF interaction 
predisposes platelets to collagen-induced activation and facilitates thrombus 
formation
84,85
. The subsequent order of events differs from platelet to platelet both in 
man and mouse
86
. Some platelets on collagen become rapidly activated by the collagen 
receptor, GPVI, which signals to PLC-γ2 and Ca
2+
 mobilization, as described above. 
Signaling via GPVI leads to activation of a second collagen receptor, integrin α2β1. This 
event is required for stable adhesion and full activation
87
. However, other platelets, 
perhaps interacting with different motifs in collagen, follow a different order of events by 
first stably adhering to the collagen via integrin α2β1 before showing GPVI-induced 
activation responses. Collagen-adhered platelets release autocoids like ADP and TxA2, 
which stimulate passing platelets to activate their αIIbβ3 integrins
88-90
. Instantaneously, 
these platelets then aggregate via multiple αIIbβ3-fibrinogen interactions, which are 
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enforced by GPIb-V-IX binding to  plasma-derived vWF
81
. Such thrombi are intrinsically 
unstable structures that require strong adhesion to collagen and continuous platelet 
activation. This appears from the findings that they disintegrate in the absence of α2β1
91
 
or when P2Y12 signaling is blocked
92,93
. 
Platelet adhesion to collagen also triggers the so-called procoagulant 
response
73,94
. In response to prolonged elevation in cytosolic Ca
2+
, platelets can start to 
expose PS and form blebs, which later shed as microparticles (Figure 4). Both the 
blebbing platelets and the shedding of microparticles contribute to the stimulation of 
coagulation. Thus, in the presence of plasma, this response greatly stimulates thrombin 
generation
95
. Although the importance of this platelet response is known upon flow over 
fibrinogen
96
, still pertinent questions are how platelet interaction with collagen and vWF 
can trigger procoagulant activity under venous and arterial flow conditions, and how the 
various receptors communicate in establishing this platelet response. 
In vitro experiments have significantly contributed to our understanding of the 
mechanisms of platelet activation and thrombus formation. However, in vivo thrombosis 
 
Figure 3 Platelet adhesion and aggregation on collagen under high shear. Platelets bind to 
collagen fibres containing vWF via multiple receptors and become activated via GPVI. Various 
signaling pathways mediate activation of integrins and release of paracrine agonists, such as TxA2 and 
ADP. Platelet aggregates are formed under shear via interactions of activated αIIbβ3 and GPIb-V-IX 
with fibrinogen and vWF, respectively. 
 
Chapter 1 
20 
 
studies are needed for ultimate verification of the (patho)logical importance of these 
mechanisms
97
. In the last few years, several animal models have been developed to 
investigate the role of platelets in the thrombotic process in vivo. Here, only murine 
models that are relevant for the present thesis are introduced. The possibilities and 
limitations of these models have been discussed more extensively elsewhere
98
. 
In a well established microvascular model, thrombus formation is induced by 
topical application of the free radical generating agent, ferric chloride, on mouse 
mesenteric vessels
99
. Ferric chloride treatment leads to substantial damage of the vessel 
wall, i.e. denudation of the endothelial cells and exposure of the collagen-containing 
extracellular matrix to the blood stream. The ensuing thrombotic process is usually 
followed by intravital microscopic imaging techniques
100
. An other way of injury of these 
microvessels is by application of high-energy laser light that is focused through 
microscope optics, which are also used to detect thrombus formation
101
. An advantage of 
the latter technique is that more precise, local damage can be applied, but a 
disadvantage is the likelihood of damaging vascular structures by the high energy power 
of the laser beam. In addition, several macrovascular arterial thrombosis models have 
been developed. In one of these, vascular injury is induced by ligation of the mouse 
carotid artery, which also causes loss of the endothelial cell layer
102
. 
 
Figure 4 Function of collagen receptors in platelet procoagulant activity. Platelets binding to 
collagen and activated by GPVI can, depending on their activation state, transform into round 
structures with membrane blebs and shedding microparticles. These platelets expose PS and are 
active in thrombin generation and coagulation. Modified after Heemskerk et al.
94
. 
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In both these micro- and macrovascular modeIs, collagen-induced platelet 
activation has been proposed to play a key role in triggering the thrombotic process
102-
105
. Alternatively, in both ferric chloride and laser-induced thrombus formation, an 
important role for tissue factor and thrombin and, hence, for coagulation has been 
identified
99,105
. In this respect, some authors have even questioned the importance of 
platelet-collagen interaction
106
. These apparent discrepancies in the literature may be 
resolved by the possibility that collagen (platelet activation) and thrombin (coagulation) 
have additive or synergistic roles in arterial thrombosis, and that the relative importance 
of either of them can vary depending on the local conditions, e.g. the precise way of 
vascular damage, the local flow and the responsiveness of platelets. Accordingly, in spite 
of all the in vitro and in vivo work, it is still unclear whether and how the processes of 
platelet activation and coagulation integrate in thrombus formation in arteries and veins. 
 
Figure 5 Morphology of procoagulant platelets adhering to collagen under static conditions. 
Scanning electron microscopic images of human platelets adhered to fibrinogen, collagen, or 
specific GPVI-binding surfaces. Note sponge-like structures (arrow) and microparticles (arrow head) 
representing procoagulant structures. Bars represent 2 µm. Modified after Siljander et al.
74
. 
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Heterogeneity in platelet responses 
Platelets that come into contact with a collagen surface or that are stimulated 
with GPVI-activating agents can show three different morphologic responses: pseudopod 
formation followed by spreading, clustering into aggregates, and formation of blebs 
which shed as microparticles
74
. Some spread platelets may also show membrane 
contraction and subsequent fragmentation
72
. This heterogeneity in responses even 
occurs when platelets are adjacent on a collagen surface (Figure 5). A similar 
heterogeneity is found under flow conditions, when whole blood is perfused over 
collagen, in which case some platelets integrate into multi-cellular aggregates while other 
platelets develop into blebbing cells
85,90
. There are some, but incomplete, indications in 
the literature that may explain these typical differences between platelet responses. 
Explanations can be found in inherent, biochemical differences between 
platelets from an individual as well as in differences in environmental factors. Evidence 
that not all platelets are structurally similar comes from many flow cytometric studies, 
where the staining of platelets with antibodies or probes against surface glycoproteins or 
receptors in many instances shows considerable differences in binding extent among 
platelets of one subject, regardless of the antigen or probe used. Thus, even 
independent of their size, some platelets will express more surface receptors than 
others
107
. Such structural heterogeneity has already been seen at the level of 
differentiating megakaryocytes. For instance, individual human megakaryocytes express 
different levels of αIIbβ3 and GPIb-V-IX, while they simultaneously differ in Ca
2+
 
signaling properties
108
. Furthermore, some differentiating megakaryocytes appear to 
keep their immature signaling properties (e.g. prostacyclin-induced Ca
2+
 mobilisation), 
and can transmit these to a subpopulation of circulating platelets
109
. Thus, platelets in the 
blood are derived from megakaryocytes with a markedly different expression of adhesive 
receptor and signaling molecules. It is therefore not a surprise that single platelets from 
one subject, when placed on a coverslip, also show large differences in Ca
2+
 signal 
patterns 
29
. Such differences in responsiveness may explain why, upon stimulation with 
collagen and thrombin, only a subpopulation of platelets expresses PS
110
, sheds 
microparticles
72
, transforms into coated platelets with serotonin binding sites
111
, or 
preferentially binds coagulation factors
112
. 
Especially under shear conditions, individual platelets are likely to encounter 
different activating environments. For instance, during flow over collagen, the first 
platelets that bind to collagen (designated as vanguard cells) were found to 
communicate their activation status to subsequent follower platelets, and thus recruiting 
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the latter into developing aggregates
113
. Vanguard platelets may differ from other 
platelets by releasing ADP, which implicates that some collagen-bound platelets are 
more capable in attracting other (follower) platelets than others. 
Taken together, it is well conceivable that, during the thrombotic process, 
biochemical and structural differences between platelets as well as micro-environmental 
diversity sensed by these platelets determines the different types of platelet responses. 
However, the present literature has only begun to determine the extent and relevance of 
this heterogeneity for the thrombus-forming process. 
Research outline of this thesis 
In this thesis the interaction mechanisms between platelet activation and 
coagulation are studied on different levels of complexity: using isolated platelets; by way 
of an in vitro model of thrombus formation under flow in the presence and absence of 
coagulation; and by in vivo models of thrombus formation in small and large vessels. 
Since store-mediated Ca
2+
 entry is essential for the procoagulant response of platelets, 
we have investigated in chapter 2 whether the Ca
2+
 entry process is impaired in the 
Scott syndrome. Measurements are performed of Ca
2+
 fluxes and PS exposure in 
isolated platelets and in B-cell lymphoblasts from two Scott patients. In chapter 3, we 
describe a study on the role of various PI3K isoforms in the regulation of Ca
2+
 signaling 
and procoagulant activity using platelets that are stimulated via their collagen or thrombin 
receptors. In the in vitro flow studies reported in chapter 4, the interacting roles of the 
adhesive receptors for vWF (GPIb-V-IX and αIIbβ3) and collagen (GPVI and α2β1) are 
examined upon thrombin formation and procoagulant activity during high-shear perfusion 
of whole blood. Novel antibodies and peptides directed against the two collagen 
receptors are used to specifically unravel the function of each receptor molecule. 
Chapter 5 introduces the processes of thrombin generation and coagulation in flow-
adhesion experiments. The investigations aim to determine how signaling modules of the 
GPVI pathway of platelet activation control thrombus formation under coagulant 
conditions both in vitro and in vivo. Particular attention is paid to the generation and 
importance of PS-exposing platelets. To study the interaction mechanisms between 
platelet activation and thrombin generation in vivo, chapter 6 describes the development 
and use of a mouse model of arterial and venous thrombosis. Intervention experiments 
have allowed to study the synergy and interplay of these two processes. In chapter 7, 
this work is extended by demonstrating that temporal changes in intracellular signaling 
properties determine the ‘fate’ of a platelet to become either procoagulant or 
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proaggregatory in vitro and in vivo. Finally, in chapter 8 I have discussed the novel 
findings of this thesis in relation to the current literature. 
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Abstract 
The Scott syndrome is a bleeding disorder, characterized by impaired surface 
exposure of procoagulant phosphatidylserine (PS) on platelets and other blood cells, 
following activation with Ca
2+
-elevating agents. Since store-mediated Ca
2+
 entry (SMCE) 
forms an important part of the Ca
2+
 response in various blood cells, it has been proposed 
that deficiencies in Ca
2+
 entry may relate to the impaired PS exposure in the Scott 
syndrome. Here, we have tested this hypothesis by investigating the relationship 
between Ca
2+
 fluxes and PS exposure in platelets as well as B-lymphoblasts derived 
from the original Scott patient (M.S.), a newly identified Welsh patient (V.W.) with similar 
bleeding symptoms, and two control subjects. Procoagulant activity of V.W. platelets in 
suspension, measured after stimulation with collagen/thrombin or Ca-ionophore, 
ionomycin, resulted in 52% or 17%, respectively, compared to that of correspondingly 
activated control platelets. Procoagulant activity of V.W. erythrocytes treated with 
ionomycin resulted in less than 6% of the activity of control erythrocytes.  Single-cell 
Ca
2+
 responses of M.S. and V.W. platelets, adhering to collagen, were similar to those of 
platelets from control subjects, while PS exposure was reduced to 7% and 15%, 
respectively, compared to controls. Stimulation of non-apoptotic B-lymphoblasts derived 
from both patients and controls with ionomycin or agents causing Ca
2+
 mobilization and 
SMCE, resulted in similar Ca
2+
 responses. However, in lymphoblasts from M.S. and 
V.W. Ca
2+
-induced PS exposure was reduced to 7% and 13% of the control 
lymphoblasts, respectively. We conclude that i. patient V.W.  is a new case of Scott 
syndrome, ii. Ca
2+
 entry in the platelets and lymphoblasts from both Scott patients is 
normal, and iii. elevated [Ca
2+
]i as caused by SMCE is not sufficient to trigger PS 
exposure. 
Introduction 
Cell surfaces containing anionic phospholipids, in particular phosphatidylserine 
(PS), play a pivotal role in blood coagulation. These procoagulant lipid membranes form 
a catalytic surface for the assembly and proper conformation and juxtaposition of the 
factor X and prothrombin activating enzyme complexes. Formation of these complexes 
strongly accelerates the rate of thrombin formation, which is responsible for the 
production of a stabile fibrin clot. Cellular procoagulant lipid surfaces are mainly provided 
by platelets. Upon appropriate stimulation, platelets lose their asymmetric transbilayer 
phospholipid distribution, resulting in exposure of PS at the exterior cell surface. 
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The Scott syndrome is a rare, hereditary bleeding disorder characterized by 
impaired surface exposure of PS at the plasma membrane of activated platelets and 
decreased shedding of procoagulant platelet-derived microvesicles
1
. The Scott 
phenotype, as apparent in platelets, has also been observed in erythrocytes and 
Epstein-Bar virus (EBV)-transformed B-lymphocytes
2-4
, indicating a cell type-
independent trait. Weiss et al., in 1979, were the first to identify a patient (M.S.) with this 
disorder
1
. One year later, a report was published on ten individuals from three unrelated 
Welsh families, who also suffered from an unusual bleeding disorder
5
. The latter patients 
have not been studied extensively since then, but the original data suggest that their 
bleeding abnormality might be similar or possibly identical to the Scott syndrome. Later, 
also a French family has been found of which the propositus had platelets deficient in PS 
exposure and microvesiculation, but not in secretion and aggregation
6-8
. Recently, a 
colony of German shepherd dogs was discovered with a hereditary bleeding disorder 
and deficient PS exposure in platelets, characteristic of Scott syndrome
9
. The inability of 
platelets and other blood cells to scramble phospholipids, and thus expose PS, has been 
assigned to abnormal activity of a Ca
2+
-dependent phospholipid scramblase activity in 
the plasma membrane of these cells.  
Cytosolic [Ca
2+
]i serves as an intracellular mediator for many extracellular 
signals in platelets and other cells, regulating processes such as cellular shape, 
secretion, growth and differentiation
10-12
. In earlier work with platelets, it appeared that a 
prolonged, high increase in [Ca
2+
]i is required for PS exposure, e.g. as achieved by Ca
2+
 
ionophore, collagen receptor (glycoprotein VI) stimulation
13-15
 or the combination of 
thrombin and thapsigargin
16
. Release of Ca
2+
 from intracellular stores is insufficient for 
full platelet activation. However, following depletion of the intracellular Ca
2+
 stores, a 
mechanism is activated which allows Ca
2+
 entry across the plasma membrane. This 
store-mediated Ca
2+
 entry (SMCE) from the extracellular medium is a prerequisite to 
reach the high Ca
2+
 signals required for full platelet activation
17
. In platelets and related 
cells at least a substantial part of the SMCE is mediated by plasma membrane ion 
channels of the Trp family
18
. Blocking of this Ca
2+
 entry process abolishes agonist-
induced PS exposure
15,19
 and, conversely, increased Ca
2+
 influx in platelets is correlated 
with higher PS exposure
20,21
. Recently, Martinez et al. reported of a reduced SMCE in B-
lymphoblasts derived from the propositus of the French Scott family, whereas the 
release of Ca
2+
 from intracellular stores in these cells was normal
4,22
. Together, these 
observations suggest that defective store-mediated (capacitative) Ca
2+
 entry may be part 
of the Scott phenotype. However, studies on SMCE have thus far only been performed 
with the French Scott patient.  
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In this paper, we examine the relationship between Ca
2+
 fluxes and exposure of 
procoagulant PS in the plasma membrane of both platelets and immortalized, EBV-
transfected B-cells from two control subjects and two different Scott patients. We 
simultaneously measured Ca
2+
 fluxes and PS exposure in individual platelets from these 
patients using fluorescence imaging microscopy. In the viable, non-apoptotic population 
of the B-cell lines, we determined the Ca
2+
 responses evoked by store-depleting 
agonists, as well as the PS exposure by dual-label flow cytometry.  
Materials and methods 
Materials 
Fibrillar type-1 collagen from equine tendon (Collagen reagent Horm
®
) was 
purchased from Nycomed (Munich, Germany). Fluorescein isothiocyanate (FITC)-
labeled annexin V (FI-annexin V) was a product from Nexins Research (Hoeven, The 
Netherlands). Fura-2 and Fluo-3 acetoxymethyl esters, Pluronic F-127 and Alexa Fluor 
647-labeled annexin V (AF-annexin V) were purchased from Molecular Probes (Leiden, 
The Netherlands). Bovine serum albumin (BSA), apyrase (grade V), ionomycin, caffeine 
and thapsigargin were from Sigma (St. Louis, MO, USA). RPMI-glutamax I was obtained 
from Bio-Whittaker (Walkersville, MD, USA). Fetal calf serum and antibiotic antimycotic 
solution were obtained from Life Technologies (Paisly, UK), and Lymphoprep came from 
Nycomed Pharma AS (Oslo, Norway). Coagulation factors thrombin, prothrombin, factor 
Xa and factor Va were purified as described before
23
. Thrombin-specific chromogenic 
substrate, H-D-Phe-Pip-Arg-para-nitroaniline (S2238) was from Chromogenix (Mölndal, 
Sweden). 
Patients 
Clinical features of patient M.S. have been described extensively before
24
. 
Patient V.W. had presented initially at the age of 14 years with a history of excessive 
bleeding after dental extractions on five occasions. Dental surgery at age 22 again 
resulted in excessive blood loss, with a fall in haemoglobin concentration from 14.6 to 
9.3 g/dl. At 34 years of age she suffered life-threatening post partum haemorrhage after 
an uncomplicated forceps delivery. Studies at that time
 
revealed an isolated severe 
abnormality of prothrombin conversion consistent with a defective interaction between 
plasma and platelets or phospholipid. All other tests of haemostasis were normal
5
. 
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Platelet preparation and culturing of B-lymphoblasts 
Freshly obtained citrated blood from patients M.S., V.W. and two control 
subjects was shipped at 4°C by airmail to Maastricht (The Netherlands). Immediately 
upon arrival (24-48 hours later), platelets were washed and used for the experiments.  
Loading of platelets with Fura-2 and washing procedures have been described 
elsewhere
25,26
. Washed platelets were resuspeded in Hepes buffer (10 mM Hepes, 136 
mM NaCl, 2.7 mM KCl, 2 mM MgCl2, 0.1% BSA and 0.1% glucose, adjusted at pH 7.45) 
at a final concentration of 1.0 x 10
8
 platelets/ml. Erythrocytes were washed 3 times in the 
same Hepes buffer (pH 7.45) and resuspended at 1 x 10
8
 cells/ml. 
Data of platelets from M.S. presented in this study were obtained in 1996 on the 
last occasion that we received blood from this patient. Since M.S. deceased that same 
year, there was no opportunity to study the platelets from this patient with those from 
patient V.W. simultaneously. Experiments with blood cells from patient V.W. were 
performed in 2002. 
EBV-transformed B-cells from M.S. and a control subject were available from 
previous studies
27
. EBV-transformed B-cells from patient V.W. were prepared by 
Professor E.G.D. Tuddenham (Imperial College School of Medicine, London). Before 
use, the EBV-infected cells were expanded in RPMI-glutamax I culture medium 
containing 10% (v/v) fetal calf serum and antibiotic antimycotic solution. Cells were kept 
at 37°C in a humidified atmosphere with 5% CO2, and were sub-cultured in 3 volumes 
fresh medium every 2 or 3 days. Data of EBV-transformed B-lymphocytes from both 
patients and two corresponding controls were collected from experiments performed in 
2002. 
Procoagulant activity of platelets and erythrocytes in suspension 
Prothrombinase activity of washed platelets in suspension, either activated for 
15 min with collagen (10 µg/ml) plus thrombin (4 nM) or for 5 min with ionomycin (1 µM), 
was determined by measuring the rate of conversion of prothrombin to thrombin by the 
enzyme complex factor Xa-factor Va, as described before
26
. The assay conditions were: 
3 x 10
6
 platelets/ml, 3 mM CaCl2, 3 nM factor Xa, 6 nM factor Va and 4 µM prothrombin 
(all final concentrations). Chromogenic thrombin substrate S2238 (250 µM) was used to 
determine the amount of thrombin formed. To measure procoagulant activity of 
erythrocytes, washed cells at a concentration of 2 x 10
8
/ml were incubated with 5 µM 
ionomycin in the presence of 1 mM CaCl2 for 60 min. Samples from this incubation are 
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diluted to a cell count of 10
7
/ml, and prothrombinase activity was measured using the 
conditions described above. 
Dual measurement of [Ca
2+
]i and phosphatidylserine exposure by fluorescence 
imaging microscopy 
Intracellular Ca
2+
 and PS exposure in was determined by a quasi-simultaneous 
measurement of fluorescence from Fura-2 and FI-annexin V using a combined 
fluorescence imaging and microphotometric system as described previously
15
. Changes 
in fluorescence were measured in single platelets after 25 minutes adhering to a 
collagen-coated coverslip. The incubation chamber contained 5 x 10
7
 Fura-2-loaded 
platelets in 300 µl Hepes buffer with 2 mM CaCl2 and 0.5 µg/ml FI-annexin V. 
Fluorescence of about 100 cells in three or more microscopic fields was measured. 
Conversion of Fura-2 fluorescence ratio to levels of [Ca
2+
]i was made as described 
before
17
. During the measurements in 1996 (patient M.S. and control 1) the optical 
pathway was slightly different from that used in 2002 (patient V.W. and control 2), 
resulting in slightly different calibration values of [Ca
2+
]i. Platelets were considered to be 
elevated in [Ca
2+
]i when their Fura-2 ratio was increased with 0.2 compared to basal, 
corresponding to a rise of about 85 nM; annexin V positivity was defined as all localized 
fluorescence in the fluorescein channel of >30 pixels. 
Dual measurement of [Ca
2+
]i and phosphatidylserine exposure by flow cytometry 
Cultured EBV-transformed B-lymphocytes derived from patients and control 
subjects were centrifuged at 700 g for 10 min, and resuspended in Hepes buffer pH 7.45 
and the cell count was adjusted to 10
6
 cells/ml. Washed B-lymphoblasts were loaded 
with 3 µM Fluo-3 acetoxymethyl ester in the presence of 1 mg/ml Pluronic F-127 at room 
temperature for 30 min. Loaded cells were activated with 10 µM ionomycin (5 min), 1 µM 
thapsigargin (5 min), or 10 mM caffeine (10 min). Activations were carried out in the 
presence of either CaCl2 (2 mM) or EGTA (2 mM) to study total Ca
2+
 responses and Ca
2+
 
mobilization separately. Where indicated, the loaded cells were pre-incubated with AF-
annexin V, as described by the manufacturer, to monitor PS exposure. After activation, 
Fluo-3 and Alexa Fluor 647 fluorescence were simultaneously measured using a 
FACScan flow cytometer, and Cell-Quest software (Becton-Dickinson, CA, USA). For 
analysis, viable B-cells were gated based on their forward and side scatter, to exclude 
apoptotic cells and cellular fragments. Per assay, a minimum of 5000 events was 
counted. Control measurements were always run with unlabeled/stimulated as well as 
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labeled/unstimulated cells. Green (Fluo-3) and red (Alexa Fluor 647) fluorescence 
intensities were expressed as arbitrary units. Dot-plots of fluorescence versus forward 
scatter of control cells in the absence of fluorescent annexin V were used to define the 
region containing 99% of the annexin V-negative cells. Events outside this region were 
considered to be positive. List-mode data were analyzed using WinMDI 2.8 software 
(http://facs.scripps.edu). 
Results 
Procoagulant activity of platelets and erythrocytes in suspension 
First we established the Scott syndrome phenotype of the Welsh patient, V.W. 
As shown in Table 1, washed platelets of this patient in suspension activated by collagen 
plus thrombin resulted in a prothrombinase activity of 52% of that achieved with similarly 
activated platelets from the control subject, whereas stimulation with ionomycin induced 
a procoagulant response of only 17% of that of ionomycin-treated control platelets. 
Considering the normal levels of coagulation factors and normal platelet aggregation
5
, 
these findings confirm the phenotype of a Scott syndrome of patient V.W. This was 
further substantiated by the observation that washed erythrocytes of V.W., treated with 
ionomycin and Ca
2+
, were deficient in forming a procoagulant surface: prothrombinase 
activity was 5.6 ± 1% (mean ± SD, n=5) of that of control erythrocytes. When the 
prothrombinase activity of completely lysed cell preparations (obtained by sonication) of 
either platelets or erythrocytes was measured, there was no appreciable difference 
between patients and controls. This excludes that the decreased procoagulant activity in 
the patient’s platelets and erythrocytes is due to alterations in the overall phospholipid 
 Prothrombinase (nM thrombin/min) 
Activation Control 1 Patient M.S. Control 2 Patient V.W. 
None 136 ± 11 54 ± 3 (40%) 130 ± 22 84 ± 16 (65%) 
Collagen + thrombin 358 ± 37 119 ± 44 (33%) 336 ± 10 176 ± 30 (52%) 
Ionomycin 1159 ±247 247 ± 71 (18%) 1172 ± 6 200 ± 6 (17%) 
      
Table 1 Prothrombinase activity of suspensions of platelets from control subjects and Scott 
patients. Values presented are means ± SD of three independent measurements performed in 
1996 for patient M.S and in 2002 for patient V.W., each with their corresponding control. In 
brackets is given the activity expressed as a percentage of the correspondingly treated control 
platelets. It should be emphasized that due to the time between collection of the blood and the 
prothrombinase measurement (24-48 hrs), the prothrombinase activity of the non-stimulated 
platelets is slightly increased compared to that of freshly prepared platelet suspensions. 
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composition, i.e. a reduced content of PS.   
Finally, similar to previous findings on the morphology of the erythrocytes of 
propositus M.S.
2
, the red cells of V.W. did not change into echinocytes after treatment 
with ionomycin and were unable to produce microvesicles. 
Relation between calcium responses and phosphatidylserine exposure of single 
platelets 
Fluorescence video microscopic imaging was used to examine whether the 
Ca
2+
 fluxes and PS exposure of the platelets from the patients differ from those of control 
subjects. In one set of experiments, Fura-2-loaded platelets from M.S. were compared 
with the simultaneously collected platelets from control 1. In a later set of experiments, 
 
Figure 1 Collagen-induced Ca
2+
 responses of single platelets from control subjects and Scott 
patients. Fura-2-loaded platelets were allowed to adhere to collagen fibers in the presence of CaCl2 (2 
mM). Changes in Fura-2 fluorescence ratio in single platelets were measured by fluorescence video 
imaging microscopy. (A) Experiments were performed in 1996 with platelets from control 1 and patient 
M.S. (B) Experiments with platelets from control 2 and patient V.W. were carried out in 2002. Changes 
in Fura-2 fluorescence ratio (340/380 nm excitation) were recorded during adhesion and activation, as 
described in Materials and Methods. Traces are averaged overlays of single traces obtained from at 
least twenty platelets per subject (n≥3 incubations/subject). 
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platelets from V.W. were compared with those of control 2. The platelets were allowed to 
interact with collagen fibers, during which glycoprotein VI-induced changes in [Ca
2+
]i 
were measured at a single-cell level by capturing fluorescence ratio images. Patient and 
control platelets showed prominent increases in [Ca
2+
]i shortly after adhesion to collagen 
(Figure 1). It appeared that the collagen-induced rises in [Ca
2+
]i in the platelets from 
either patient were similar in magnitude to those of the platelets from the two controls. 
As the glycoprotein VI-induced increase in [Ca
2+
]i is a major signal in the 
procoagulant response, i.e. PS exposure
19
, we determined in the same experiment also 
the binding to platelets of FI-labeled annexin V, which binds to surface-exposed PS
28,29
. 
After 25 min adhesion to collagen, 40% of the activated platelets of control 1 were 
annexin V positive, in comparison to less than 3% of the platelets of Scott patient M.S. 
(Figure 2A). Similarly, the collagen-activated platelets from patient V.W. showed a 
strongly reduced PS exposure in comparison to those of control 2, although still 8% of 
the patient platelets did bind FI-annexin V, i.e. slightly more than observed for patient 
M.S. (Figure 2B). These observations confirm the Scott syndrome phenotype in patient 
V.W. 
 
Figure 2 Phosphatidylserine exposure of activated, collagen-adherent single platelets from 
control subjects and Scott patients. Fura-2-loaded platelets were allowed to adhere to collagen 
fibers in the presence of FI-annexin V and CaCl2, as described for Figure 1. Results given are 
percentages of annexin V-positive platelets which exhibit an increased Fura-2 fluorescence ratio, i.e. 
elevated [Ca
2+
]i. Values are means ± SD from at least three independent incubations. (A) Experiments 
were performed in 1996 with platelets from control 1 and patient M.S. (B) Experiments with platelets 
from control 2 and patient V.W. were carried out in 2002. 
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Calcium responses of activated B-lymphoblasts 
Immortalized B-cells from patient M.S. and control subject 1 and from patient 
V.W. and control subject 2 were compared simultaneously. To analyze the Ca
2+
 
responses of these four lymphoblast cell lines, the cells were loaded with the fluorescent 
probe Fluo-3 and then stimulated with agonists, reported to cause reduced SMCE in B-
lymphoblasts derived from the French Scott patient
22
. Activation was carried out in the 
presence of EGTA to measure Ca
2+
 mobilization from intracellular stores only, and in the 
presence of CaCl2 to allow complementary SMCE. Agonist-evoked changes in Fluo-3 
fluorescence were measured in single cells by flow cytometry, using a gating profile so 
that only fluorescence from non-apoptotic, viable cells was analyzed. Treatment of 
lymphoblasts from patients and control subjects with a high dose of ionomycin (10 µM) in 
the presence of EGTA caused the same increase in Fluo-3 fluorescence, indicative for a 
similar, maximal degree of Ca
2+
 store depletion (Table 2). Activation with the 
sarco/endoplasmic reticulum Ca
2+
-ATPase (SERCA) inhibitor thapsigargin (1 µM) in the 
presence of EGTA to deplete SERCA-related store compartments, induced similar [Ca
2+
]i 
rises in control and patient cell lines, but the levels were slightly lower than obtained with 
ionomycin (Table 2). Addition of caffeine (10 mM) in the presence of EGTA, which 
causes depletion of the ryanodine-sensitive Ca
2+
 stores (in which Ca
2+
 is released 
through ryanodine- rather than inositol-trisphosphate-activated receptors)
22
, had an 
effect on all cell lines comparable to that of thapsigargin. Together, these data indicate 
that the Ca
2+
 release from the intracellular store compartments is similar for the various 
control and patient B-cell lines. 
  
 Fluo-3 fluorescence (fold increase) 
Condition Control 1 Control 2 Patient M.S. Patient V.W. 
Unstimulated 1.00 1.00 1.00 1.00 
Ionomycin, EGTA 1.4 ± 0.2 1.5 ± 0.1 1.3 ± 0.1 1.4 ± 0.2 
Thapsigargin, EGTA 1.3 ± 0.2 1.2 ± 0.1 1.2 ± 0.1 1.4 ± 0.1 
Caffeine, EGTA 1.4 ± 0.1 1.3 ± 0.2 1.3 ± 0.1 1.5 ± 0.3 
Ionomycin, CaCl2 7.5 ± 1.4 6.6 ± 0.6 6.6 ± 1.1 6.3 ± 2.2 
Thapsigargin, CaCl2 4.8 ± 0.8 5.0 ± 0.8 4.9 ± 0.7 4.2 ± 1.6 
Caffeine, CaCl2 2.9 ± 1.1 3.1 ± 1.2 2.3 ± 0.9 3.9 ± 1.1 
      
Table 2 Total Ca
2+
 responses and Ca
2+
 mobilization in activated EVB-B lymphoblasts from 
two controls and two Scott patients. Flow cytometric results are expressed as fold increase in 
fluorescence intensity (arbitrary units) relative to the control (1.00). Under unstimulated conditions, 
averaged fluorescence intensities of the populations of Fluo-3-loaded cells were similar for all four 
cell lines. Values shown are means ± SD from at least four independent experiments. 
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To allow capacitative Ca
2+
 entry, the Fluo-3-loaded B-lymphoblasts were 
activated using the same agonists with extracellular CaCl2 present. Ionomycin/CaCl2 
caused a high increase in [Ca
2+
]i, which was similar for the control and patient B-
lymphoblasts (Table 2). Thapsigargin/CaCl2 resulted in a smaller increase in [Ca
2+
]i due 
to SMCE. This response was somewhat lower in the V.W. cells in comparison to the 
control, but the difference was not statistically significant (Table 2). When capacitative 
Ca
2+
 entry was induced with caffeine/CaCl2, the Ca
2+
 responses were lower than with 
thapsigargin/CaCl2, but no differences in responsiveness were observed between the 
various cell lines. Combined treatment with thapsigargin/caffeine/CaCl2 did not further 
increase the thapsigargin-induced Ca
2+
 response (fold fluorescence increase: 4.6 ± 0.2 
for control 1, 4.7 ± 0.4 for M.S. (mean ± SD, n=3)), indicating efficient coupling of the 
thapsigargin-sensitive stores to the SMCE Ca
2+
 influx channels. These results typically 
differ from those obtained with EBV-transfected B-cells from the French Scott patient, in 
which case both Ca
2+
-ionophore/CaCl2 and thapsigargin/CaCl2 induced substantially 
lower Ca
2+
 responses
22
. Thus, the present observations show that Ca
2+
 release from 
intracellular stores and Ca
2+
 entry are not significantly altered in viable, non-apoptotic B-
lymphoblasts cells from these two different Scott patients. 
Relation between calcium responses and phosphatidylserine exposure in B-
lymphoblasts from patients 
To address the question whether the B-lymphoblasts from the patients have 
retained the Scott-type characteristics, we used a double-labelling procedure to directly 
compare Ca
2+
 responses (Fluo-3 loading) and PS exposure (AF-annexin V addition) by 
flow cytometric analysis. Knowing that apoptosis of B-lymphoblasts, even from Scott 
patients, is accompanied by PS exposure
27
, all analysis were performed exclusively on 
 
 % AF-annexin V binding cells 
Condition  Control 1 Control 2 Patient M.S. Patient V.W. 
Unstimulated 4.0 ± 1.8 2.0 ± 0.5 1.0 ± 0.1
*
 3.0 ± 2.0 
Ionomycin, CaCl2 90.0 ± 2.7 85.0 ± 18.0 6.0 ± 1.4
*
 11.0 ± 2.1
*
 
Thapsigargin, CaCl2 5.0 ± 2.5 5.0 ± 2.9 2.0 ± 0.7 4.0 ± 1.9 
Caffeine, CaCl2 3.0 ± 0.1 2.0 ± 1.4 1.0 ± 0.1 1.0 ± 1.3 
      
Table 3 Phosphatidylserine exposure in non-apoptotic Fluo-3-loaded B-lymphoblasts from 
two controls and two Scott patients. Data represent percentages of AF-annexin V positive cells 
(means ± SD, n = 4-6). *P<0.05 compared to value of corresponding control cells. 
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the non-apoptotic cell population. In the absence of stimulation, both the control B-cells 
and the cells derived from patients M.S. and V.W. exhibited comparably low PS 
exposure (Table 3). When treated with ionomycin (10 µM) in the presence of CaCl2, 85-
90% of the B-lymphoblasts from the controls became PS-positive, versus only 6%  and 
11% of the B-lymphoblasts of patient M.S. and V.W., respectively. 
When SMCE was induced by CaCl2 after emptying the Ca
2+
 stores with 
thapsigargin, no PS exposure was observed in either control or patient B-lymphoblasts 
(Table 3), despite the fact that the thapsigargin-induced Ca
2+
 responses were high (see 
Table 2). Similarly, addition of caffeine – either alone or in combination with thapsigargin 
– did not lead to significant PS exposure in viable cells for any of the cell lines. 
Further analysis of the double label flow-cytometric data clearly indicate that the 
Ca
2+
 signals caused by thapsigargin/CaCl2 were lower but in the same range as those 
evoked by ionomycin/CaCl2, whereas only the latter agonist was capable to induce PS 
exposure in control B-lymphoblasts (Figure 3). Thus, in the control cells, ionomycin 
appears to be a much better stimulus for PS exposure than thapsigargin or caffeine, 
 
Figure 1 Collagen-induced Ca
2+
 responses of single platelets from control subjects and Scott 
patients. Fura-2-loaded platelets were allowed to adhere to collagen fibers in the presence of CaCl2 (2 
mM). Changes in Fura-2 fluorescence ratio in single platelets were measured by fluorescence video 
imaging microscopy. (A) Experiments were performed in 1996 with platelets from control 1 and patient 
M.S. (B) Experiments with platelets from control 2 and patient V.W. were carried out in 2002. Changes 
in Fura-2 fluorescence ratio (340/380 nm excitation) were recorded during adhesion and activation, as 
described in Materials and Methods. Traces are averaged overlays of single traces obtained from at 
least twenty platelets per subject (n≥3 incubations/subject). 
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despite the fact that the latter agents cause substantial Ca
2+
 influx, suggesting a 
particular action of ionomycin/Ca
2+
 on the phospholipid scrambling process. 
Discussion 
The transmembrane phospholipid asymmetry, characteristic of the plasma 
membrane of most mammalian cells, is maintained by two distinct plasma membrane 
proteins: the aminophospholipid translocase, which causes a rapid inward transport of 
aminophospholipids, and –as demonstrated for erythrocytes- the multidrug resistance 
protein MRP1, which facilitates a slow outward movement of membrane phospholipids, 
irrespective the composition of the polar headgroup. These proteins assure that 
procoagulant anionic phospholipids, such as PS, remain localized in the cytoplasmic 
leaflet of the plasma membrane (reviewed in
30
).  A third protein is responsible for a rapid 
bidirectional transbilayer movement of the phospholipids in the plasma membrane. 
Activation of this protein causes a collaps of the asymmetric lipid distribution in the 
plasma membrane; hence this protein has been termed ‘phospholipid scramblase’
30
. 
Activation of the scramblase causes exposure of PS at the cell surface, which serves an 
important function in the process of blood coagulation. Patients with an impaired 
scramblase activity suffer from a bleeding disorder, referred to as Scott syndrome, 
illustrating the importance of this membrane remodelling process. Scrambling activity 
has been demonstrated in most haematological cells; Sims and coworkers have cloned a 
protein from erythrocytes with Ca-dependent scrambling activity, a protein which is now 
referred to as human phospholipid scramblase (hPLSCR1, reviewed in
31
). However, 
there is increasing doubt about the true function of this protein. As was found recently, 
adult PLSCR1(-/-) mice showed no obvious haematologic or haemostatic abnormality, 
and blood cells from these animals normally mobilized phosphatidylserine to the cell 
surface upon stimulation
32
. Thus, the identity of the scramblase remains to be elucidated. 
The finding that the phenotype of defective PS exposure in the Scott syndrome affects all 
cells of the haematological lineage as well as the hereditary transmission of this disorder 
strongly suggest the involvement of a protein in the scrambling process. Although it has 
been demonstrated that lipid scrambling does not require hydrolysis of ATP and that 
activity of the scramblase requires a persistent elevation of intracellular Ca
2+
, the mode 
of action and the regulation of the scramblase remain to be elucidated. 
In the present study, we introduce a new case with characteristics of the Scott 
syndrome. Patient V.W. has been described in an early study published in 1980 as the 
propositus of a family with a platelet-related bleeding disorder despite a normal 
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coagulation profile
5
, but has not been recognised as having Scott syndrome. The data 
obtained in this study clearly demonstrate an impaired Ca
2+
-induced PS exposure in the 
patient’s erythrocytes, platelets and lymphoblasts as judged from decreased 
prothrombinase activities and annexin V binding, confirming the Scott phenotype. Note 
that for patient V.W. the procoagulant response of platelets treated with ionophore 
seems to be more impaired than that of platelets activated with collagen plus thrombin. 
This has been a consistent finding over several years with the platelets of patient M.S. In 
both the French propositus with Scott syndrome and the canine model of Scott 
syndrome, platelet prothrombinase activity was virtually absent, independent of whether 
the cells were activated with ionophore or with collagen plus thrombin
6,9
. The reason for 
this difference in phenotype is as yet unclear. Whether the partially impaired 
procoagulant response after collagen plus thrombin stimulation of platelets of patients 
V.W. and M.S. illustrates different pathways of activation or the existence of more than 
one mechanism for phospholipid scrambling in platelets remains to be investigated. In 
this respect, it is of interest to mention that the defect in ionomycin-induced PS exposure 
in the EBV-transformed B cells of the two patients is not observed for the apoptotic cells 
from these patients (data not shown), in agreement with the suggestion that phospholipid 
scrambling in apoptotic cells is differently regulated from the scrambling caused by Ca
2+
-
elevating agents
27
). 
SMCE following Ca
2+
 mobilization from intracellular stores presents the most 
important Ca
2+
 entry pathway in platelets and lymphocytes. Recently, Martinez and co-
workers have described that B-lymphoblasts from a French Scott patient exhibit normal 
Ca
2+
 release from the thapsigargin- and caffeine-depletable Ca
2+
 stores, but show a 
considerably reduced subsequent Ca
2+
 entry, along with a reduced PS exposure
4,22
. 
Interestingly, Ca
2+
 entry following depletion of both the thapsigargin and caffeine-
sensitive stores became normalized in these B-lymphoblasts. In the present study, we 
also measured thapsigargin- and caffeine-mediated release of Ca
2+
 from stores as well 
as subsequent Ca
2+
 entry. In agreement with their observations, we found no indications 
for disturbances in the release from stores. However, in contrast to the French Scott B-
lymphoblasts, the B-cells from both patients M.S. and V.W. appeared to have normal 
Ca
2+
 influx via SMCE with thapsigargin or caffeine as well as Ca
2+
 ionophore. 
Furthermore, the combination of thapsigargin and caffeine did not further increase the 
Ca
2+
 signal or the PS exposure. The reason for this discrepancy is not known, but may 
reflect a variant of the Scott syndrome. 
The finding that Ca
2+
 responses in both the platelets and B-cells from patients 
M.S. and V.W. are unaltered indicates that aberrant Ca
2+
 signaling -at least in these two 
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patients- is not part of the Scott phenotype. The double-labelling techniques applied with 
both platelets and non-apoptotic B-cells show that Scott cells of either type are greatly 
diminished in PS exposure although being high in [Ca
2+
]i. Even for the control B-cells, 
there is no simple relationship between elevated [Ca
2+
]i and PS exposure (Figure 3), 
suggesting that the scrambling process is not dependent on high [Ca
2+
]i only, but relies 
on other intracellular processes as well, in agreement with previous findings
16
. This 
suggestion is supported by recent evidence that also in stimulated human T-lymphocytes 
the phospholipid scrambling with Ca
2+
 ionophore is mediated by factors other than 
elevated [Ca
2+
]i only
33
. 
 In summary, the present study shows that patient V.W. can be 
considered as having a Scott syndrome phenotype. The impaired lipid scrambling in 
platelets and B-cells from both Scott patients presented here, cannot be ascribed to 
alterations in Ca
2+
 release from intracellular stores or subsequent Ca
2+
 entry. 
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Abstract 
Platelets contain various forms of phosphoinositide 3-kinase (PI3K), which 
contribute to platelet activation in a non-clarified way. Here, we investigated the roles of 
platelet PI3K isoforms in glycoprotein VI (GPVI)-induced Ca
2+
 signaling and 
procoagulant activity during thrombus formation. We used mouse platelets deficient in 
the p85α regulatory PI3K subunit or the p110γ catalytic subunit, as well as high-affinity 
PI3K inhibitors, specifically blocking the p110 α, β, γ or δ catalytic subunits. Under high-
shear flow conditions, absence of murine p85α or inhibition of PI3Kα or β lowered GPVI-
induced Ca
2+
 responses and subsequent procoagulant activity (phosphatidylserine 
exposure). In contrast, absence of p110γ only delayed the GPVI-induced Ca
2+
 signal and 
did not influence procoagulant activity. Experiments with human platelets showed that 
the contribution of PI3K to GPVI-induced Ca
2+
 signaling and procoagulant activity was 
independent of autocrine released ADP. Furthermore, blockage of either PI3Kα or β 
catalytic activity was sufficient to completely suppress the enhancing effect of PI3K on 
mobilisation of Ca
2+
 from internal stores. Combined inhibition of PI3Kα and β was without 
extra effect, while inhibition of PI3Kδ was only partly effective. Taken together, the 
present results indicate that the principle mechanism of action of PI3K on GPVI-induced 
Ca
2+
 signaling and PS exposure is enhancement of phospholipase Cγ2-mediated 
stimulation of Ca
2+
 depletion from internal stores, and subsequent store-mediated Ca
2+
 
entry. Furthermore, particularly the PI3Kα and β isoforms, acting via p85α, appear to be 
involved in this activation pathway, with PKI3δ playing a minor role. 
Introduction 
Cytosolic [Ca
2+
]i elevation is a key regulating signal for most platelet activation 
processes, such as shape change, release of autocoid mediators, aggregation and, 
particularly, development of procoagulant activity
1,2
. The signal transduction processes 
to the procoagulant platelet response are not well investigated, although it is clear that 
these require a high, threshold [Ca
2+
]i elevation, which mediates scrambling of plasma 
membrane phospholipids, exposure of the phosphatidylserine (PS) at the platelet 
surface, and shedding of microparticles
3
. The PS-exposing platelets and microparticles 
avidly assemble coagulation factors, and thus mediate massive formation of factor Xa 
and thrombin during the propagation phase of the coagulation process
4
. 
In both human and mouse platelets, the Gq protein-coupled receptor agonists 
thrombin, ADP and thromboxane A2 activate phospholipase C (PLC)β and form inositol 
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1,4,5-trisphosphate (IP3)
5,6
. By themselves, these agonists are unable to trigger the 
platelet procoagulant response, likely because of the relative short duration of the Ca
2+
 
signal. In contrast, platelet stimulation of the immunoglobulin family receptor, 
glycoprotein VI (GPVI) – using agonists as collagen, collagen peptide and convulxin – 
results in a more prolonged elevation in [Ca
2+
]i
4,7,8
. The GPVI receptor signals via Src 
and Syk tyrosine kinases to activate PLCγ2 in a pathway that is supported by several 
other protein kinases, particularly of the Btk/Tec and phosphoinositide 3-kinase (PI3K) 
families
9,10
. 
In lymphocytes and mast cells, triggering of immunoglobulin receptors also 
leads to activation of PLCγ isoforms, in a way promoted by PI3K activation
11,12
. In these 
cells, plasma membrane accumulation of the PI3K product, phosphatidylinositol 3,4,5-
trisphosphate (PIP3), is assumed to function as an anchoring site of the activated PLCγ 
via its N-terminal pleckstrin homology (PH) domain. Accordingly, the PIP3 ensures 
sustained formation of IP3 and Ca
2+
 signals
13
. 
Human and murine platelets contain various PI3K isoforms, which are 
distinguished according to their catalytic subunits. These are the class IA isoforms 
PI3Kα, β and δ (p110α, p110β and p110δ), and the class IB isoform PI3Kγ (p110γ)
14-16
. 
Platelets further contain the class IA PI3K regulatory subunits, p85α, p85β and p55γ, and 
a unique class IB regulatory subunit, p101γ. 
In general, the class IA isoforms bind to SH2 domain-containing regulatory 
subunits, particularly p85α and, therefore, are considered to be regulated by tyrosine 
kinases. In contrast, class IB isoforms are supposed to be activated by G-protein 
coupled receptors
15
. Whether this is also the case for platelets, has not yet been 
investigated. It is also not completely sure which regulatory subunit can bind to which 
catalytic subunit. As far as known, the inter-SH2 domains of p85α, p55α, p50α, p85β 
and p55γ constitutively interact with the N-terminal domain of p110α, β and δ. Binding of 
the dual SH2 domains to tyrosine-phosphorylated adaptor proteins activates the kinase 
function of the p110 subunits. However, for platelets only little is known of the 
contribution of the individual PI3K isoforms in signal transduction. In mouse and human 
platelets, PI3K p85α was found to play a role in GPVI/FcR γ-chain signaling
8,17,18
. This 
corroborates with the finding that PI3K inhibition reduces the Ca
2+
 signal evoked by 
collagen peptides
8
, although the mechanism of this is still unclear. Furthermore, both 
PI3Kβ and PI3Kγ have been implicated in ADP-induced platelet aggregation and 
aggregate stabilization
16,19,20
, which deviates from the paradigm of class 1A and 1B 
isoforms being triggered by distinct signaling processes. To date, the role of individual 
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PI3K catalytic isoform activities in regulating GPVI-induced Ca
2+
 signaling and 
procoagulant activity is still unknown. 
There are several pieces of evidence that platelet PI3K contributes to Ca
2+
 
signaling in response to collagen peptides in yet another way. The PI3K product PIP3 
was found to mediate activation of Ca
2+
 entry either directly by influencing the Ca
2+
 
channels themselves
21
, or via the Tec-family protein kinase, Btk, independently of 
PLCγ
22
. This Ca
2+
 influx pathway was suggested to be responsible for collagen-evoked 
PS exposure
22
. However, the mechanism of inhibition has not further been studied. 
In this paper, we studied the contribution of PI3K in GPVI-induced platelet Ca
2+
 
responses, using mice deficient in distinct PI3K subunits, p85α or p110γ,  and using a 
panel of isoform-specific PI3K inhibitors in combination with human platelets. Hereby, we 
focussed on monitoring of Ca
2+
 signaling and PS exposure under physiologically relevant 
flow conditions. 
Materials and methods 
Animals 
Animal experiments were approved by the local animal experimental 
committees. Mice deficient in the p85α regulatory PI3K subunit on C57BL/6 genetic 
background were generated, as described
23
. Mice deficient in the p110γ catalytic subunit 
(PI3Kγ) were bred on a 129Sv background as described
24
. Wildtype mice of the same 
genetic background and same breeding programs were used as control animals. 
Materials 
Fibrillar type-1 collagen (Horm) from equine tendon was purchased from 
Nycomed. Collagen-related peptide (CRP), containing triple-helical polymers of Gly-Pro-
Hyp, was prepared and cross-linked, as described before
25
. The GPVI agonist, 
convulxin
26
, was purified to homogeneity from the venom of Crotalus durissus terrificus 
(Latoxan), as described
27
. Fura-2 and Fluo-3 acetoxymethyl esters and Pluronic F-127 
were purchased from Molecular Probes. Oregon green 488-labelled annexin A5 (OG488-
annexin A5) was from Nexins Research. Bovine serum albumin (BSA), apyrase (grade 
V), aspirin, thrombin, wortmannin and MRS2179, a P2Y1 antagonist, were from Sigma. 
LY294002 and H-Phe-Pro-Arg chloromethyl ketone (PPACK) were from Calbiochem. 
Isoform-selective PI3K inhibitors were a kind gift from the Baker Heart Research 
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Institute, and synthesized as described
16,28
. These were (with cell-free IC50 
concentrations): PI103 and YM024, selective for p110α (0.008 and 0.3 µM, respectively); 
TGX221, selective for the p110β isoform (0.05 µM); AS252424, selective for 
p110γ (0.035 µM); and IC87114, selective for p110δ (0.5 µM). Cangrelor (AR-
C69931MX), an antagonist of the P2Y12 receptor, was kindly provided by The Medicines 
Company. Acetylsalicylic acid (aspirin) was purchased from Lorex Synthelabo. Other 
reagents were of analytical grade and from sources as described
29
. 
Blood collection and platelet isolation 
For flow experiments, human blood was collected into 40 µM PPACK, and 
mouse blood was collected into 40 µM PPACK and 5 U/ml heparin, as described 
previously
29,30
. For measurements of cytosolic [Ca
2+
]i, human or mouse blood was 
collected on one-sixth volume of acid-citrate-dextrose anticoagulant, composed of 85 
mM sodium citrate, 78 mM citric acid and 11 mM D-glucose. Platelet-rich plasma and 
washed platelets were obtained by centrifugation, as described before for human
30
 and 
mouse
29
 platelets. Mouse platelets were finally resuspended in Hepes buffer I (5 mM 
Hepes, 136 mM NaCl, 2.7 mM KCl, 0.42 mM NaH2PO4, 2 mM MgCl2, 0.1% glucose and 
0.1% BSA, pH 7.45). Cells were counted with a Coulter counter. 
Measurement of thrombus formation and procoagulant response under flow  
Whole blood perfusion experiments were performed, as described previously for 
human
30
 and mouse
29
 blood. Briefly, coverslips were coated with collagen fibres (12.5 
µg/cm
2
) and blocked with Hepes buffer at pH 7.45 containing 1% BSA. Blood 
anticoagulated with PPACK was perfused over the coverslip through a transparent 50-
µm deep flow chamber by using a 1-ml syringe and a pulse-free pump, at a shear rate of 
1000 s
-1
 for 4 min. The blood was incubated for 10 min prior to perfusion with various 
inhibitors, as indicated. During and after perfusion, microscopic phase-contrast and 
fluorescence images were recorded in real-time using a Visitech imaging system, 
equipped with two intensified CCD cameras. After 4 min of perfusion, flow chambers 
were rinsed with Hepes buffer I, supplemented with 1 U/ml heparin and 2 mM CaCl2 at 
the same shear rate for 4 min. Exposure of PS was detected with OG488-annexin A5 (1 
µg/ml) in CaCl2 Hepes buffer I. Recorded images were analysed on surface area 
coverage, as described before
31
. 
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Measurement of Ca
2+
 responses under flow 
Human platelet-rich plasma was incubated with 7 µM Fluo-3 acetoxymethyl 
ester for 45 min at 20°C, gentle rotating. Washed mouse platelets were incubated with 5 
µM Fluo-3 acetoxymethyl ester and 0.2 mg/ml Pluronic F-127 under the same conditions. 
After labelling, the platelets were added back to whole blood from the same donor or 
mouse strain to give 10% labelled platelets. Changes in fluorescence in Fluo3-loaded, 
collagen-adhered platelets were obtained using the Visitech imaging system by high-
speed (5 Hz) recording of fluorescence images, and off-line analysis of regions-of-
interest representing single platelets
32
. Calibration to [Ca
2+
]i was by pseudo-ratioing to 
give F/Fo values and fixed calibration values
33
. For quantitative data, traces from 
individual cells were superimposed, so that [Ca
2+
]i initially increased after 3.0 s. 
Measurements of Ca
2+
 responses in platelet suspension 
Human Fura-2-loaded platelets were prepared as described previously
34
. ACD-
anticoagulated platelet-rich plasma was incubated with aspirin (100 µM) and apyrase 
(0.2 U ADPase/ml) at 37°C with 2.5 µM Fura-2 acetoxymethyl ester for 45 min. Platelets 
were collected by centrifugation at 350 g for 20 min. The cells were resuspended in 
Hepes buffer II, containing 145 mM NaCl, 10 mM Hepes, 10 mM D-glucose, 5 mM KCl, 1 
mM MgSO4 and 0.1% BSA, which was supplemented with 40 µg/ml apyrase. 
Concentrations of vehicle Me2SO did not exceed 0.2 vol%, and equivalent volumes of 
Me2SO vehicle were present in control samples. 
Fluorescence was recorded from 1.5 ml aliquots of magnetically stirred platelet 
suspension (10
8 
cells/ml) at 37°C using a Cairn Research spectrofluorometer
35
 or a 
SLM-Aminco spectrofluorometer
1
, at excitation wavelengths of 340 and 380 nm and 
emission at 500 nm. Changes in [Ca
2+
]i were determined using the calibrated 340/380 
fluorescence ratio method
36
. When coloured antagonists were used interfering with the 
Fura-2 fluorescence signal, calibrations were performed in the presence of these 
antagonists. Time plots were constructed of agonist-evoked increases in [Ca
2+
]i relative 
to basal level (i.e. the level before addition of agonist). Mobilisation and total Ca
2+
 influx 
induced by specific agonists were measured by comparing 2.5 min-integrals of the 
agonist-evoked rises in [Ca
2+
]i
37
. Therefore, Ca
2+
 response curves were determined in 
the presence of either 1 mM EGTA (allowing only intracellular Ca
2+
 mobilisation) or 1 mM 
CaCl2 (allowing Ca
2+
 mobilisation and Ca
2+
 influx). 
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Statistics  
Differences between experimental groups were statistically tested with the non-
parametric Mann-Whitney U test. Effects of inhibitors were tested in paired incubations 
using the Student’s paired t test. The statistical package for social sciences was used 
(SPSS 11.0). Data are presented as means ± SEM. 
Results 
Absence of murine p85α or blocking of PI3Kβ reduces GPVI-evoked PS exposure 
under flow 
With mice lacking the p85α regulatory PI3K subunit (which links to class IA 
catalytic subunits) and mice deficient in the class IB catalytic subunit p110γ, we studied 
the contribution of the PI3K isoform classes to GPVI-induced platelet responses. These 
mice had normal levels of platelets and, furthermore, their platelets expressed normal 
levels of adhesive receptors (data not shown, but see Refs.
18,24
). Whole blood of these 
mice, anticoagulated with PPACK-heparin, was used to measure collagen-induced 
thrombus formation and platelet procoagulant activity under high-shear perfusion. 
Earlier, we have shown for murine and human blood that, under these conditions, 
platelet activation, thrombus build-up and procoagulant activity are strictly GPVI-
dependent processes
29-31,38
. Perfusion of wildtype blood at a high shear rate of 1000 s
-1
 
resulted in platelet aggregate formation on collagen, while staining with OG488-labeled 
annexin A5 indicated that many of the collagen-bound platelets expressed PS (Figure 
1A). With blood from p85α -/- or p110γ -/- mice, platelet aggregates were still formed, 
although in case of the p110γ -/- platelet aggregate size was relatively small, such in 
agreement with earlier observations that this PI3K isoform is implicated in aggregate 
stability
20
. Typically, for p85α -/- blood, platelet deposition on the collagen surface was 
unaltered, while the number of PS-exposing platelets was significantly reduced (Figure 
1B, C) With blood from PI3Kγ -/- mice the number of PS-exposing platelets was 
unchanged in spite of reduced aggregate formation. 
It has been shown, using the specific PI3Kβ inhibitor, TGX221, that this isoform 
is involved in shear- and ADP-dependent platelet adhesion to vWF
16
. We used this 
compound at a dose of 1 µM, shown to be selective in whole blood
16
, to study the 
contribution of p110β (PI3Kβ) to thrombus formation and platelet procoagulant activity in 
wildtype and knockout blood. Addition of TGX221 to p85α -/- blood reduced platelet 
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deposition but not PS exposure (Figure 1B, C). In contrast, with p110γ -/- blood, TGX221 
lowered platelet PS exposure. These results thus demonstrate that both p85α and p110β 
subunits, but not p110γ, are involved in collagen- and GPVI-induced PS exposure under 
flow. 
Absence of murine p85α and blocking of PI3Kβ reduces and delays GPVI-evoked 
Ca
2+
 signaling under flow  
Knowing the relation between GPVI-evoked rises in [Ca
2+
]i and extent of PS 
exposure under these flow conditions
29,30
, we measured the Ca
2+
 responses of platelets 
 
Figure 1 Absence of murine platelet p85α but not p110γ restricts collagen-evoked 
procoagulant activity under flow. PPACK/heparin-anticoagulated blood from indicated mice was 
perfused over a collagen surface for 4 min at 1000 s
-1
, followed by a 4-min wash with buffer in the 
presence of fluorescently labelled annexin A5 (0.5 µg/ml). Blood was pre-incubated for 10 min with 
Me2SO vehicle or PI3Kβ inhibitor TGX221 (1 µM), as indicated. (A) Upper panels: representative 
phase-contrast microscope images of platelet thrombi formed after 4-min perfusion (120×120 µm). 
Lower panels: representative fluorescence images after staining with OG488-labeled annexin A5, 
detecting PS-exposing platelets (150×150 µm). Surface area coverage of all platelets (B) and PS-
exposing platelets (C) with untreated blood (white bars) or blood treated with TGX221 (black bars). 
Data are mean±SEM (n=4). *p<0.05 compared to wildtype; 
#
p<0.05 compared to vehicle control. 
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adhering to and activated by collagen under flow
33
. Whole blood was spiked with Fluo-3-
loaded platelets derived from the same mouse strain to reach a concentration of 10% 
labelled platelets. Upon perfusion of blood over collagen, wildtype platelets showed a 
potent and prolonged Ca
2+
 response (Figure 2A), as is required for PS exposure. Traces 
from single platelets indicated a rapid rise in [Ca
2+
]i that was followed by a persistent, 
elevated plateau level. With blood from p85α null mice, platelets on average showed 
lower Ca
2+
 responses compared to the wildtype cells (Figure 2A, B). Interestingly, 
averaged traces with platelets from p110γ -/- mice showed that initial but not later 
increases in [Ca
2+
]i were reduced, thus pointing to a delayed response. Indeed, in single 
cell traces, often a long delay time between stable adhesion and start of the Ca
2+
 
response was observed (Figure 2A). 
 
Figure 2 Absence of murine platelet p85α or blocking of PI3Kα or β suppresses collagen-
evoked Ca
2+
 responses under flow. Whole murine blood, spiked with 10% Fluo-3-loaded 
platelets from the same mouse strain, was perfused over collagen at 1000 s
-1
. Changes in 
fluorescence were measured during flow in single, adhered platelets. (A) Upper traces show 
averaged changes in [Ca
2+
]i, of 15-20 platelets during 60 s (≥3 mice per condition). Lower traces 
show Ca
2+
 responses of representative, single platelets. (B) Blood was pre-incubated with vehicle 
(Ctrl), PI3Kα inhibitor YM024 (1 µM) or PI3Kβ inhibitor TGX221 (1 µM), as indicated. Quantification 
is given of changes in [Ca
2+
]i, at 20 s (black bars) and 60 s (white bars) after initial increase. Data 
are mean±SEM (n=3-5). *p<0.05 compared to wildtype; 
#
p<0.05 compared to vehicle control. 
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To study the additional contribution of PI3Kβ and other class IA isoforms in the 
GPVI-induced Ca
2+
 signal generation under flow conditions, the PI3Kβ inhibitor TGX221 
and the PI3Kα inhibitor YM024 were used. In wildtype mice, TGX221 only reduced the 
initial phase of the Ca
2+
 response, while YM024 significantly suppressed the full 
response to the level observed in platelets from p85α -/- mice. In these cells, TGX221 
still further reduced the initial Ca
2+
 signal. In platelets from p110γ -/- mice, no additional 
effect of TGX221 or YM024 was observed. Together, these data suggest that p85α and 
p110α (PI3Kα) markedly contribute to the GPVI-evoked Ca
2+
 responses of platelets on 
collagen under flow, while the β and γ PI3K isoforms only contribute to the initial phase of 
this response. 
 
 
Figure 3 Blocking of human platelet PI3K suppresses collagen-evoked aggregate formation 
and procoagulant activity under flow. PPACK-anticoagulated human blood was perfused over a 
collagen surface at 1000 s
-1
, as indicated for Figure 1. Blood was pre-incubated for 10 min with 
vehicle (control), wortmannin (1 µM) and/or ADP receptor blockers (40 µM MRS2179, 20 µM 
cangrelor and 1 unit/ml apyrase), where indicated. (A) Upper panels: representative phase contrast 
images after 4-min of perfusion (120×120 µm). Lower panels: representative fluorescence images 
after staining with OG488-annexin A5, detecting PS-exposing platelets (150×150 µm). (B) Surface 
area coverage of all platelets (white bars) and PS-exposing platelets (black bars), expressed as 
percentages of control condition (mean±SEM, n=4). *p<0.05 compared to control. 
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Human platelet PI3K contributes to GPVI-evoked aggregate formation, Ca
2+
 
signaling and PS exposure under flow 
To investigate the importance of PI3K for the human system, we performed 
similar flow experiments with PPACK-anticoagulated human blood at a shear rate of 
1000 s
-1
. Under control conditions, platelets rapidly adhered to the collagen fibres and 
assembled into aggregates, covering much of the collagen surface (Figure 3A). Post-
staining with OG488-annexin A5 again revealed many PS-exposing platelets. 
Pre-incubation of blood with the high-affinity general PI3K inhibitor wortmannin 
(1 µM) profoundly inhibited the GPVI-evoked aggregation (Figure 3A), but did not affect 
platelet adhesion to the collagen surface, as surface area coverage of platelets was still 
about 75% of the control condition (Figure 3B). In contrast, wortmannin treatment 
significantly reduced the presence of PS-exposing platelets to 65% of the control. Similar 
effects were obtained with another general PI3K inhibitor, LY294002 (not shown). 
Because paracrine ADP release contributes to thrombus formation via the ADP-
 
Figure 4 Blocking of human platelet PI3K inhibits collagen-evoked Ca
2+
 responses under 
flow. Human whole blood was spiked with autologous Fluo-3 loaded platelets, and perfused over 
collagen, as indicated for Figure 2. Blood was treated with vehicle (control), wortmannin (1 µM) 
and/or ADP receptor blockers (40 µM MRS2179, 20 µM cangrelor and 1 U/ml apyrase), as 
indicated. (A) Traces of [Ca
2+
]i changes shown are averaged curves of single-cell responses from 
15-25 platelets. (B) Quantification of changes in [Ca
2+
]i, at 20 s (black bars) and 60 s (white bars) 
after initial increase. Data are mean±SEM (n=3). *p<0.05 compared to control. 
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receptors P2Y12 and P2Y1
38,39
, and because PI3K isoforms play a role in P2Y12-mediated 
aggregation under flow
20
, we investigated whether ADP release and signaling interfered 
in the wortmannin effects. Therefore, blood was pre-incubated with saturating doses of 
ADP-degrading apyrase and the P2Y1 and P2Y12 receptor blockers, MRS2179 and 
cangrelor, respectively. Blockade of the ADP receptors resulted in high deposition of 
mostly single platelets and small aggregates at the collagen surface (Figure 3A), with as 
a result a higher surface area coverage with platelets (Figure 3B). However, the ADP-
receptor blockade failed to reduce the number of PS-exposing platelets. Interestingly, 
treatment of wortmannin in combination with ADP receptor blockers reduced platelet 
deposition, and lowered PS exposure to the level obtained with wortmannin alone. 
Accordingly, the PI3K contribution to platelet procoagulant activity seems to be 
independent of indirect, ADP-mediated effects. 
Using Fluo-3-loaded platelets, which were added to the human blood, effects of 
wortmannin and ADP receptor blockade were also investigated on the collagen-evoked 
Ca
2+
 responses. As indicated in Figure 4, treatment with wortmannin, but not with ADP 
receptor blockers, greatly reduces the increases in [Ca
2+
]i. Taken together, these data 
indicate that under flow blocking of PI3K with wortmannin suppresses collagen-evoked 
Ca
2+
 signaling and procoagulant activity, independently of secondary ADP effects. 
Human platelet PI3K α and β isoforms contribute to GPVI- but not thrombin-
evoked Ca
2+
 mobilisation and entry in platelet suspension  
To more directly investigate the involvement of PI3K in agonist-induced Ca
2+
 
signal generation, suspension measurements were performed with washed, Fura-2-
loaded platelets, which were stimulated by near-maximal doses of the GPVI agonist, 
CRP (5 µg/ml) or the Gq protein-coupled receptor agonist, thrombin (10 nM). Platelets 
were pre-treated with aspirin and contained apyrase to abolish secondary effects due to 
released thromboxane and ADP, respectively. Activations were in the presence of EGTA 
to measure only Ca
2+
 mobilisation from internal stores, while others were with CaCl2, 
where the Ca
2+
 signal consists of both internal mobilisation and Ca
2+
 entry. Dose-
response curves indicated that the general PI3K inhibitors reduced the Ca
2+
 signal 
evoked by CRP to about 50%, at saturating concentrations of 100 nM wortmannin and 
10 µM LY294002 (Figure 5A). Furthermore, with either compound a similar dose-
dependency of inhibition was seen for experiments in the presence of EGTA or CaCl2, 
thus indicating that internal Ca
2+
 mobilisation and Ca
2+
 influx were similarly influenced. 
Control experiments, performed in the presence of extra MRS2179 (40 µM) plus 
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cangrelor (20 µM) to block P2Y receptors, gave a similar, maximal inhibition with 
wortmannin and LY294002 of 45±1.4% and 52±2.8% of control, respectively. Similar 
results were obtained when platelets were stimulated with the GPVI agonist, convulxin 
instead of CRP: wortmannin (10 nM) and LY294002 (1 µM) inhibited the Ca
2+
 response 
to 37±0.9 and 58±10.4% of control, respectively. However, in contrast, platelet treatment 
with wortmannin or LY294002 no more than slightly lowered the Ca
2+
 responses evoked 
by thrombin (Figure 5B). 
A panel of currently available high-affinity isoform-specific PI3K inhibitors was 
then used to established the isoforms contributing to the GPVI-induced Ca
2+ 
response 
with convulxin in the presence of external CaCl2. The compounds were used at 
concentrations around their IC50 and higher, as was established in vitro using cell-free 
 
Figure 5 Inhibition of human platelet PI3K suppresses GPVI-, but not thrombin-evoked Ca
2+
 
mobilisation and influx. Suspensions of human, Fura-2-loaded platelets were incubated for 10 
min at 37°C with Me2SO vehicle, wortmannin (0.1-1000 nM) or LY294002 (0.1-30 µM). Platelets 
were then stimulated with (A) GPVI-stimulating CRP (5 µg/ml), or (B) thrombin (10 nM) in buffer 
containing 1 mM Ca
2+
 or 1 mM EGTA. The platelets were pre-treated with aspirin while loading 
with Fura-2, and suspensions contained apyrase. Elevations in [Ca
2+
]i were measured as time-
[Ca
2+
]i integrals. Black diamonds represent total Ca
2+
 response with CaCl2, and open squares Ca
2+
 
mobilization with EGTA. Results are expressed as percentages of the vehicle control condition 
(mean±SEM, n=5). *p<0.05 compared to control. 
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systems
28
. Platelet treatment with the PI3Kα inhibitor PI103 (0.02-0.5 µM), but not with 
the analogous control substance, PIK112, resulted in a dose-dependent inhibition of the 
Ca
2+ 
response up to 50% of control (Figure 6A). A quite similar effect was obtained with 
the PI3Kα inhibitor, YM024 (0.1-2.5 µM).  
Also, PI3Kβ inhibition with TGX221 (0.1-2.5 µM) gave a 50% reduction in Ca
2+ 
response. Interestingly, combined inhibition of PI3Kα and β (PI103 + TGX221) did not 
have an additional effect, when compared to either inhibitor alone. Platelet treatment with 
the PI3Kγ inhibitor AS252424 (0.1-1 µM) failed to have an effect on the Ca
2+
 response, 
but interfered with the Fura-2 fluorescence at high doses. The compound IC87114 (0.2-5 
 
Figure 6 Inhibition of human platelet PI3Kα or β suppresses GPVI-, but not thrombin-evoked 
Ca
2+
 signaling. Suspensions of human Fura-2-loaded platelets were incubated for 10 min at 37°C 
in the presence of vehicle or one or more of the following inhibitory substances (0.02-5 µM): 
PIK112 (negative control), PI103 (PI3Kα), YM024 (PI3Kα), TGX221 (PI3Kβ), AS252424 (PI3Kγ) or 
IC87114 (PI3Kδ) to block indicated PI3K isoforms. Numbers below bars indicate concentrations of 
inhibitors. Cells were then stimulated with (A) convulxin (70 ng/ml) or (B) thrombin (10 nM) in 
Hepes buffer containing 1 mM CaCl2. The platelets were pre-treated with aspirin, while loading with 
Fura-2, and suspensions contained apyrase, MRS2179 and cangrelor. Elevations in [Ca
2+
]i were 
determined as described for Figure 5. Histograms indicate percentage changes in [Ca
2+
]i rises 
relative to control condition. Values are mean±SEM from three independent experiments. *p<0.05 
versus vehicle control, 
#
 interference with Fura-2 fluorescence. 
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µM) slightly, but significantly reduced the GPVI-evoked Ca
2+
 response only at the highest 
concentration of 5 µM, which is still specific for PI3Kδ inhibition. In marked contrast to the 
profound effects of PI3Kα and β inhibitors with GPVI agonist, YM024 (1 µM) only slightly 
lowered the Ca
2+
 response with thrombin (Figure 6B). Thus, inhibition of PI3Kα and/or β, 
and only weakly of δ, with fair specificity suppressed the Ca
2+
 response induced by GPVI 
agonists for up to 50%. 
Discussion 
The present results with mouse platelets indicate that absence of the p85α 
regulatory PI3K subunit as well as blocking of the p110α or p110β activity significantly 
suppresses Ca
2+
 signaling and PS exposure elicited by GPVI-induced platelet activation 
under flow. For platelets from these p85α -/- mice, it has been established that selective 
disruption of the p85α protein does not results in significant up-regulation of the isoform 
p55α, p50α and p85β proteins to compensate for the lack of p85α . However, in these 
knock-out platelets expression of the p110α catalytic subunit (PI3Kα) is almost 
undetectable, along with a reduced p110β and δ expression, resulting in only 5% kinase 
activity
18,23,40
. That the class IA isoforms PI3Kα and β play a role in GPVI-dependent 
Ca
2+
 signaling was confirmed by the suppressive effects of PI103/YM024 and TGX221 
which block the p110α and p110β subunits with preference, respectively. However, it 
should be noted that the PI3Kα inhibitors, PI103 and YM024, also have limited inhibitory 
activity towards PI3Kβ (S. Jackson, unpublished results).The PI3Kβ inhibitor TGX221 
was unable to further suppress the lower Ca
2+
 signal in p85α -/- platelets. Importantly, 
these compounds showed the same degree of inhibition on GPVI-induced (with 
convulxin) Ca
2+
 responses in human platelets, thus indicating that the isoform-specific 
regulation of this signaling pathway is conserved in mouse and human platelets. Earlier 
work has demonstrated that collagen activation results in association of p85α with the 
LAT adaptor protein
41
, and that absence of p85α results in defective collagen-induced 
platelet aggregation and degranulation
18
. The current findings significantly extend this, 
and indicate that p85α acts by activating p110α/β, which potentiate GPVI-induced Ca
2+
 
signaling and PS exposure. 
Previous studies have shown that GPVI agonist like collagen and CRP 
stimulate the formation of PIP3 and PI(3,4)P3 in human platelets, and that this stimulation 
is antagonized by wortmannin and LY294002, two structurally unrelated inhibitors of all 
platelet PI3K isoforms. Indeed, it has been shown that PI3K activity and PIP3 formation 
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are required for full activation of PLCγ2 in response to GPVI stimulation
8,42,43
. 
Interestingly, the present data with mouse and human platelets indicate that combined 
inhibition of PI3Kα and β gives a similar reduction in Ca
2+
 response, and hence in PLCγ2 
activity, as inhibition of either isoform alone. While this finding agrees with the concept 
that the PI3K product PIP3 acts as a membrane anchoring site of PLCγ2, it argues 
against a redundancy in function of the two PI3K isoforms. One explanation is that 
threshold levels of PIP3 need to be formed – i.e. by simultaneous activity of either 
isoform – in order to anchor and stimulate PLCγ2, perhaps because of its competition 
with other PH-domain containing signaling proteins. Thus, the activity of both PI3K 
isoforms is needed to reach sufficient lipid kinase activity. 
In contrast to PI3Kα and β, the class IA PI3Kδ and the class IB PI3Kγ appeared 
to have a less prominent role in GPVI-induced Ca
2+
 responses. In human platelets, the 
PI3Kδ inhibitor IC87114 provoked a small reduction of the Ca
2+
 signal, but not the PI3Kγ 
inhibitor AS252424. This is in agreement with recent data with platelets from PI3Kδ 
deficient mice, which point to a small but detectable role for the δ isoform in mediating 
platelet activation by collagen
44
. Typically, under flow conditions, absence of murine 
p110γ resulted in a collagen-induced Ca
2+
 signal, which was only initially reduced in 
comparison to that of wildtype platelets. This appeared to be due to an often prolonged 
delay time between adhesion and start of the Ca
2+
 signal, thus pointing to a delayed 
onset in GPVI signaling under flow rather than to a reduction in GPVI signaling per se. 
This conclusion is also supported by the observation that GPVI-induced and Ca
2+
-
mediated PS exposure of platelets is not reduced in the absence of p110γ. 
We and others have shown that both the PI3Kβ and γ isoforms play an 
enhancing role in ADP-induced integrin αIIbβ3 activation, stable adhesion and thrombus 
stabilization under static and flow conditions
16,19,20
. This was also apparent in the present 
experiments, i.e. from the reducing effects of wortmannin and ADP receptor blockage on 
human platelet aggregate formation under flow. However, these ADP-mediated effects of 
PI3K are independent of the GPVI-mediated effects, because wortmannin still 
suppresses collagen-induced Ca
2+
 responses and PS exposure under conditions of full 
blockade of the ADP receptor blockers (MRS2179, cangrelor and apyrase). Similarly, in 
platelet suspensions, the general PI3K inhibitors, wortmannin and LY294002, and the 
isoform-specific inhibitors, PI103, YM024 and TGX221, suppress GPVI-induced Ca
2+
 
signaling up to 50%, again under conditions where ADP receptors are blocked. This high 
involvement of PI3K in Ca
2+
 rises was specific for GPVI signaling, as the same inhibitors 
had only a small, reducing effect on thrombin-evoked Ca
2+
 rises. This agrees well with 
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the earlier observation that thrombin mobilises Ca
2+
 nearly entirely via PLCβ isoforms 
with only little contribution of PLCγ1
5,45
. 
Dose-response curves with either wortmannin or LY294002 showed a similar 
degree of inhibition of GPVI-mediated Ca
2+
 responses in the presence of EGTA 
(measuring only internal Ca
2+
 mobilisation) and CaCl2 (recording both Ca
2+
 mobilisation 
and Ca
2+
 influx from the external medium). This argues against a specific stimulation of 
platelet PI3Ks on Ca
2+
 entry processes. Moreover, wortmannin or LY294002 also failed 
to give extra inhibition of thrombin-induced Ca
2+
 responses, when Ca
2+
 entry was 
allowed in the presence of CaCl2. Accordingly, our results do not support the earlier 
suggestion by others that PI3K phosphoinositides, e.g. as generated by stimulation of 
GPVI or thrombin receptors, stimulate a specific pathway of Ca
2+
 entry
21,22
. This 
discrepancy may come from the higher doses of LY294002 or wortmannin used by Lu et 
al., at which also PI4-K activity and, thus, e.g. PIP2 formation is affected
46
. Further, it is 
possible that increased Ca
2+
 influx, noted in the absence of the PIP3-degrading SH2 
domain-containing inositol 5-phosphatase (SHIP)
22
, is caused by a distinct mechanism 
than that influenced by PI3Ks, e.g. related to the higher basal Ca
2+
 levels in SHIP -/- mice. 
Taken together, the present results indicate that the principle mechanism of 
action of PI3K on GPVI-induced Ca
2+
 signaling and PS exposure is by enhancement of 
PLCγ2-mediated stimulation of Ca
2+
 depletion from internal stores, and subsequent 
store-mediated Ca
2+
 entry. Furthermore, particularly the PI3Kα and β isoforms, acting via 
p85α, appear to be involved in this activation pathway, with PKI3δ playing a minor role. 
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Abstract 
The platelet glycoproteins (GPs) Ib, integrin α2β1, and GPVI are
 
considered 
central to thrombus formation. Recently, their relative
 
importance has been re-evaluated 
based on data from murine knockout
 
models. To examine their relationship during 
human thrombus
 
formation on collagen type I fibers at high shear (1000 s
–1
),
 
we tested a 
novel antibody against GPVI, an immunoglobulin single-chain
 
variable fragment, 10B12, 
together with specific antagonists
 
for GPIbα (12G1 Fab2) and α2β1 (6F1 mAb or 
GFOGER-GPP peptide).
 
GPVI was found to be crucial for aggregate formation, Ca
2+
 
signaling,
 
and phosphatidylserine (PS) exposure, but not for primary adhesion,
 
even with 
more than 97% receptor blockade. Inhibiting α2β1 revealed
 
its involvement in regulating 
Ca
2+
 signaling, PS exposure, and
 
aggregate size. Both GPIbα and α2β1 contributed to 
primary adhesion,
 
showing overlapping function. The coinhibition of receptors
 
revealed 
synergism in thrombus formation: the coinhibition of
 
adenosine diphosphate (ADP) 
receptors with collagen receptors
 
further decreased adhesion and aggregation, and, 
crucially,
 
the complete eradication of thrombus formation required the
 
coinhibition of 
GPVI with either GPIbα or α2β1. In summary, human
 
platelet deposition on collagen 
depends on the concerted interplay
 
of several receptors: GPIb in synergy with α2β1 
mediating primary
 
adhesion, reinforced by activation through GPVI, which further
 
regulates the thrombus formation. 
Introduction 
The platelet response to exposed subendothelial matrix is fundamental
 
to 
thrombosis and hemostasis. Uniquely, collagen, the most abundant
 
vessel wall protein, 
mediates platelet adhesion and activation,
 
localizing and regulating the hemostatic 
response at sites of
 
injury. Discovering the molecular mechanisms that control platelet-
collagen
 
interaction is crucial for understanding the pathogenesis of
 
arteriothrombotic 
diseases such as stroke and myocardial infarction.
 
Under high shear rate conditions, the 
glycoprotein (GP) Ib/V/IX
 
complex allows initial platelet rolling over von Willebrand
 
factor 
(VWF) bound to subendothelial collagen fibers, and subsequently
 
collagen receptors 
come into contact with their specific binding
 
sequences in the collagen. For the next step, 
platelet arrest
 
and activation, firm evidence exists of a role for only 2 receptors,
 
integrin 
α2β1 and immunoglobulin superfamily member GPVI, despite
 
the apparent redundancy 
in collagen receptors (for a review,
 
see Siljander PRM and Farndale RW
1
).
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According to the 2-site, 2-step model, high-affinity interaction
 
through α2β1 
stops the platelet, allowing low-affinity binding
 
of GPVI, which generates signaling 
required for the subsequent
 
thrombus formation. Platelet deposition under flow was 
found
 
to be dependent on GPIb/V/IX and α2β1
2-4
,whereas no platelet
 
deposition occurred 
on the GPVI-specific substrate collagen-related
 
peptide (CRP), even under low shear 
rates
5
. The limited number
 
of studies with human platelets deficient in either GPVI or
 
α2β1 support the 2-site, 2-step model. Blood depleted of functional
 
GPVI showed only 
severe impairment of the collagen-induced "second-wave"
 
aggregation response under 
flow
6
. Although thrombus volume was
 
reduced, the initial adhesive layer of platelets was 
fully preserved.
 
The few patients with defective α2β1 displayed bleeding problems,
 
suggesting a central role for the integrin in hemostasis
7-10
.
 
Genetic diversity of α2β1 
expression also correlates with predisposition
 
to thrombotic events (for a review, see 
Kunicki TJ
11
).
 
Recently, several lines of evidence strongly encouraged revision
 
of the 
step-wise model, promoting the idea that GPVI is the
 
primary collagen receptor. Integrin 
α2β1 was found to change its
 
affinity for collagen when stimulated by noncollagenous 
agonists
 
such as adenosine diphosphate (ADP) or thrombin, or through
 
GPVI
12
, implying 
that high-affinity interaction through α2β1 requires
 
the involvement of platelet receptors 
that induce secretion
 
or inside-out signaling. Moreover, mice with Cre/loxP-mediated
 
loss 
of α2β1 from the platelets displayed undisturbed bleeding
 
times, and their platelets 
exhibited normal collagen adhesion
 
and signaling
13
. Similarly, α2(–/–) mice showed no
 
changes in platelet aggregation and adhesion to fibrillar collagen
14
,
 
whereas Fcγ (–/–) 
mice, generating a deficiency in
 
the coexpressed GPVI, completely lacked a response to 
collagen
 
under flow, as did wild-type mouse blood incubated with an anti-GPVI
 
monoclonal antibody (mAb), indicating a key role for GPVI
13
.
 
Following the deposition of platelets, their procoagulant response
 
is essential for 
thrombus formation. Platelet aggregates are
 
stabilized through fibrin formation, and 
newly generated thrombin
 
recruits further platelets and activates other cells. At an
 
advanced stage of activation, collagen-adherent platelets undergo
 
a procoagulant 
transformation that includes the exposure of
 
phosphatidylserine (PS), the secretion of 
coagulation factors,
 
and the distinctive morphology of blebbing cells and 
microvesiculation
15
.
 
We have previously shown that GPVI is essential for triggering
 
this 
response in collagen-adherent platelets, which is preceded
 
by extensive intracellular 
Ca
2+
-signaling
16
. Supporting this,
 
prothrombinase activity was shown to correlate with 
GPVI density
17 
and genotype
18
.
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This study was undertaken to clarify the role of the human collagen
 
receptors 
GPVI and α2β1 in thrombus formation under flow. Studies
 
with GPVI have been 
hindered by the lack of antagonists of human
 
GPVI. Recently, 10B12, an anti-GPVI, 
single-chain, variable
 
domain antibody fragment (scFv) was cloned by phage display
 
from a library of human immunoglobulin variable domains, using
 
its capacity to block the 
recombinant GPVI-CRP interaction
19
.
 
Because it blocks CRP- and fibrillar collagen-
induced platelet
 
activation, 10B12 provides a small and efficient tool for human
 
studies. 
To inhibit α2β1 function, a collagen-derived triple-helical
 
peptide, GFOGER-GPP
20
, was 
used along with well-defined inhibitory
 
mAbs
21,22
. Simultaneous ADP and collagen 
receptor antagonism
 
were also studied. Under high shear rate conditions, specific
 
parameters of thrombus formation—surface coverage of platelets,
 
aggregate size 
distribution, and PS exposure—were monitored.
 
Further, the intracellular Ca
2+
 response, 
which regulates these
 
platelet processes and secretion and thromboxane A2 (TxA2) 
production,
 
was measured from adherent platelets.
  
Our results show that GPVI is crucial to collagen-induced Ca
2+ 
responses, 
aggregate formation, and PS expression but that α2β1
 
also contributes to these 
processes. Although GPVI is not directly
 
involved in primary platelet adhesion to 
collagen, the inhibition
 
of GPVI, along with GPIb and α2β1, was mandatory to eradicate
 
thrombus formation. 
Materials and methods 
Materials 
Fibrillar type I collagen (Horm) from equine tendon was obtained
 
from Nycomed 
(Munich, Germany). Apyrase (grade 7), heparin,
 
and MRS2179, a P2Y1 antagonist, were 
from Sigma (St Louis, MO),
 
H-Phe-Pro-Arg chloromethyl ketone (PPACK) was from 
Calbiochem
 
(La Jolla, CA), and Fluo-3 and calcein acetoxymethyl esters
 
were from 
Molecular Probes (Leiden, The Netherlands). Annexin
 
V (Apoptest) labeled with Oregon 
Green 488 (OG488) was obtained
 
from Nexins Research (Hoeven, The Netherlands). 
AR-C69931MX,
 
an antagonist of the P2Y12 receptor, was from Astra-Zeneca 
(Charnwood,
 
United Kingdom). Acetylsalicylic acid (ASA) was from Lorex Synthelabo
 
(Maarssen, The Netherlands), and low-molecular–weight
 
heparin (Fragmin) was from 
Pharmacia N.V. (Puurs, Belgium).
 
The GFOGER-GPP and CRP peptides were 
synthesized as described
20,23
.
 
ScFv antibodies 10B12 and 1C3
19
 and mAb 12G1 against 
GPIbα has
 
been previously described
24,25
: 12G1 inhibits platelet deposition
 
to type 1 
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collagen by 90% at 5 µg/mL, ristocetin-induced
 
platelet aggregation with an IC50 of 1.25 
µg/mL, ristocetin-induced
 
VWF binding to GPIb by 35%
24
, and 35% of thrombin 
generation
 
under intermediate shear
25
. Fab2 fragments were generated by
 
standard 
methodology. The mAb 6F1 against α2 was a generous gift
 
from Prof B. Coller (Mount 
Sinai Hospital, New York, NY)
21
.
 
The anti-β1 mAb 4B4 was from Beckman Coulter (High 
Wycombe, United
 
Kingdom). Saratin was kindly provided by Dr M. Hoylaerts (KU,
 
Leuven, Belgium)
26
.
 
Blood collection  
Blood from 9 healthy volunteers was collected in 40 µM
 
PPACK in 0.1 vol 
saline, supplemented hourly with 10 µM
 
PPACK. Donors had not taken medication for 2 
weeks. Platelet
 
counts were determined with a Coulter counter (Coulter Electronics,
 
Hialeah, FL). Donors were genotyped for receptor polymorphisms:
 
GPVI (a/b), α2β1 (α2 
807 C/T), and GPIb (5-C/T) using TaqMan at
 
the National Blood Service (Cambridge, 
United Kingdom). All
 
donors expressed high GPVI levels (7 aa, 2 ab)
18
. Five donors
 
were 
CT for C807T α2 polymorphism, implying an average density
 
of α2β1 on the platelet 
surface. Three donors were low expressors
 
of α2β1 (CC), and one was a high expressor 
(TT). In this small
 
population, C807T α2 polymorphism had no apparent effect on any
 
of 
the platelet responses. Two donors were CT for GPIb C5T.
 
 
Static platelet adhesion  
Static platelet adhesion to CRP and fibrillar collagen was performed
 
exactly as 
previously described
27
, using cation-free conditions
 
to examine the adhesive role of GPVI 
in the absence of α2β1.
 
 
Intracellular Ca
2+
 and thrombus volume measurements  
Acid citrate dextrose–platelet-rich plasma (ACD-PRP) was
 
incubated with 7 µM 
Fluo-3 acetoxymethyl ester or calcein
 
for 30 minutes at 37°C. Platelets were centrifuged 
with
 
0.1 vol ACD, washed once with HEPES (N-2-hydroxyethylpiperazine-N'-2-
ethanesulfonic
 
acid) buffer containing 10 mM HEPES, 136 mM NaCl, 2.7 mM KCl,
 
2 mM 
MgCl2, 0.1% glucose, 0.1% bovine serum albumin (BSA), pH
 
6.6, centrifuged again with 
0.1 vol ACD, and suspended in the
 
original volume of PRP with HEPES buffer, pH 7.45. 
PPACK-anticoagulated
 
blood was spiked with Fluo-3–labeled platelets at 10%
 
of the 
original platelet count and with 30 µM PPACK.
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In control perfusions over collagen, 30% of 7 µM calcein-prelabeled
 
autologous 
platelets were added. In real-time, Z-stacks of x-y
 
scans were taken during the perfusion 
(box volume of 171.8 x
 
171.8 x 50 µm) at a 2-photon excitation wavelength of
 
800 nm 
and an emission of 485 to 515 nm (8% of full power) using
 
a Radiance 2000 multiphoton 
laser scanning fluorescence microscope
 
system (BioRad, Hemel Hempstead, United 
Kingdom), equipped with
 
a pulsed sub-picosecond Tsunami Ti:sapphire laser (Spectra-
Physics,
 
Mountain View, CA). Two-photon images were analyzed with Laserpix
 
software 
(Bio-Rad).
 
 
Flow experiments and image recording  
Whole blood perfusion experiments were performed essentially
 
as described for 
mouse blood
28
. Briefly, glass coverslips were
 
coated with collagen fibers (12.5 µg/cm
2
) 
and blocked
 
with HEPES buffer, pH 7.45, containing 1% BSA and 1% glucose.
 
The blood 
was placed in a syringe and perfused over the coverslip
 
through a transparent 50 µm 
deep chamber using a pulse-free
 
pump
29
, at a shear rate of 1000 s
–1
 for 4 minutes. Blood
 
was incubated for 15 minutes before perfusion with various concentrations
 
of scFv 
10B12 or 1C3, 10 to 20 µg/mL 6F1, 500 µg/mL
 
GFOGER-GPP, 10 µg/mL 4B4, 20 µg/mL 
Fab2 fragment
 
12G1, ASA (100 µM), MRS2179 (40 µM), and AR-C69931MX
 
(20 µM) or 
1 U/mL apyrase, as described. Where indicated,
 
autologous Fluo-3–labeled platelets 
were added to the
 
blood before antagonists.
 
 
Microscopic phase-contrast and fluorescent images from Fluo-3–labeled
 
platelets were recorded in real-time using a Visitech digital
 
imaging system (Sunderland, 
United Kingdom) equipped with 2
 
intensified, charge-coupled device (CCD) cameras
30
. 
After perfusion,
 
flow chambers were rinsed at the same flow rate for 4 minutes
 
with 
HEPES buffer, pH 7.45, supplemented with 1 U/mL heparin
 
and 2 mM CaCl2. Phase-
contrast and fluorescent images were collected
 
with a 40x UV-transparent objective and 
15x to 20x image magnification.
 
Exposure of PS was detected after incubation of the 
slide with
 
100 µL HEPES/CaCl2 buffer, pH 7.45, containing OG488-labeled
 
annexin V (1 
µg/mL) for 5 minutes. Antibodies and antagonists
 
were also added to the rinsing buffer 
and the annexin V incubation.
 
 
Image analysis  
Surface coverage from phase-contrast images was analyzed using
 
Image-Pro 
(Silver Spring, MD) software version 4.1, and it was
 
analyzed from platelets stained with 
OG488-annexin V using Quanticell
 
software (Visitech). Distribution of aggregate sizes in 
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phase-contrast
 
images was measured using Leica QWin image analysis software
 
(Leica 
Imaging Systems, Cambridge, United Kingdom). Changes
 
in Fluo-3 fluorescence from 
individual platelets were converted
 
to [Ca
2+
]i as described
31
. To provide a measure of the 
proportion
 
of procoagulant cells independent of platelet deposition, the
 
ratio of annexin 
V–binding surface coverage to phase-contrast
 
surface coverage was calculated and was 
termed procoagulant
 
index (Pi). Although the procoagulant area was overestimated
 
through fluorescent glare in the optics, Pi provided a means
 
of distinguishing the effects 
of treatments on procoagulant
 
expression from those on platelet deposition. 
 
Experimental design and statistics  
Each experimental condition was tested on at least 3 occasions
 
using blood 
from different donors, and each donor provided blood
 
for at least 10 perfusion 
experiments. Control conditions were
 
included for each blood sample, together with other 
permutations
 
of conditions. For each perfusion surface, images from 9 random
 
microscopic fields were collected, and the average percentage
 
area covered by adherent 
platelets was measured either by phase-contrast
 
or by OG-labeled annexin V 
fluorescence. Phase-contrast, fluorescent
 
surface coverage (mean ± SE) and Pi were 
compared among
 
all experimental groups using analysis of variance (ANOVA),
 
with 
Newman-Keuls or Dunnett posttesting. Data derived from
 
the same donors were 
compared by paired sample t tests or ANOVA.
 
The effect of ADP blockade under 
different conditions was tested
 
by 2-way ANOVA.
 
Image analysis provided estimates 
(area and roundness of separate
 
features, such as platelets and aggregates) of 
thrombus size
 
and shape. Features were segmented digitally and measured with
 
minimal 
operator intervention. From an average of 9 images,
 
using 3 different donors, at least 
200 different features were
 
measured for each treatment, the effects of which were 
determined
 
by 
2
 analysis. Data are plotted as frequency distributions with
 
mean values 
per field (± SE). Prism (GraphPad Software,
 
San Diego, CA) was used throughout for 
multiple comparisons
 
and linear regression.
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Results 
Blocking of GPVI abolishes aggregate formation, Ca
without eradicating primary platelet adhesion  
PPACK-anticoagulated whole blood was perfused at high shear
 
rate (1000 s
–1
) 
over a surface covered with native collagen
 
type I fibrils. Phase-contrast and 
fluorescence microscopic
 
images were captured to monitor 2 independent parameters of
 
thrombus formation measured as the surface coverage of deposited
 
platelets and of 
procoagulant, PS-exposing platelets that stained
 
with OG488-conjugated annexin V. In 
control perfusions, platelets
 
rapidly adhered to the collagen fibers, forming aggregates 
that
 
later coalesced (Figure 1A). The deposition of platelets measured
 
by surface 
coverage was linear in time, indicating regular and
 
continuous scavenging of platelets 
(Figure 2A). To confirm that
 
the measuring surface area represents a linear progression 
of
 
thrombus build-up, the thrombus volume was measured by using
 
calcein-labeled 
platelets from the same donor and real-time
 
scanning of the 2-photon fluorescence 
signal, which even at
 
more than 50 µm penetration was typically not distorted
 
by the 
 
Figure 1 Effects of inhibitory antibodies and receptor antagonists on thrombus formation. 
Images (120 x 120 µm) were recorded using a phase-contrast microscope after the perfusion of 
PPACK-anticoagulated whole blood over a collagen-coated surface for 4 minutes at a shear rate of 
1000 s
–1
 Antibodies or inhibitors were added 15 minutes before perfusion. (A) Control. (B-D) 10B12 at 
50, 100, or 300 µg/mL, respectively. (E) scFv 1C3 at 100 µg/mL. (F) 6F1 at 20 µg/mL. (G) GFOGER-
GPP at 500 µg/mL. (H) ADP-receptor and TxA2 blockade by 40 µM MRS2179, 20 µM AR-C69931MX, 
1 U/mL apyrase, and 100 µM ASA. Images shown are representative of 3 to 9 independent 
experiments. Collagen fibers are visible in some of the panels. Original magnification, x 60. 
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flowing blood. Again, thrombus volume increased linearly
 
in time (Figure 2B). No 
differences in platelet deposition were
 
observed within the donor population, relating to 
genetic polymorphisms
 
of GPVI, α2β1, or GPIbα. By the 4-minute end point, 17.9% ±
 
0.8% of the surface was covered by platelets. Most platelets
 
were deposited as 
interconnected islets originating from individual
 
aggregates. The mean feature size was 
176 ± 16 µm
2
,
 
an area corresponding to approximately 40 platelets. Single
 
platelets 
made up 22% of features, whereas 10% were large aggregates
 
corresponding to 130 
platelets or more (Figure 3A). Large numbers
 
of blebbing platelets were observed in 
direct contact with collagen
 
fibers, and staining with OG488-annexin V revealed 8.3% ±
 
0.7% coverage of PS-exposing platelets. To provide a measure
 
of procoagulant platelets 
independent of the total number of
 
adherent cells, the ratio of the 2 surface parameters 
was expressed
 
as Pi, giving a value of 0.43 ± 0.03. Thrombin generation
 
was absent 
during and after perfusion because no fibrin or D-dimer
 
was observed. Including Fragmin 
(0.5 U/mL) as an additional
 
anticoagulant did not change platelet deposition or annexin
 
V 
binding from PPACK-only controls (data not shown).
 
 
Blocking GPVI by 10B12 inhibited CRP- and collagen-induced platelet
 
aggregation in vitro
19
. Static platelet adhesion to CRP was
 
abolished at 5 µg/mL and 
decreased by 80% ± 4%
 
(n = 4) to collagen fibers at 25 µg/mL. However, under
 
flow, a 
concentration curve for 10B12 (Figure 4) showed that, up to 300 µg/mL, surface 
coverage with platelets did not significantly decrease (r  = 0.22; P = .42), though, 
 
 
Figure 2 Thrombus formation measured by surface area coverage or thrombus volume is linear 
in time. (A) Phase-contrast video images captured during the flow of PPACK-anticoagulated whole 
blood over collagen at 1000 s
–1
 were analyzed for platelet surface area coverage, which was plotted 
against perfusion time. Linear regression showed R
2
 = 0.97-0.99 (n = 3). (B) Thrombus volume was 
measured using blood supplemented with 30% of calcein-labeled autologous platelets. Z-stacks of x-y 
scans were measured in real-time by 2-photon laser scanning microscopy. Fluorescence image stacks 
were reconstructed 3 dimensionally and analyzed. Plots of thrombus volume compared with time were 
linear up to 300 s (R
2
 = 0.99). Representative plots are shown in panels A and B. 
2
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dramatically, platelet aggregates were absent (Figure 1B-D).  
Biosensor data
 
indicated that at 300 µg/mL 10B12, occupancy of recombinant
 
GPVI had reached more than 97% (data not shown). The predominance
 
of single 
platelets with increasing 10B12 concentrations, obvious
 
to the eye, was quantified by 
image analysis as almost complete
 
elimination of larger aggregates (P < .0001) at 50 
µg/mL
 
10B12, and the mean area was reduced to 37 ± 2 µm
2 
from 176 ± 16 µm
2
 (P < 
.001) (Figure 3B). In contrast to platelet adhesion, surface coverage of PS-exposing 
platelets decreased progressively with the 10B12 concentration with an IC value of 23 
µg/mL (r2 = 0.94; P < .01) (Figure 4), and blebbing platelets were no longer visible. At
 
the highest concentration of 10B12 tested, the Pi was reduced
 
to 0.02 ± 0.005 (P < .001), 
indicating strong blockade
 
of GPVI function.
 
 
ScFvs 1C3 and 10B12 recognizes distinct epitopes, and 1C3 is
 
incapable of 
blocking static platelet adhesion to CRP or collagen-induced
 
platelet aggregation
19
. As 
expected, 1C3 (100 µg/mL) did
 
not alter either the surface coverage (Figure 1E) or the 
size
 
and morphology (Figure 3C) of the formed thrombi. However, 1C3 halved the PS 
expressing surface coverage (Figure 4), suggesting
 
that the 1C3-binding site is relevant 
for GPVI function, possibly
 
by influencing receptor clustering or dimerization. The Pi 
obtained
 
with 1C3 was reduced to 0.24 ± 0.07 (P < .05, relative
 
to control), a significantly 
higher Pi than with 100 µg/mL
 
10B12 (P < .001). Coinhibition with 10B12 and 1C3 did not
 
change surface coverage from that of 10B12 alone (data not shown).
 
 
To study the dynamics of platelet activation, Ca
2+
 signal generation
 
was 
measured in real-time under flow from single, Fluo-3-labeled
 
platelets coming in contact 
with collagen. Control platelets
 
exhibited a strong Ca
2+
 response, sometimes preceded 
by an initial
 
Ca
2+
 spike (Figure 5A). A submaximal dose (50 µg/mL) of 10B12 decreased 
the Ca
2+
 signal amplitude (Figure 5B). Although blocking GPVI did not abolish primary 
adhesion, the increased translocation of platelets across the collagen surface was 
observed
 
during Ca
2+
 measurements. Increasing the 10B12 concentration
 
to 300 µg/mL 
reduced the Ca
2+
 signal slightly further
 
(Figure 5C). No difference from controls was 
observed in the averaged Ca
2+
 response with 1C3 (100 µg/mL), though Ca
2+-
spiking 
occurred in individual platelets (Figure 5D). Together, these
 
data indicate that blocking of 
GPVI with 10B12 potently suppressed
 
collagen-dependent platelet activation pathways 
without eradicating
 
primary adhesion.
  
    50
Collagen receptors and human thrombus formation 
 
 
79 
 
 
Figure 3 Effects of inhibitory antibodies and receptor antagonists on size distribution of platelet 
aggregates during thrombus formation. Histograms were obtained by image analysis of phase-contrast 
micrographs obtained from perfused collagen surfaces. Estimated numbers of platelets per feature 
were 1 to 2 ( ), 2 to 8 ( ), 8 to 40 (  ), 40 to 130 ( ), and more than 130 platelets ( ). (A) 
Control. (B) 10B12 at 50 µg/mL. (C) 1C3 at 100 µg/mL. (D) ADP receptor and TxA2 blockade. (E) 6F1 
at 20 µg/mL. (F) GFOGER-GPP at 500 µg/mL. Data (A-F) are mean ± SE from 3 donors. Statistical 
significance compared with the control was established from contingency tables (
2
analysis). 
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Blocking of GPIb or α2β1 reduces primary adhesion and aggregate formation, but 
blocking only α2β1 inhibits PS exposure  
High levels of VWF and high α2β1 density have been correlated
 
with increased 
platelet deposition on collagen
32,33
, whereas
 
patients with VWF concomitant with low 
α2β1 expression bleed more
 
than patients with either condition alone
34
. The essential 
nature
 
of GPIb and α2β1 in human platelet deposition on collagen under
 
flow has been 
emphasized
23,32,35
, though other studies failed
 
to detect consistent involvement of α2β1
4
. 
This prompted us to
 
revisit the topic in the context of molecular interplay with
 
GPVI using 
the following antagonists: 12G1 Fab2 fragment, recognizing
 
amino acids 1 to 59 of 
GPIbα, hinders platelet adhesion to collagen
 
by inhibiting VWF-GPIb interaction at high-
shear
24,25
; anti-α2
 
mAb 6F1, whose epitope within the I-domain is separate from
 
the 
MIDAS motif and lies between residues 173 and 259
36
; and
 
the GFOGER-GPP peptide, 
which inhibits collagen binding through
 
the α2 MIDAS
37
.
 
 
 
Figure 4 Inhibition of GPVI causes dose-dependent reduction in platelet PS exposure but not in 
total surface coverage. Blood was treated with 10B12 at 10-300 µg/mL (white symbols) or 1C3 at 
100 µg/mL (black symbols). Total surface coverage of platelets (squares) and surface coverage of 
OG488-labeled annexin V binding platelets (circles) were measured after 4 minutes of perfusion. Data 
represent mean ± SE from 3 to 17 experiments performed on the blood of 3 donors. **Significant 
difference from 10B12 treatment (P < .001) and from control (P < .05). 
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The importance of GPIb in primary adhesion
4
 was reconfirmed
 
under the shear 
rate conditions used here. Using 12G1 Fab2 at
 
a maximally effective dose of 40 µg/mL, 
the overall surface
 
coverage was reduced by 50% ± 14% (Figure 6), which confirms
 
that 
at (arterial) shear rates of approximately 1000 s
–1
,
 
platelet adhesion to collagen is only 
partially dependent on
 
VWF-GPIb interaction
38,39
. Although in 2 donors surface coverage
 
was strongly inhibited (63% and 67%), 2 gave a weaker reduction
 
in thrombus formation 
(38% and 45%), but the differential response
 
did not correlate with –5C/T polymorphism. 
For all donors,
 
blocking of GPIb strongly influenced platelet tethering. GPIb -blocked
 
platelets moved swiftly over the collagen surface, but, once
 
adherent, they became fully 
activated. Adding 12G1 Fab2 reduced
 
the PS exposure of platelets, but this simply 
reflected the
 
decrease in surface coverage (Figure 6A) without a change in
 
Pi. Like 
12G1, saratin, which blocks the binding of VWF to collagen
40
,
 
caused only a partial 
reduction of platelet surface coverage
 
(68% ± 14.5%) and annexin V staining (27% ± 
0.3%;
 
n = 2).
 
 
 
Figure 5 Effects of inhibitory antibodies and receptor antagonists on Ca
2+
 responses of platelets 
interacting with collagen under flow. Blood was spiked with 10% Fluo-3–loaded autologous platelets, 
incubated with antagonists, and perfused over collagen, as indicated for Figure 1. Changes in [Ca
2+
]i 
were recorded during perfusion in single collagen-adherent platelets. Traces above are averaged 
curves from 15 to 25 platelets (3 donors); traces below are representative curves from single platelets. 
(A) Control. (B) 10B12 at 50 µg/mL. (C) 10B12 at 300 µg/mL. (D) 1C3 at 100 µg/mL. (E) 6F1 at 20 
µg/mL. (F) GFOGER-GPP at 500 µg/mL. (G) ADP-receptor and TxA2 blockade, as in Figure 1. 
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Inhibition of α2β1 integrin by mAb 6F1, at a saturating concentration
 
of 10 to 20 
µg/mL, reduced surface coverage in all donors
 
by approximately 30% ± 11% (Figure 6A). 
The tethering platelets reluctantly anchored to collagen fibers and, on arrest, formed only 
small, dense aggregates (Figure 1F). Image analysis indicated a smaller mean 
 
Figure 6 Blocking of GPIbα or α2β1 partially reduces surface coverage on collagen, but 
blocking only of α2β1 affects PS exposure. (A) Blood was treated with 12G1 Fab2 at 40 µg/mL 
and 6F1 at 20 µg/mL or GFOGER-GPP at 500 µg/mL and was perfused over collagen, as 
described for Figure 1. Data present surface coverage of platelet deposition or OG488-labeled 
annexin V binding (mean ± SE, from 4-6 experiments). **P < .01, and *P < .05 compared with 
matched controls. (B) Blood was treated with combinations of anti-α2 6F1 or GFOGER and anti-β1 
4B4 (10 µg/mL). Data (mean ± SE) present the proportion of phase- or annexin V–positive surface 
coverage relative to matched controls. All combinations significantly inhibited platelet responses 
compared with respective controls (*P < .05; n = 2) but not with each other. 
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aggregate size of 117 ± 9 µm   with a shift toward round structures (P < .001). Aggregate 
sizes showed a kurtotic distribution (P < .0001), with a 50% increase in mid-sized 
features (Figure 3E). Similarly, GFOGER-GPP significantly reduced surface coverage by 
approximately 45% ± 13% at a maximally effective dose of 500 µg/mL (Figure 6A). 
Changes in aggregate morphology closely matched those obtained with 6F1 mAb—that 
is, aggregates appeared as round structures (Figure 1G), of smaller, average size 
(Figure 3F).  
Inhibition of α2β1 with either mAb 6F1 or GFOGER-GPP had a small
 
but 
significant effect (P < .01) on the exposure of PS (Figure 6A). The Pi was reduced from 
0.43 ± 0.03 to 0.30 ± 0.04 (P < .05) and 0.37 ± 0.08 (not significant), respectively. To 
ensure maximal blocking of α2β1, we tested combinations of antagonists binding 
different epitopes. The most effective of 3 anti-β1 mAbs tested, 4B4—against the 
activatory hinge region 207 to 21822—caused less inhibition than GFOGER or 6F1 (data 
not shown). Slight further inhibition was seen when 6F1 was combined with 4B4 or 
GFOGER, but these reductions were not significant (Figure 6B). A role of α2β1 in 
platelet signaling was also supported by the decreased Ca
2+
 response of the collagen-
adherent
 
platelets. With both 6F1 (Figure 5E) and GFOGER-GPP (Figure 5F), the 
average Ca
2+
 response was decreased, and the responses of most single platelets 
showed transient or spiking increases
 
in intracellular Ca
2+
. These findings reconfirm the 
contribution
 
of GPIb and α2β1 to collagen-induced thrombus formation but underscore
 
their different roles. Blocking GPIb interfered with platelet
 
tethering and initial anchorage 
and dispersed aggregates with
 
little effect on PS exposure, but α2β1 blockade reduced 
primary
 
adhesion (partially by prolonging firm anchorage) and restricted
 
thrombus size, 
platelet activation, Ca
2+
 signaling, and PS exposure.
 
 
Combined inhibition of GPVI with either GPIb or α2β1 integrin completely 
abolishes thrombus formation  
Coinhibition of GPVI with 10B12 (100 µg/mL) and of GPIb
 
with 12G1 Fab2 (40 
µg/mL) resulted in almost complete
 
abolition of platelet adhesion, with remaining single 
platelets
 
covering not more than 2% of the surface; PS-exposing platelets
 
were hardly 
detected (Figure 7A-B). Similarly, coinhibition of GPVI and α2β1 with 6F1 (20 µg/mL) or 
GFOGER-GPP (500 µg/mL) completely inhibited stable platelet adhesion and all 
subsequent activation events, eradicating thrombus formation (Figure 7A-B). Calcium 
responses, measured in platelets adhering in the presence of 6F1 and 10B12, 
resembled the responses measured
 
in the presence of 10B12 alone (data not shown). 
2
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In contrast, combined blocking of GPIb and α2β1 had a less dramatic
 
effect on 
platelet deposition and aggregation because significant
 
numbers of small aggregates 
could still be observed. Surface
 
coverage after combined blockade of GPIb with α2β1 
was reduced
 
by approximately 70% (Figure 7A), a greater effect than achieved
 
by 
blocking either receptor individually (P < .05). The remaining
 
platelets were in an 
activated state, judged by the relatively
 
high surface coverage of PS-exposing platelets 
and the apparent
 
increase in Pi to 0.72. In conclusion, our data show that GPIb
 
and α2β1 
have partially overlapping functions in mediating human
 
platelet adhesion and GPVI-
dependent thrombus formation.
 
 
 
Figure 7 Combined inhibition of GPVI with GPIb or α2β1 abolishes collagen-induced 
thrombus formation. Blood was treated with the indicated combination of antagonists before 
perfusion over collagen: 10B12 at 100 µg/mL and 6F1 at 10 to 20 µg/mL, GFOGER-GPP at 500 
µg/mL or 12G1 Fab2 at 40 µg/mL perfused over collagen as in Figure 1. (A) Surface coverage of 
platelet deposition or OG488-labeled annexin V binding (mean ± SE, from 4-6 donors). **P < .001, 
and *P < .05 compared with single antibody controls. (B) Representative phase-contrast images 
after perfusion, also showing visible collagen fibers. Original magnification, x 60. 
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Blocking of ADP receptors further inhibits thrombus formation restricted by GPVI 
or α2β1 blockade  
ADP regulation of thrombus size has been attributed to the platelet
 
P2Y12 
purinergic receptor; P2Y1 regulates the onset of thrombus
 
formation
41
. To obliterate any 
effects of ADP, we used apyrase
 
in conjunction with specific P2Y12 and P2Y1 inhibitors. 
Full
 
inhibition of ADP- or TxA2-mediated (inhibited by ASA) effects
 
reduced the surface 
coverage by 43% (P < .001). The morphology
 
of platelet deposition was similar to that 
under GPVI blockade:
 
a layer of single platelets remained on the collagen (Figure 1H), 
and aggregates were eradicated (Figure 3E). However, combined blockade of ADP and 
TxA2 actions had no effect on Pi (0.53 ± 0.15 [not significant]) or platelet blebbing, 
though it slightly reduced the Ca
2+
 response (Figure 5G).  
 
Figure 8 ADP antagonism further reduces thrombus formation after the inhibition of GPVI or 
α2β1. Blood was treated with 10B12 at 50 or 300 µg/mL, 6F1 at 20 µg/mL with or without ADP 
receptor antagonism (40 µM MRS2179, 20 µM AR-C69 931MX, and 1 U/mL apyrase). (A) Total 
surface coverage of platelets and of annexin V–positive platelets was measured (mean ± SE from 
4-6 donors). **P < .01 compared with control condition. (B) Histograms of feature sizes from 
phase-contrast micrographs, determined as in Figure 2, where individual antibody effects are 
shown. Estimated numbers of platelets per feature were 1 to 2 ( ) , 2 to 8 (  ), 8 to 40 ( ) , 40 
to 130 ( ), and more than 130 platelets ( ). Data are means ± SE from 3 donors. 
Chapter 4 
86 
 
Inhibiting the ADP pathway further decreased surface coverage
 
when combined 
with GPVI blockade. Irrespective of the 10B12
 
concentration (50 or 300 µg/mL), ADP 
receptor antagonism
 
caused an additional reduction in platelet surface coverage
 
(55%; P 
< .001) (Figure 8A), suggesting that the presence of ADP was not solely derived from 
GPVI-dependent secretion. Because GPVI inhibition itself abolished aggregate 
formation, the additional blockade of ADP receptors had no further effect on the mean 
feature size: 24 ± 2.6 µm2 (ADP + GPVI blockage) and 23 ± 1.8 µm2 (GPVI blockade 
alone) (Figure 8B). When applied together with 10B12, ADP receptor
 
blockade reduced 
the number of PS-exposing platelets by attenuating
 
platelet deposition because the Pi 
did not significantly decrease.
 
When the ADP receptors were coinhibited with α2β1 (20 µg/mL
 
6F1), surface 
coverage decreased by 41% (Figure 8A), and the mean aggregate size decreased from 
121 ± 8 to 44 ± 4 µm2 (P < .0002) (Figure 8B). Again, this was accompanied
 
by a small 
decrease in PS-exposing platelets and an unaltered
 
Pi value. These results let us 
conclude that ADP (from various
 
sources) stimulates GPVI- and α2β1-dependent 
adhesion and contributes
 
to aggregate formation but is insufficient to promote PS 
exposure.
 
Thus, platelets respond to ADP by inducing one of the thrombus
 
end points, 
aggregation, in contrast to full activation through
 
GPVI.
 
 
Discussion 
The present study shows that, in humans, collagen-induced thrombus
 
formation 
under high shear rate requires the orchestrated interplay
 
of several platelet receptors. 
Using antibodies and peptides
 
allowed clarification of the complementary and 
overlapping roles
 
of the GPIb/V/IX complex, α2β1 integrin, GPVI, and the platelet
 
purinergic receptors in the processes of platelet adhesion,
 
aggregation, and procoagulant 
activity. Our results, though
 
formally in line with the original 2-step adhesion-activation
 
model, also revealed its oversimplification. Although the main
 
role of GPIb is to provide 
initial contact with collagen-bound
 
VWF, it stabilizes the anchorage of thrombi on 
collagen together
 
with α2β1. GPVI is involved in GPIb- and α2β1-mediated adhesion
 
through activation, and it is the main signaling receptor during
 
thrombus formation. 
Conversely, α2β1 assists GPVI in signaling.
 
Complete abrogation of adhesion and 
subsequent activation thus
 
requires simultaneous inhibition of GPVI together with either
 
GPIb or with α2β1.
 
 
We find that GPVI has a crucial role in regulating human thrombus
 
growth. 
Inhibiting GPVI resulted in the complete loss of platelet
 
aggregates and the full inhibition 
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of collagen-induced Ca
2+ 
mobilization and PS exposure. In contrast, the adhesion of 
single,
 
nonaggregated platelets was not significantly diminished unless
 
ADP was also 
antagonized, probably eliminating the contribution
 
of α2β1. These results corroborate 
findings from earlier flow
 
studies with GPVI-deficient platelets in which the surface 
coverage
 
equaled that obtained with αIIbβ3 antagonists
6
. A recent study
 
using the blood 
of patients with GPVI deficiency also showed
 
the obliteration of collagen-induced 
thrombus formation though
 
a layer of single platelets was still visible in the PDF-format
 
micrographs
42
, supporting our conclusions. In contrast, these
 
results clearly deviate from 
those obtained in the first flow
 
study using GPVI-deficient mice
13
, which showed the total 
abolition
 
of platelet-collagen adhesion. In mice, GPVI function was severely
 
impaired 
when more than 90% of receptors are blocked. At the
 
highest level of the scFv 10B12 
used here (300 µg/mL),
 
calculated receptor occupancy was 97%, supporting the idea 
that
 
unaltered platelet adhesion was not caused by the inadequate
 
inhibition of GPVI. 
Although it is possible that antibody dissociation
 
or displacement by ligand may allow a 
proportion of GPVI to
 
remain functional during multireceptor interaction under flow,
 
10B12 caused the near-complete, concentration-dependent abolition
 
of platelet 
activation processes such as PS exposure, Ca
2+
 response,
 
and aggregate formation. 
While this paper was in preparation,
 
a true GPVI knockout model was generated in mice 
in which thrombus
 
formation was similar to that observed in our study
43
. The reasons
 
for 
the discrepancies regarding the different mouse data remain
 
to be elucidated.
 
 
Both GPIb and α2β1 were implicated in the primary adhesive step
 
at high shear 
rate, as others suggested after using recombinant
 
receptors in liposomes
44
.
 
Inhibiting 
GPIb or α2β1 on its own,
 
but not GPVI, dramatically reduced the number of collagen-
adherent
 
platelets, though those remaining became activated. The interplay
 
of GPVI with 
both receptors is implicit in the near-complete
 
suppression of adhesion using the 
combined blockade of GPIb
 
and GPVI or α2β1 and GPVI. This indicates that all 3 
receptors
 
are required for optimal adhesion. As a first step, GPIb tethers
 
the platelet, 
allowing other receptors to interact, which perhaps
 
further regulates GPIb function, as 
recently reported
42,45
.
 
Adhesion through α2β1 follows closely, with GPVI and α2β1 acting
 
interdependently. Initial α2β1 binding to high-affinity collagen
 
sequences, not requiring 
activation, supports the weak GPVI-collagen
 
interaction, which, in turn, mediates the 
switch of the integrin
 
to the high affinity required for stable adhesion. In line with
 
this, 
blocking GPVI with 10B12 caused a more dramatic (but not
 
full) reduction in surface 
coverage on collagen type III containing
 
only low-affinity xxxGER sequences, but not on 
collagen type
 
I containing the high-affinity GFOGER sequence used in this
 
study (P.A.S., 
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unpublished data, 2002). Collagen-dependent differences
 
in GPVI inhibition were also 
observed elsewhere
6
. The failure
 
of α2β1 blockade to cause further reduction in Ca
2+
 
response and
 
PS exposure in the presence of 10B12 implies that α2β1 signaling
 
occurs 
downstream from GPVI. This conclusion was reinforced
 
by almost complete loss of 
binding to adherent platelets, in
 
the presence of 300 µg/mL 10B12, of an antibody that 
recognizes
 
only the fully activated state of α2-integrin, IAC-1 (7F6)
46
.
 
However, the 
signaling end points of this study (Ca
2+
, PS exposure,
 
and aggregate size) were 
measured to identify the contribution
 
of specific receptors rather than to study the detail 
of the
 
signaling processes, which will be subject to further study.
 
 
The present model of human thrombus formation deviates in certain
 
respects 
from that derived from murine data. Although murine
 
thrombus formation seems to rely 
more on GPVI, it was recently
 
shown that the interplay of α2β1 with GPVI is required for 
full
 
GPVI-induced platelet activation and procoagulant activity,
 
using β1-deficient mouse 
platelets
28
. In addition, in another
 
α2(–/–) mouse flow model, platelet-collagen interaction
 
was severely impaired
47
. Thus, the main deviation between human
 
and mouse concerns 
the role of primary receptors in platelet
 
adhesion to collagen under flow. There may be 
several nonexclusive
 
reasons for discrepancy. First, human α2β1 may be competent to
 
bind GFOGER sequences in type I collagen but not those of lower
 
affinity, such as 
GASGER
48
, before GPVI involvement. Second,
 
human α2β1 may become activated 
independently of GPVI, perhaps
 
caused by GPIb activity. It has been proposed that GPIb 
uses
 
the same Fcγ-mediated signaling pathway as GPVI
49
, and it reportedly
 
induces 
rapid Ca
2+
 signaling under flow
50
. Similarly, the GPVI-independent
 
presence of ADP in 
the blood may activate α2β1 at an early stage.
 
Third, the threshold for α2β1 activation of 
human platelets may
 
be low, that is, small signals from the slight percentage of
 
GPVI not 
blocked by 10B12 may still be sufficient to trigger
 
α2β1 for adhesion. Fourth, the human 
integrin-collagen contact—though
 
dependent on GPIb and GPVI—may be more prone to 
autocrine
 
signaling than that in mouse platelets. Finally, the considerable
 
differences in 
human and murine GPVI structures may influence
 
their contribution to the platelet-
collagen interaction. Murine
 
GPVI shares only 64% homology with the human receptor, 
and its
 
cytoplasmic domain, half the length of the human 51-amino acid
 
tail, lacks 
signaling motifs
51,52
. A human-to-mouse mutation,
 
K59E, was shown to decrease GPVI 
binding to CRP, indicating
 
important differences in the function of human and murine 
receptors
19
. 
After the primary platelet-collagen contact, platelets form
 
aggregates or become 
procoagulant; both processes contribute
 
to full-blown thrombus formation. We defined 2 
Collagen receptors and human thrombus formation 
 
 
89 
conditions in
 
which the formation of thrombi was inhibited: blocking GPVI
 
and blocking 
ADP- and TxA2-mediated events. Inhibiting GPVI
 
suppressed aggregate formation and 
signaling processes, detected
 
as the greatly reduced Ca
2+
 and procoagulant response. 
However,
 
ADP/TxA2 antagonism reduced Ca
2+
 signaling only slightly, though
 
no 
aggregates were formed, with no effect on Pi. GPVI regulates
 
aggregate formation 
through autocrine ADP/TxA2 secretion, in
 
part through synergism with Gi/q-coupled 
receptors
53
. We found
 
that ADP contributed to aggregation and primary adhesion but
 
that 
its influence was not eliminated by GPVI inhibition. This
 
implies that ADP was derived 
from sources other than GPVI-stimulated
 
platelets.
 
 
Platelet aggregation was mostly accompanied by high Ca
2+
 signaling
 
and PS 
exposure, even when blocking shear-dependent adhesion
 
through GPIb. The platelets 
that escaped inhibition were activated,
 
as demonstrated by an unchanged Pi. A notable 
exception occurred
 
with the blocking of α2β1 function. Ca
2+
 signaling, PS exposure,
 
and 
aggregate formation were all affected. This implies that
 
α2β1 has an activatory effect on 
these processes, in synergy with
 
GPVI. Most, if not all, integrins exhibit inside-out and 
outside-in
 
signaling
54
, suggesting that outside-in signaling from activated
 
α2β1 can 
participate in platelet activation. We have previously
 
shown that integrin-mediated 
adhesion to fibrinogen or collagen
 
increases the responsiveness of platelets toward 
GPVI agonists
55
.
 
Similar cross-talk between GPVI and α2β1 also likely controls
 
platelet 
activation in the present experiments. Previously,
 
others have linked α2β1 activation with 
αIIbβ3 up-regulation
56,57 
and established cross-talk between α2β1 and αIIbβ3
58
.
 
 
Together, the results presented here advance the idea that human
 
thrombus 
formation occurs through the concerted action of several
 
receptors: the interplay of 
GPIb/V/IX, integrin α2β1 and GPVI
 
enables platelet deposition, and GPVI in cross-talk 
with α2β1 mediates subsequent thrombus formation, additionally supported
 
by ADP. Yet 
these receptors may not be the only determinants
 
of human platelet collagen interaction 
because other collagen
 
receptors
35,57,59,60
 may participate in the early stages of
 
platelet 
contact with collagen, and new receptors are being
 
discovered
61,62
. Ultimately, these 
other receptors may participate
 
in the interaction and may be shown to allow further fine-
tuning
 
of the receptor cross-talk identified in this study. 
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Abstract 
Both collagen and tissue factor can be initiating factors in thrombus formation. 
We investigated the signaling pathway of collagen-induced platelet activation in 
interaction with tissue factor-triggered coagulation during the thrombus-forming process. 
In murine blood flowing over collagen, platelet exposure of phosphatidylserine and 
procoagulant activity, but not adhesion, completely relied on each of the following 
signaling modules: glycoprotein VI (GPVI), FcR γ-chain, Src kinases, adaptor protein 
LAT, and phospholipase Cγ2 (PLCγ2). Upon flow in the presence of tissue factor, these 
signaling components were essential for platelet aggregation and greatly enhanced fibrin 
clot formation. Collagen-stimulated thrombin generation relied on the presence and 
activity of GPVI, FcR γ-chain, Src kinase, LAT and PLCγ2. The physiological importance 
of this GPVI pathway was shown in a FeCl3-induced in vivo murine thrombosis model. In 
both venules and arterioles, signaling through GPVI, FcR γ-chain and Src kinases 
enhanced the formation of phosphatidylserine-exposing and fibrin-rich thrombi. In 
conclusion, the GPVI-PLCγ2 activation pathway regulates collagen-dependent 
coagulation in venous and arterial thrombus formation. 
Introduction 
 Thrombus formation can be initiated by both platelet- and coagulation-
activating factors. Collagens in the extracellular matrix and other vascular layers are 
though to act as principal platelet-activating components of the damaged vessel wall; 
they also provide a surface for von Willebrand factor (vWf) adhesion
1
. Tissue factor, also 
exposed in damaged vessels, is a key trigger of the coagulation process
2
. Because of 
the proposed major role of platelets in arterial thrombosis and the importance of 
coagulation in venous thrombosis, current understanding is that collagen/vWf-mediated 
events are more important in arteries, while tissue factor plays a more prominent role in 
venous thrombus formation. 
Flow studies with human and mouse blood have established that the signaling 
receptor, glycoprotein VI (GPVI), exclusively mediates collagen-induced platelet 
procoagulant activity, thus linking the processes of platelet activation and coagulation
3-5
. 
This procoagulant platelet response is mediated by a prolonged and potent rise in 
cytosolic [Ca
2+
]i, which results in exposure of procoagulant phosphatidylserine (PS) at 
the platelet outer surface
6
. PS exposure is a key regulating factor in the coagulation 
process. For instance, PS-containing membrane surfaces dramatically increase the 
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formation of factor Xa and thrombin
7
. However, several authors have argued that this 
platelet response has only an assistant role in coagulation and that, in vivo, other platelet 
reactions may play important roles as well
2,8
. Thus, while there is no doubt that platelets 
enhance thrombin generation (coagulation) in plasma or whole blood, the precise 
mechanism is still a matter of debate. 
The platelet immunoreceptor GPVI is co-expressed with the Fc receptor (FcR) 
γ-chain, although the latter also interacts with other platelet receptors, e.g. GPIb
9
. In 
human and mouse platelets, activation of GPVI by collagen or other ligands results in a 
complex cascade of signaling events
10-12
. The initial step is tyrosine phosphorylation of 
the FcR γ-chain by the Src family kinases, Fyn and Lyn. Subsequent activation of the 
tyrosine kinase Syk leads to phosphorylation of multiple signaling proteins, including the 
adaptor proteins LAT, SLP-76 and SLAP-130, and further the G-protein regulator Vav 
and phospholipase C-γ2 (PLCγ2)
13
. GPVI stimulation activates various other protein 
kinases, including Btk, Tec, phosphoinositide 3-kinase and, further downstream, protein 
kinase C, Erk1/2 and focal adhesion kinase, as a result of which platelets respond by 
integrin activation, Ca
2+
 increase, aggregation, shape change, secretion and 
procoagulant activity. Although earlier work has shown that GPVI plays a key role in the 
collagen-induced platelet procoagulant activity in both stasis and flow
14
, it is still unclear 
which signaling elements downstream of GPVI contribute to this platelet reaction. 
Evidence that GPVI plays a key role in arterial thrombosis comes from recent in 
vivo studies with mice, where the platelet aggregation in vivo was followed after ligation 
of arteries, causing exposure of vascular collagen
1,15
. Absence of GPVI (as in FcR γ-
chain null mice) or down-regulation of GPVI (as in mice treated with JAQ1 antibody) 
appeared to suppress intravascular formation of platelet aggregates. Thus, knowing the 
in vitro evidence for a procoagulant effect of GPVI, we hypothesized that GPVI can also 
drive the coagulation process during thrombus formation. 
In the present study, we used mice deficient in GPVI or in one of the signaling 
proteins downstream of GPVI to investigate the signal transduction route leading to 
GPVI-induced PS exposure, coagulation stimulation and fibrin formation both in vitro and 
in vivo. We performed whole-blood flow studies partly in the presence of tissue factor-
triggered coagulation to determine the functional effects of PS exposure. Furthermore, in 
vivo experiments where thrombus formation was induced with free radical-forming FeCl3, 
allowed us to study the importance of this process in a thrombosis model known to rely 
on thrombin generation and coagulation
16
. The data showed that also in vivo the 
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signaling cascade from GPVI to PLCγ2 led to coagulant activity and enhanced thrombus 
formation. 
Materials and Methods 
Materials 
Fibrillar type-I collagen (Horm) was purchased from Nycomed (Munich, 
Germany). MRS2179, a P2Y1 antagonist, was from Sigma (St. Louis, Mo, USA). Annexin 
A5 labeled with Oregon green 488 (OG488) came from Nexins Research (Hoeven, The 
Netherlands). OG488-conjugated fibrinogen and annexin A5 labeled with Alexa fluor 647 
(AF647) were from Molecular Probes (Leiden, The Netherlands). PD173952 was a gift 
from Pfizer (Ann Arbor, MI, and Sandwich, UK).Lotrafiban was a gift from 
GlaxoSmithKline (Middlesex, UK). Anti-GPVI antibody JAQ1 was produced and modified 
as described
9
; Fab fragments were generated and in part used for fluorescein labeling
3
. 
Blocking anti-murine GPIb monoclonal antibody (mAb) Xia.B2 was from Emfret Analytics 
(Würzburg, Germany). ARC69931MX, an antagonist of the P2Y12 receptor, was from 
AstraZeneca R&D (Charnwood, UK). Aspirin was from Lorex Synthélabo (Maarssen, The 
Netherlands). Recombinant tissue factor came from Dade (Düdingen, Switzerland); Z-
Gly-Gly-Arg aminomethyl coumarin (Z-GGR-AMC) from Bachem (Bubendorf, 
Switzerland); H-Phe-Pro-Arg chloromethyl ketone (PPACK) from Calbiochem (La Jolla, 
CA); FeCl3 from Merck (Darmstadt, Germany). Other materials were obtained from 
sources described before
3
. 
Animals and blood collection 
Healthy 4-5 weeks old (11-21 g) or 12 week old C57Bl/6 (20-25 g) (wildtype) 
mice of either sex were obtained from Charles River (Maastricht, The Netherlands). 
C57Bl/6 mice deficient in the FcR γ-chain (-/-) were obtained from Taconics 
(Germantown, NY). Mice homozygously deficient in LAT or PLCγ2 were generated as 
described previously
17,18
, and bred from heterozygotes on a B6 background. Wildtype 
littermates were used as controls. Where indicated, wildtype mice were injected under 
anesthesia with 100 µg anti-GPVI JAQ1 antibody (in 100 µL saline) at 5 days before start 
of the experiment. Other anesthetized animals were injected with 100 µL of 1 mM Src 
kinase inhibitor, PD173952 (diluted in saline), at 10 min before experimentation. Efficacy 
of these treatments was verified with collected blood by flow cytometry and platelet 
aggregation measurements. For experiments in the absence of coagulation, blood was 
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collected under anesthesia by orbital puncture in 40 µM PPACK and 5 U/mL heparin, as 
described
3
. For experiments involving coagulation, blood was collected into 10% 0.129 
M citrate. Studies were approved by the local animal
 
care and use committees. 
Thrombus formation on collagen under flow 
Thrombus formation was measured ex vivo with blood from 12 week old mice 
which was perfused over a collagen surface as described before
4
. Briefly, an area of 
20×5 mm in the centre of a glass coverslip was coated with fibrillar Horm type-I collagen 
(50 µg/mL for 20 min at 37°C), blocked with Hepes buffer pH 7.45 (5 mM Hepes, 136 
mM NaCl, 2.7 mM KCl, 0.42 mM NaH2PO4 and 1% bovine serum albumin (BSA), and 
then placed in a parallel plate flow chamber (slit depth of 50 µm). Blood was incubated 
for 15 min with various inhibitors and/or fluorescent probes, and then perfused over the 
coverslip at a shear rate of 150-1000 s
-1
 for 4 min. Thereafter, the flow chamber was 
perfused with Hepes buffer pH 7.45 with 2 mM CaCl2 and 1 U/mL heparin and containing 
fluorescent-labeled annexin A5 (0.5 µg/mL) for 4 min. Bright-field phase contrast as well 
as non-confocal fluorescence images of adherent platelets were recorded using a 
Visitech microscope system equipped with two cameras
5
 or an inverted stage video 
microscope system (DM-IRB, Leica, UK)
19
. To inhibit GPIb activity we used the blocking 
anti-murine GPIbα mAb Xia.B2 (40 µg/ml), which was demonstrated to be equally 
effective as the earlier used blocking anti-GPIb antibody p0p/B (B. Nieswandt, 
unpublished results).  
For flow experiments without coagulation, blood collected in PPACK/heparin 
was used. For coagulation experiments, citrated whole blood was used, which was 
during perfusion exposed to 10% volume of 20 pM tissue factor in 200 mM CaCl2 upon 
entry into the flow chamber, as described for rat and human blood
5
. Platelet surface 
coverage of images was analyzed using ImagePro software (Media Cybernetics, Silver 
Spring, MD) for phase contrast images and Quanticell software (Visitech, Sunderland, 
UK) for fluorescent annexin A5 images. At least 10 different fields of view were averaged 
per experiment (no image processing). 
Two-photon laser scanning microscopy (TPLSM) 
For two-photon laser scanning microscopy (TPLSM), coverslips with thrombi 
were observed with a Bio-Rad 2100 multiphoton system. Excitation was by a Spectra-
Physics Tsunami Ti:Sapphire laser, tuned and mode-locked at 800 nm, producing pulses 
of 100 fs wide (repetition rate 82 MHz). Excitation at 647 nm was by a parallel-placed red 
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diode laser. Fluorescence was detected at 508 to 523 nm and above 660 nm. Thrombi in 
flow chambers, double labeled with OG-488 fibrinogen (green) and AF647-annexin A5 
(red), were scanned at the end of perfusions. Optical sections were recorded in Kalman 
filtering mode; no further image processing was performed. Mouse mesenteric vessels 
were imaged in situ using TPLSM, taking advantage of the high penetration depth and 
intrinsically high optical sectioning of this technique
20
. 
Thrombin generation measurement 
Murine platelet-rich plasma (PRP) and platelet-poor plasma (PPP) collected on 
citrate were used to measure thrombin generation with the thrombogram method
21
, 
adapted for murine plasma. Briefly, normalized PRP (1.5×10
8
 platelets/mL) was 
preincubated with an antagonist for 15 min and then with collagen for 10 min. Samples of 
40 µL PRP or PPP were pipetted into wells of a 96-well plate (Immulon 2HB; Dynex 
Technologies, Chantilly, VA), containing 10 µL tissue factor (6 pM) in buffer A (20 mM 
Hepes, 140 mM NaCl, 5 mg/mL BSA, pH 7.35). Coagulation was started by addition of 
10 µL Z-GGR-AMC (2.5 mM), dissolved in buffer B (20 mM Hepes, 100 mM CaCl2, 60 
mg/mL BSA, pH 7.35). Plates were immediately inserted into a fluorescence well-plate 
reader (Thermolab Systems, Helsinki, Finland or Molecular Devices, Spectra Max 
Gemini XS) and processed at 37°C
22
. Fluorescence accumulation from cleaved AMC 
was measured, and first derivative curves of accumulation of fluorescence were 
generated; calibrations were performed with human thrombin. 
Animal preparation and intravital microscopy 
Four to 5-week old mice were anesthetized by subcutaneous injection of 0.1 
mg/g body weight ketamine and 0.02 mg/g xylazine. Anesthesia was maintained by 
continuous infusion of ketamine (0.07 mg/g/h) through a subcutaneous polyethylene 
(PE)-10 catheter in the neck. Pharmacological agents were administered intravenously 
through a PE-10 catheter in the tail vein. Body temperature was kept at 37°C using an 
infrared heating lamp, controlled by a thermoanalyzer system connected to a rectal 
probe. 
A segment of the ileum was exteriorized through a right side abdominal incision. 
The mesentery was spread over a siliconized glass plate mounted on an electrically 
heated table (37°C) of a Leitz (Jena, Germany) intravital microscope, and continuously 
superfused with a Tyrode solution (130 mM NaCl, 5.6 mM KCl, 2.2 mM CaCl2, 0.56 mM 
MgCl2, 11 mM glucose, 13 mM sucrose, 25 mM NaHCO3 and 1.2 mM NaH2PO4; pH 7.35 
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at 37°C), supplemented with 1 µg/mL isoprenaline and saturated with 95% N2 and 5% 
CO2. The exteriorized ileum was kept moist with overlying wet gauze. Where indicated, 
fluorescently labeled compounds were infused (bolus, 100 µL) via the tail vein catheter 
either before or after FeCl3 application. 
Thrombus formation in vivo 
For in vivo experiments, fat-free mesenteric arterioles and proximate venules 
were selected. Before start of FeCl3 application, superfusion with Tyrode solution was 
stopped, and remaining fluid was carefully removed from the selected mesenteric tissue. 
Vessel wall damage was induced by topical application of 30 µL FeCl3 (500 mM), which 
remained on the tissue during experimentation. The intravascular reactions were 
observed by trans-illumination and fluorescence microscopy using a LL25x objective (NA 
0.35) and a CCD camera (Hamamatsu) for 600 s
23
. For each vessel, the following 
parameters were quantified off-line: lagtime to first observation of thrombus formation, 
thrombus height perpendicular to the vessel wall (percentage of the vessel diameter) at 
2, 5 and 10 min after FeCl3 application. Damaged mesenteric vessels were observed in 
situ, as described above, while specimens for histology were fixed in formaldehyde (10% 
in PBS), routinely processed and embedded in paraffin. Sections of 4 µm were cut and 
stained with hematoxylin and eosin. 
To determine wall shear rates in representative mesenteric arterioles and 
venules, several mice were injected with rhodamin 6G (30 µL of 1 mg/mL, intravenous) 
for labeling of circulating leucocytes. Fluorescence microscopy was applied to quantify 
centerline blood flow velocities of passing leucocytes, as described. Mean wall shear 
rates were 1183 s
-1
 in arterioles and 344 s
-1
 in venules. 
Statistical analysis 
Data from in vivo experiments displayed non-symmetrical distribution and are 
presented as median values with interquartile ranges. Differences between experimental 
groups were tested on significance with a non-parametric Mann-Whitney U test using the 
statistical package for social sciences (SPSS 11.0, Chicago, IL). 
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Results 
Components of the GPVI-PLCγ2 signaling pathway required for collagen-induced 
procoagulant activity of platelets in flowing blood 
In mouse and human platelets, functional activity of GPVI is required for 
collagen-induced aggregation and surface exposure of procoagulant PS
4,5
. To 
investigate which signaling proteins downstream of GPVI are involved in the 
procoagulant platelet response, we used genetically modified mice and specific blockers 
 
Figure 1 GPVI-PLCγ2 signaling pathway is required for collagen-induced PS exposure in 
flowing blood. PPACK-anticoagulated blood was perfused over collagen in the absence of 
coagulation. Perfusion was at 1000 s
-1
 for 4 min, followed by staining with fluorescent annexin A5 
(0.5 µg/mL). Wildtype blood was pre-incubated for 15 min with vehicle (control), 40 µg/mL JAQ1 
Fab (blocking GPVI) or 25 µM PD173952 (blocking Src kinases). Blood from mice lacking FcR γ-
chain, LAT or PLCγ2 was compared to blood from genetically matched wildtype mice. Otherwise, 
wildtype blood was pre-treated with vehicle or 40 µg/mL Xia.B2 mAb (blocking GPIbα), 10 µM 
lotrafiban (blocking integrin αIIbβ3) or 20 µM MRS2179, 50 µM AR-C69931MX and 100 µM aspirin 
(blocking effects of autocrine ADP/thromboxane A2). Data represent surface area coverage of all 
platelets (A) and of PS-exposing platelets (B), expressed as percentage of corresponding controls. 
Surface area coverage with wildtype platelets under control conditions was 17.5±5.5%, and 
coverage with fluorescent annexin A5 was 7.2±4.1%. Mean±SD (n=5-7); *P≤0.05 compared to 
control. 
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of key proteins in the PLCγ2 activation pathway. We used Fab fragments of JAQ1 mAb 
to block GPVI receptors and, in comparison, GPVI-null mice lacking the FcR γ-chain. Src 
kinase activity was abolished with the compound PD173952, which has recently been 
identified as a selective and specific inhibitor of Src-family kinases that is still active in 
blood. It essentially abolishes all collagen- but not thrombin-induced tyrosine 
phosphorylation events in platelets
19
. Furthermore, mice deficient in LAT
18
 or PLCγ2
17
 
were used to study the contribution of these downstream signaling entities. 
In the first experiments, PPACK-anticoagulated whole blood from wildtype or 
genetically modified mice was perfused over a collagen surface at a shear rate of 1000 s  ,
-1
i.e. representative of that found in murine arterioles. Using wildtype blood, platelets 
rapidly adhered to the collagen surface and partly assembled into aggregates. As shown 
before
4,24
, platelet deposition and aggregate growth on collagen increased about linearly 
with time. Blocking of GPVI with JAQ1 Fab fragments abolished platelet adhesion and 
aggregation (Figure 1A), also confirming earlier results
4,15
. Absence of FcRγ or treatment 
with Src kinase inhibitor resulted in a moderately reduced deposition of platelets on 
collagen; these platelets remained single and showed little tendency to aggregate. 
Similar results were obtained with blood from LAT-null or PLCγ2-null mice (Figure 1A). 
Post-staining of wildtype/control thrombi with OG488-annexin A5 revealed many 
single PS-exposing platelets (Figure 1B). Strikingly, virtually no PS-exposing platelets 
were detected when: GPVI was blocked (with JAQ1 Fab), FcR γ-chain was absent, Src 
kinases were blocked (with PD173952), or LAT or PLCγ2 was absent (Figure 1B). In 
sharp contrast, platelet deposition was only little affected by either blocking of GPIb-vWf 
interactions (with Xia.B2 mAb), secondary platelet responses due to release of ADP 
(with receptor antagonists MRS2179 and AR-C69931MX), thromboxane A2 (aspirin), or 
by blocking integrin αIIbβ3 (with lotrafiban) (Figure 1A). Also, these blocking conditions 
did not significantly influence PS exposure compared to the control situation (Figure 1B). 
A typical observation under control conditions was that wildtype platelets on the 
collagen surface only showed PS exposure when not assembled into aggregates. 
Conversely, aggregated platelets did not expose PS. We used the high resolution of 
TPLSM, allowing simultaneous detection of two fluorescent probes, to better 
characterize the populations of PS-exposing and aggregated platelets. With OG488-
fibrinogen and AF647-annexin A5 added to wildtype blood, fibrinogen label exclusively 
incorporated into platelet aggregates, whereas labeled annexin A5 was differently 
localized, only staining single platelets around the aggregates. After perfusion, platelets 
from FcR γ-chain null mice and also wildtype platelets treated with PD173952 failed to 
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bind fibrinogen, pointing to the requirement of the FcR γ-chain and Src kinases to the 
aggregate-forming process
19
. Together, these results indicate that the signaling 
components of the GPVI-PLCγ2 pathway (involving Src kinases, FcRγ, Syk and LAT) are 
indispensable for PS exposure on collagen under flow. The PS-exposing platelets 
typically represent a different population than the platelets assembled into aggregates 
and binding fibrinogen. 
Components of the GPVI signaling pathway determining platelet procoagulant 
activity and thrombus formation in flowing blood triggered with tissue factor 
To induce coagulation under flow conditions, citrated blood was mixed with 
tissue factor and CaCl2 just before entering the flow chamber. The perfusion protocol 
was such that coagulation occurred at physiological, millimolar Mg
2+
 and Ca
2+
 
concentrations
25
. With wildtype blood, perfusion in the presence of tissue factor resulted 
in PS exposure and the formation of platelet aggregates, which gradually transformed to 
 
Figure 2 GPVI/FcR γ-chain signaling pathway controls tissue factor-induced fibrin formation 
and platelet activation in flowing blood. Citrate blood from wildtype mice was incubated for 15 
min with vehicle, GPVI-blocking JAQ1 Fab, or Src kinase inhibitor PD173952 (see Figure 1). Blood 
was then perfused over collagen together with tissue factor (2 pM, f.c.) and CaCl2 (2 mM free Ca
2+
, 
f.c.) to allow coagulation. Standard perfusion time was 4 min at shear rate of 1000 s
-1
. Post-
labeling was with OG488-annexin A5 (0.5 µg/mL). Upper panels: phase-contrast images after 
perfusion (120×120 µm); middle panels: images of OG488-annexin A5 fluorescence (different 
fields, 150×150 µm); lower panels: TPLSM images of OG488-fibrinogen and AF647-annexin A5 
fluorescence (77×77 µm). Images are representative of 5-10 experiments. 
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clots trapping erythrocytes (Figure 2). TPLSM analysis indicated that the thrombi 
contained extensive networks of fibrin and aggregated platelets, which were surrounded 
by single PS-exposing platelets. Perfusion of JAQ1-treated blood (with blocked GPVI) or 
blood from FcRγ-null mice in the presence of tissue factor gave only limited platelet 
adhesion without aggregate formation. Fibrin formation was greatly suppressed, and only 
few PS-exposing platelets were observed (Figure 2). PD173952 was somewhat less 
inhibitory in the presence of tissue factor, with small fibrin(ogen)-binding aggregates still 
being formed (Figure 3). This reflects the presence of Src kinase-independent pathways 
of platelet aggregation. Pre-treatment of blood from FcR γ-chain null mice with 
PD173952 did not further reduce platelet adhesion. 
Quantitative image analysis indicated that platelet deposition and PS exposure 
were significantly reduced by the various treatments (Figure 3). Pre-treatment of wildtype 
blood with the anti-GPVI Fab JAQ1 reduced total surface area coverage of platelets from 
25.8% (control) to 6.3% and PS exposure from 7.9% (control) to 0.1% (Figure 3). This 
was also the case when using FcR γ-chain null blood or PD173952-treated blood, where 
platelet deposition was decreased to 3.8% and 4.9%, and annexin A5 binding was even 
more reduced to 0.5% and 0.7%, respectively (Figure 3). Reduced thrombus formation 
and coagulant activity under all above conditions was also seen at a lower shear rate of 
 
 
Figure 3 GPVI/FcR γ-chain signaling pathway controls platelet deposition and procoagulant 
activity in blood triggered with tissue factor under flow. Citrate blood was perfused over 
collagen in the presence of tissue factor and CaCl2, as described for Figure 2. Post-perfusion was 
with AF647-labeled annexin A5. Data are percentages of area coverage of all platelets (white bars) 
or PS-exposing platelets (black bars). Mean±SD (n=5); *P≤0.05 as compared to control. 
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150 s
-1 
(data not shown), which is representative of that in venules. 
Together, these results stress the importance of the GPVI pathway in aggregate 
formation on collagen under flow. They also significantly extend earlier work by showing 
that, independently of the shear rate, GPVI signaling plays a key role in the coagulation 
process, i.e. in thrombin and fibrin formation triggered by tissue factor. Apparently, 
collagen-induced PS exposure via the FcR γ-chain is a key regulatory factor in 
coagulation. 
Components of the GPVI-PLCγ2 signaling pathway involved in collagen-enhanced 
thrombin generation 
To investigate more directly how coagulation is controlled by collagen-GPVI 
interaction and subsequent signaling, we examined the effect of collagen on thrombin 
generation in mouse PRP triggered with tissue factor under static conditions. Addition of 
tissue factor/CaCl2 to wildtype PRP resulted in high thrombin generation, a process 
which was greatly enhanced with a submaximal dose of collagen (peak level increased 
by 97%, (Figure 4). Control experiments demonstrated that essentially no thrombin was 
formed during 60 min, when platelets or tissue factor were absent (not shown). Collagen 
did not alter the thrombin generation curve with PRP from FcR γ-chain null mice (Figure 
4). In agreement with this, in PRP from wildtype mice, blocking of GPVI (with JAQ1 Fab) 
 
Figure 4 GPVI-PLCγ2 signaling pathway mediates collagen-enhanced thrombin generation. 
Mouse PRP (1×10
8
 platelets/mL, f.c.) was pre-incubated with vehicle (control), JAQ1 Fab (40 
µg/mL) or Src kinase inhibitor, PD173952 (25 µM). PRP was activated with vehicle (control) or 5 
µg/mL collagen, after which coagulation was initiated with tissue factor (1 pM) and CaCl2. PRP 
(1×10
8
 platelets/mL, f.c.) from mice deficient in FcR γ-chain, LAT or PLCγ2, or from matched 
wildtype mice was similarly activated. Enhancing effect of collagen on thrombin peak height; peak 
height normalized to control condition or wildtype PRP (mean±SD, n=4). 
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or Src kinases (with PD173952) completely abolished the enhancing effect of collagen 
on thrombin generation. These interventions did not affect thrombin generation in PRP 
from FcR γ-chain null mice. In the absence of collagen, PRP from mice deficient in LAT 
or PLCγ2 showed normal thrombin generation curves compared to wildtypes. Collagen 
addition did not increase the thrombin-generating activity in this PRP (Figure 4). 
Accordingly, the enhancing effect of collagen on thrombin generation was lost in case 
one of these components of the GPVI-PLCγ2 signaling pathway was missing. 
Absence of GPVI signaling diminishes thrombus formation in venules and 
arterioles on exposed extracellular matrix 
To determine the physiological relevance of the collagen-induced activation 
pathway, we used an in vivo mouse model of microvascular thrombus formation that 
relies on exposure of the extracellular matrix and ensuing thrombin generation
26
. Injury of 
the mesenteric vessels of anesthetized mice was induced by topical application of FeCl3, 
which caused local, but complete denudation of the endothelium in venules and nearby 
arterioles. Intravital microscopy was used for real-time imaging of thrombus formation in 
the damaged vessels (Figure 5). 
To study the involvement of GPVI, wildtype mice were injected with JAQ1 
antibody, which causes biphasic, long-term in vivo depletion of GPVI on platelets, 
without affecting other platelet glycoproteins
15,27
. After 10 min, this injection resulted in a 
 
Figure 5 In vivo thrombus formation in venules and arterioles of wildtype and FcR γ-chain 
null mice. Thrombi were raised in vivo by application of FeCl3 on selected mesenterial venules (v) 
and arterioles (a) from wildtype or FcR γ-chain null mice. Shown are representative trans-
illumination images (280×350 µm) from damaged venules and arterioles, captured at indicated 
times after FeCl3 application; thrombus area is indicated by dotted lines. 
 
Chapter 5 
108 
 
greatly reduced platelet concentration (20% of normal platelet count) and a specific 
disappearance of GPVI on the platelet surface with other platelet glycoproteins 
remaining unchanged (not shown)
15
. At 5 days after injection, however, platelet count 
was normalized, while GPVI expression on platelets was still completely absent. 
In venules from wildtype mice, thrombus formation started after seconds, while 
in arterioles there was a lagtime of several minutes. Thrombus size, quantified as 
thrombus height perpendicular to the vessel wall, increased with time in the vessels from 
wildtype mice. After 10 min, 39% and 31% of the venules and arterioles were occluded, 
respectively. When FeCl3 was applied to vessels from mice that were injected with JAQ1 
antibody (5 days before), thrombus formation in both venules and arterioles was greatly 
delayed and reduced (Figure 6). Similarly, in FcR γ-chain null mice, thrombus formation 
induced by FeCl3 was markedly delayed in both venules and arterioles. Thrombi in this 
case remained small in size in venules, and were not formed at all in arterioles (P≤0.05). 
No occlusion was observed within 10 min. Furthermore, pre-injection of mice with 
PD173952 at 10 min before FeCl3 application (estimated final plasma concentration of 
50 µM), resulted in a significant decrease in arterial thrombus size (P≤0.05), but not in 
venular thrombus size (Figure 6). PD173952 injection caused full blockage of collagen-
induced aggregation in vitro. We conclude that, in this microvascular model of 
extracellular matrix exposure, the presence of GPVI, FcRγ and Src kinase signaling are 
critical for venous and arterial thrombosis. 
 
Figure 6 Reduced thrombus formation in arterioles and venules in the absence of GPVI 
signaling. Wildtype mice were pre-infused with saline vehicle (WT control) or Src kinase inhibitor 
PD173952 (100 µL of 1 mM in saline) at 10 min before start. Other mice were injected with anti-
GPVI JAQ1 mAb (100 µg in saline) at 5 days before experimentation. Thrombi were raised by 
topical application of FeCl3 of adjacent mesenteric arterioles and venules. Thrombus size was 
measured at 10 min after FeCl3 application, and expressed as percentage of the local vessel 
diameter. Data are median values with interquartile ranges (n=6). *P≤0.1; **P≤0.05 compared to 
control. 
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Reduced fibrin formation and PS exposure in arterial thrombi after GPVI depletion 
TPLSM was used for better visualization of platelet activation and coagulation in 
arterioles after FeCl3 application. Wildtype mice were pre-injected with OG488-labeled 
fibrinogen or annexin A5, and fluorescent thrombi were subsequently scanned. In FeCl3-
treated arterioles from control mice, extensive deposition of OG488-fibrin(ogen) was 
detected and smaller spots of labeled annexin A5 (Figure 7). In contrast, in arterioles 
from mice pretreated with JAQ1 antibody (5 days) to down-regulate GPVI, FeCl3 
application led to formation of only small domains of fibrin labeling and no annexin A5 
labeling. Thus, both fibrin formation and PS exposure were reduced after down-
regulation of platelet GPVI. 
Discussion 
The present results indicate that the GPVI receptor, acting via a straightforward 
signaling pathway, acts as principal mediator of PS exposure, platelet-dependent 
thrombin generation and fibrin formation/coagulation in the presence of tissue factor. The 
signaling modules involved in the procoagulant platelet response are the FcRγ, Src 
 
Figure 7 Decreased accumulation of fluorescent fibrin(ogen) and annexin A5 in 
arteriolar thrombi from GPVI-depleted mice. Wildtype mice were untreated (control) or depleted 
in GPVI by injection of 100 µg JAQ1 mAb at 5 days before start of experimentation. Prior to 
thrombus induction, mice were infused with either 200 µg OG488-labeled 
fibrinogen or 200 µg OG488-labeled annexin A5 in 100 µl saline. Mesenteric arterioles were 
exposed to FeCl3 for 10 min, after which fluorescence was observed in situ by TPLSM. Small fibrin 
clots were formed after GPVI depletion (arrow). Ιmages (206×206 µm) are from representative 
damaged arterioles. 
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kinases (likely Fyn/Lyn), the adaptor protein LAT and PLCγ2, the latter of which is 
responsible for Ca
2+
 mobilization. In addition, we find that under flow this signaling 
pathway mediates the build-up of a platelet-fibrin thrombus. Evidence comes from a 
number of approaches to eliminate GPVI or subsequent activation steps. Blocking anti-
GPVI JAQ1 Fab fragments were used. Further, the Src kinase inhibitor, PD173952, 
which completely inhibits collagen-induced aggregation and tyrosine phosphorylation of 
mouse platelets in plasma, but leaves platelet responses to G protein-coupled receptor 
agonists unchanged
19
. Abolished PS exposure and thrombus formation was also seen in 
blood from mice lacking either the FcR γ-chain, the adaptor protein LAT or the effector 
protein PLCγ2. Especially the recognition that LAT is required for the procoagulant 
response is important, because earlier work suggested that LAT is dispensable for 
collagen- and convulxin-induced platelet aggregation
28
. 
Interestingly, addition of JAQ1 antibody fragments resulted in lower platelet 
adhesion than with FcR γ-chain deficient blood. This can be explained by the recent 
observation that GPVI and GPIb-IX-V associate on platelets
29
; and the possibility that the 
JAQ1 antibody can thereby interfere with GPIb-mediated effects, while GPIb remains 
functionally active under flow in the absence of FcRγ
30
. We have shown before that GPIb 
plays a more prominent role in platelet-collagen interaction at reduced levels of GPVI 
and FcRγ, which argues against a significant role of the FcR γ-chain in thrombus 
formation independently of GPVI, such as others have proposed
31
. 
Earlier perfusion studies have indicated that platelet-collagen interaction via 
GPVI is the principal trigger of platelet activation and aggregation in mouse and human 
blood
5,15
. Here, we significantly extend this observation by showing that GPVI signaling 
also controls thrombus formation on collagen in the presence of coagulation. We found 
that not only platelet aggregate formation, but also PS exposure and fibrin formation 
were greatly suppressed in blood from FcR γ-chain null mice, both at high (arteriolar) and 
low (venular) shear rates. This was also the case when GPVI or Src kinases were 
blocked with JAQ1 Fab or PD173952, respectively. During flow in the absence of GPVI 
activity, tissue factor was still active in triggering thrombin formation, as deduced from 
the traces of fibrin that still were formed, but apparently propagation of the coagulation 
process and fibrin clot formation were prevented. Accordingly, platelet activation by 
GPVI, most likely via PS exposure, is required for full coagulation activity. 
In a macrovascular thrombosis model triggered by mechanical damage of the 
carotid artery, it has been demonstrated that GPVI is required for platelet adhesion to the 
vessel wall
1
. Whether or not coagulation contributes to the thrombotic process in that 
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model is unknown. Here, we used a microvascular model, relying on free radical 
formation with FeCl3, known to be driven by thrombin formation and coagulation
26
. The 
application of FeCl3 resulted in almost complete disappearance of the endothelium in 
both arterioles and venules, causing exposure of the collagen-containing extracellular 
matrix (M. Kuijpers, unpublished data 2004). In either vessel type GPVI activity appeared 
to control the thrombus-forming process. For instance, in venules and arterioles from 
FcR γ-chain null mice, thrombi remained small in size (venules) or were not formed at all 
(arterioles). Long-term injection with anti-GPVI JAQ1 mAb, which completely down-
regulates GPVI on the platelet surface
15
, delayed and reduced the thrombus formation in 
venules and arterioles to a similar extent. Furthermore, observation with TPLSM 
indicated that in vessels from mice pre-injected with JAQ1 mAb only small spots of 
labeled fibrin were present, while labeled annexin A5 was not detectable at all. Finally, 
injection of PD173952 into mice to block (GPVI-activated) Src kinases suppressed the 
thrombotic process in arterioles. 
Together, these data provide first in vivo evidence that GPVI, acting via a 
relatively simple signaling pathway (Src kinase, FcRγ, Syk, LAT, PLCγ2) has a key role 
 
Figure 8 GPVI signaling cascade. Crosslinking of GPVI induces tyrosine phosphorylation of the 
FcR γ-chain ITAM by the Src kinases, Fyn and Lyn. This initiates a Syk-dependent signaling 
cascade that leads to formation of a LAT complex and activation of PLCγ2. PLCγ2 associates 
directly with LAT, and with the membrane via binding of its PH domain to PIP3. PLCγ2 activation 
causes Ca
2+
 mobilization as well as Ca
2+
 entry via plasma membrane channels, which subsequently 
leads to phosphatidylserine (PS) exposure.  
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in platelet procoagulant activity and subsequent thrombin and fibrin formation. The 
procoagulant function of GPVI appears to contribute to arterial thrombus formation and, 
interestingly, also to venous thrombus formation. These findings thus point to a dual role 
of GPVI, both procoagulant and aggregatory, in collagen-induced thrombus formation in 
vivo. 
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Abstract  
Blood coagulation and platelet activation are mutually dependent processes, but 
contribute with different extent to venous and arterial thrombosis. The processes of 
platelet activation and thrombin generation have been extensively studied in vitro, but the 
precise interactions between these processes are unclear in vivo. We investigated the 
interplay of platelet activation and coagulation in a mouse model of both arterial and 
venous thrombosis. Thrombus formation was studied in vivo by topical application of 
FeCl3 on mouse mesenteric vessels. Both in arteries and veins, the thrombotic process 
relied on tissue factor-factor VII(a) interaction and collagen exposure, followed by 
glycoprotein VI-mediated platelet activation. Mild thrombin inhibition or platelet inhibition 
suppressed arterial thrombus formation, while strong thrombin inhibition or mild thrombin 
inhibition in combination with platelet inhibition was necessary to suppress venous 
thrombosis. Thrombus formation in both vessel types was characterized by the presence 
of phosphatidylserine (PS)-exposing platelets, detected with fluorescently labeled 
annexin A5. Shielding of exposed PS by injected annexin A5 abolished formation of both 
arterial and venous thrombi, while mutant M1234-annexin A5 was ineffective. Decreased 
anticoagulant activity by using mice carrying the factor V Leiden mutation had only little 
effect. In this microvascular model of combined tissue factor/collagen-induced 
thrombosis, propagation of thrombin generation by PS-exposing platelets is a key 
regulatory process in the formation of thrombi. Platelet-dependent thrombin generation is 
most active in venous thrombus formation and may be a clinically relevant target to 
reduce thrombosis. 
Introduction 
Cardiovascular disease is still the leading cause of death in Western countries. 
Current understanding is that pathological thrombosis in veins and arteries is caused by 
the interplay between activated platelets and the coagulation system. However, these 
two processes contribute differently to either arterial or venous thrombus formation. 
Thrombi formed in the venous system are mostly rich in fibrin and trapped red cells, 
though relatively poor in platelets. This is in paradox with the fact the thrombin is one of 
the most potent platelet agonists
1
, which implicates that platelets must become activated 
by thrombin in thrombotic veins. On the other hand, arterial thrombosis is associated with 
undesired platelet activation. ‘White’ thrombi formed in atherothrombotic arteries are rich 
in aggregated platelets, although fibrin is detectable here as well. This is in agreement 
with the fact that -in clinical practice- anticoagulant drugs such as heparins and active-
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site thrombin inhibitors are preferentially used to reduce venous thromboembolism, while 
platelet inhibition is preferred in case of arterial thrombosis. Intriguingly, recent in vivo 
experiments, using several animal thrombosis models, have shown that thrombin is also 
a key regulator of thrombus formation in arteries
1-5
. How this finding relates to the 
assumed more predominant role of thrombin in venous thrombosis is unclear. 
In vitro studies on the regulation of thrombin generation in platelet-rich plasma 
(PRP) have clearly shown that platelet inhibition, e.g. with cAMP-elevating agents or 
integrin αIIbβ3 antagonists, have an anticoagulant action by slowing down the formation 
of thrombin and fibrin
6,7
. Although there is evidence that (activated) platelets stimulate 
the coagulation process
8,9
, the mechanism behind this effect is disputed. Studies in vitro 
have pointed to specific binding of coagulation factors (prothrombin and factors V, X and 
XI) to integrins and other receptor proteins on platelets
10,11
. The binding of activated 
factor V is of interest, as platelets are supposed to play a role in the inactivation of factor 
Va by activated protein C
12
. Also, tissue factor can bind to platelet aggregates and 
thrombi, and then stimulate the coagulation process
2
. Another proposed mechanism 
concerns the exposure of procoagulant phosphatidylserine (PS) at the outer surface of 
activated platelets. At least in vitro, PS serves as a site for the assembly of coagulation 
factor complexes that greatly enhance thrombin generation
13
. A strong trigger of PS 
exposure is platelet interaction with immobilized collagen, mediated by glycoprotein VI 
(GPVI)
14,15
, while platelet stimulation via thrombin receptors is less effective
16
. Whether 
and how these platelet-dependent processes indeed contribute to pathological thrombus 
formation in arteries and veins in vivo is poorly understood. 
In the present study the importance and the mechanism of platelet-dependent 
coagulation was investigated in arterial and venous thrombosis. We used an established 
murine thrombosis model of FeCl3-induced vascular damage, known to be sensitive to 
both platelet and thrombin inhibition
1,4,17-19
. The data show that thrombin and PS-
exposing platelets play prominent, but different roles in the thrombotic process in arteries 
and veins. This platelet procoagulant response may constitute an attractive novel target 
for antithrombotic therapies. 
Materials and Methods 
Animals 
C57Bl/6 mice of 4-5 weeks old (11-21 g) or 12 weeks old (20-25 g) of either sex 
were obtained from Charles River (Maastricht, the Netherlands). Mice deficient in FcRγ-
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chain of the same age and background were from Taconics (Germantown, NY, USA)
20
. 
Mice carrying the Factor V Leiden mutation (Arg 504 to Gln) were described previously
21
. 
Factor V R504Q mice were backcrossed to C57BL/6J mice (Jackson Labs, Bar Harbor, 
ME) for at least 8 generations (N8), and N8 heterozygous mice were intercrossed to 
produce homozygous (FV
Q/Q
), heterozygous (FV
Q/+
), and wildtype offspring (FV
+/+
). The 
FV
Q/Q
 and FV
+/+
 were intercrossed to produce the FV
Q/Q
 and FV
+/+
 littermates used in the 
present study. Genotyping for Factor V Leiden was performed by PCR analysis of tail 
DNA with the primers previously described
21
. Local animal care and use committees 
approved the experiments. 
Materials 
Fibrillar Horm collagen (type-I) was purchased from Nycomed Pharma (Munich, 
Germany). Unfractionated heparin (ISH 1), prostaglandin E1 and rhodamin 6G were from 
Sigma (St. Louis, MO, USA). Annexin A5, unlabeled and labeled with fluorescein 
isothiocyanate (FITC), and M1234-annexin A5 were from Nexins Research (Hoeven, the 
Netherlands); acridine red came from Chroma (Stuttgart, Germany). Recombinant 
human tissue factor was from Dade (Düdingen, Switzerland); Z-Gly-Gly-Arg aminomethyl 
coumarin (Z-GGR-AMC) and Gly-Pro-Arg-Pro (GPRP, Pefablock) were from Bachem 
(Bubendorf, Switzerland); FeCl3 was from Merck (Darmstadt, Germany). Hematoxylin 
and eosin came from Klinipath (Duiven, the Netherlands). Ketamine and xylazine were 
from Eurovet (Bladel, the Netherlands). Transfected cells expressing cDNA encoding for 
the annexin A5 mutant M1234 were provided by dr. F. Russo-Marie (Bionexins-
Pharmaceuticals, France). Melagatran was kindly provided by dr. M. Elg (AstraZeneca, 
Mölndal, Sweden). Mouse tissue factor, anti-mouse tissue factor antibody and mouse 
factor VIIai (active site-inhibited factor seven, ASIS)
22
 were kindly provided by dr. P. 
Tijburg (Novo Nordisk, Bagsværd, Denmark). 
Perfusion of whole blood under coagulant conditions 
Collagen- and tissue factor-induced thrombus formation under coagulant and 
flow conditions was measured as described
23
. Briefly, mice were bled retro-orbitally, and 
blood (9 volumes) was collected in 0.129 M citrate (1 volume). The blood was 
supplemented with FITC-labeled annexin A5 (0.5 µg/ml) and perfused through a parallel-
plate transparent flow chamber that contained a coverslip coated with collagen. 
Coagulation was introduced by co-perfusion with 0.1 volume of CaCl2 (200 mM) and 
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tissue factor (20 pM). Final wall shear rate was 1000 s
-1
. Recording of bright-field and 
fluorescent images was performed with a non-confocal microscopic imaging system. 
Thrombus formation in vivo 
Four- to 5-week-old mice were subjected to FeCl3-induced thrombus formation 
in mesenteric blood vessels as described
23
. Topical application of FeCl3 (30 µL, 500 mM) 
damaged the vessel wall of selected arteries and veins. At baseline, the wildtype arteries 
had a diameter of 68 ± 4 µm (n=30), while the venous diameter was 107 ± 8 µm (n=20). 
Diameters of the vessels monitored in genetically modified animals were not different 
(not shown). An intravital microscopic imaging system allowed continuous recording of 
thrombus formation in arteries and veins for at least 10 minutes (min). For each vessel, 
the following parameters were quantified from video recordings off-line: lag-time to first 
observation of thrombus formation, thrombus height perpendicular to the vessel wall 
(expressed relative to the local vessel diameter) at 2, 5 and 10 min after FeCl3 
application, and time to occlusion. 
Where indicated, inhibitors were injected intravenously (bolus, 100 µl) at 5-10 
min before application of FeCl3. Control mice received the same volume of saline 
(vehicle). Injection of FITC-labeled annexin A5 (0.16 µg/g body weight (bw)) shortly after 
FeCl3 application, visualized PS exposure in vivo. Epi-illumination with a Xenon lamp 
using a sensitive, high-resolution fluorescence imaging system and an intensified CCD 
camera (Photonic Sciences), enabled capture of high-resolution fluorescence images as 
described
24
. Centerline blood flow velocities (v) of labeled leukocytes were measured in 
8 arteries and 8 veins after injection of rhodamin 6G (30 µl, 1 mg/ml; i.v.). This was 
converted to wall shear rates (r) according to the Newtonian equation, r = 8 × (v / 1.6) / 
vessel diameter. 
Thrombin generation measurements 
Murine platelet-poor plasma (PPP) or PRP was prepared from blood from 12 
week old mice
25
. Thrombin generation was measured using the thrombogram method
26
, 
adapted for murine plasma. Normalized PRP (1.5×10
8
 platelets/ml) or PPP 
supplemented with 4.0 µM phospholipid vesicles of phosphatidylserine : 
phosphatidylcholine : phosphatidylethanolamine (1:3:1, mol/mol) was used. Plasmas 
were preincubated with inhibitors for 10 min at room temperature, and subsequently 
added to a 96-well plate, containing tissue factor (1 pM, final concentration) in Hepes 
buffer (20 mM Hepes, 140 mM NaCl, 5 mg/ml bovine serum albumin, pH 7.35). 
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Thrombin formation was started by addition of CaCl2 (16.6 mM) and Z-GGR-AMC (2.5 
mM) in Hepes buffer. Fluorescence was continuously measured in time at 37°C with a 
Fluoroscan Ascent well-plate reader (Thermolab Systems). First-derivative curves of 
accumulation of fluorescence were generated as described
27
. Assays were run in 
duplicates or triplicates; calibrations were performed with human thrombin. Effects on 
peak height of thrombin generation curves (maximal levels) were measured, which 
parameter is proportional to the maximal rate of thrombin generation. 
Statistical analysis 
Data are presented as means ± SEM. Differences between experimental 
groups were tested with the Mann-Whitney U test, using the statistical package for social 
sciences (SPSS 11.0). 
Results 
Interaction between tissue factor-induced thrombin formation and platelet 
phosphatidylserine exposure in blood flowing over collagen 
The importance of interactions between platelet activation and coagulation in 
thrombus formation under flow was evaluated with mouse blood. Thrombin generation 
was triggered by co-infusion of citrate-anticoagulated blood with a low dose of tissue 
factor (2 pM) in the presence of CaCl2, directly before entering a collagen-containing flow 
chamber. At an arterial shear rate of 1,000 s
-1
, this resulted in early platelet deposition, 
subsequent aggregate formation and appearance of fibrin fibers after 2-3 min. At a more 
advanced stage (7-8 min), the chamber occluded with large fibrin-platelet thrombi and 
trapped red cells (Figure 1A). Labeling of the blood with FITC-annexin A5 (0.5 µg/ml, a 
low dose not influencing coagulation) indicated that many of the platelets on collagen 
and on aggregates exposed PS, covering about 20% of the surface area (Figure 1B). In 
the presence of melagatran (10 µM), a high affinity, active-site thrombin inhibitor
28
, 
aggregate formation still occurred, but fibrin fibers and occlusive thrombi did not form 
(Figure 1C). In this case, only collagen-bound platelets exposed PS, covering 5% of the 
surface area (Figure 1D). Quantitative analysis indicated that this melagatran 
concentration markedly but incompletely delayed and reduced the appearance of PS-
exposing platelets during the flow experiment (Figure 1E), while at the same time it 
suppressed thrombin generation in PRP by 95 ± 2% (mean ± SEM, n=3). Thus, under 
these high shear flow conditions, melagatran suppressed the formation of PS-expressing 
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platelets in parallel with the formation of platelet-fibrin clots. Previously, using 
anticoagulated murine blood, we have shown that the (remaining) platelet aggregate 
formation and PS exposure results from collagen-induced GPVI activation
25
. Together 
with the present results, this indicates that the processes of GPVI-induced platelet 
activation and coagulation activation cooperate in generating procoagulant platelets. 
 
Tissue factor and collagen trigger thrombus formation in arteries and veins 
To investigate the role of procoagulant platelets in arterial and venous thrombus 
formation in vivo, we used a FeCl3 model of thrombosis induction in wildtype mouse 
mesenteric vessels, as described earlier
23
. Wall shear rates in the mesenteric arteries 
and veins were 1183 ± 187 (n=8) and 344 ± 77 s
-1
 (n=8), respectively. Topical 
application of FeCl3 resulted in damage of adjacent mesenteric arteries and veins. 
Histochemical staining indicated that in both vessel types the endothelial layer 
completely disappeared after FeCl3 treatment, while the vascular structure remained 
intact (not shown). Real-time visualization by intravital microscopy showed that FeCl3 
 
Figure 1 Role of procoagulant platelets in collagen- and tissue factor-induced thrombus 
formation under shear. Citrated mouse blood was perfused for 4 min over a collagen surface at a 
shear rate of 1,000 s
-1
. During perfusion, coagulation was triggered with 2 pM tissue factor and 20 mM 
CaCl2 (resulting in about 2 mM free Ca
2+
) in the absence (A, B) or presence (C, D) of 10 µM 
melagatran. Shown are representative phase-contrast images (A, C) and fluorescence images of PS-
exposing platelets (B, D), taken at 4 min after perfusion of blood labeled with 0.5 µg/ml FITC-annexin 
A5 (n=3). (E) Inhibitory effect of melagatran on PS exposure under flow. Surface area coverage with 
fluorescence is given during perfusion with blood labeled with 0.5 µg/ml FITC-annexin A5 and 
triggered with tissue factor/CaCl2. Control condition (•), melagatran condition (o) (n=3). 
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caused rapid adhesion of platelets in veins, followed by formation of thrombi, while these 
processes started only after several minutes in arteries (Figure 2A). Under these control 
conditions, thrombus formation was progressive in both vessel types (Figure 2B). At 10 
min after FeCl3 application, 33% of the arteries and 42% of the veins were fully occluded. 
To establish the involvement of tissue factor in this thrombosis model, we 
inhibited tissue factor activity or, alternatively, its ligand factor VII(a) in wildtype mice. 
Intravenous administration of anti-murine tissue factor antibody (3 µg/g bw) significantly 
delayed (Figure 2A) and reduced (Figure 2B) the thrombotic process in both arteries and 
veins. Injection of mouse active site-inhibited factor VII (factor VIIai, 10 µg/g bw) had 
similar inhibitory effects (Figure 2). Ex vivo experiments, using plasma samples from 
mice injected with factor VIIai, showed that tissue factor-induced (1 pM) thrombin 
generation was severely delayed and reduced to 6.8 ± 2.4% of control level (n=3). In 
 
Figure 2 Complementary contribution of tissue factor and collagen in FeCl3-induced thrombus 
formation in mesenteric arteries and veins in vivo. Wildtype mice were injected intravenously with 
vehicle (control), 3 µg/g bw anti-mouse tissue factor antibody (anti-mTF) or 10 µg/g bw factor VIIai 
(FVIIai). Mesenteric vessels of wildtype and FcRγ-chain -/- mice were damaged by topical application 
of FeCl3. (A) Lag-time to thrombus formation after FeCl3 application. (B) Thrombus height measured at 
indicated times after FeCl3 application (% of vessel diameter). Data are means ± SEM (n=6-12). 
*p<0.05; 
+
p< 0.1 compared to control. 
 
Procoagulant platelets in vivo 
 
 
123 
vitro experiments confirmed that anti-tissue factor antibody or factor VIIai (each 20 µg/ml) 
blocked thrombin generation in mouse plasma by >85%. To demonstrate the 
involvement of platelet-collagen interaction in this model, we used mice deficient in the 
FcRγ-chain, whose platelets do not express the GPVI collagen receptor
29
. In comparison 
to wildtypes, application of FeCl3 resulted in a greatly delayed and reduced thrombus 
buildup in both arteries and veins (Figure 2). Earlier results show that injection of 
wildtype mice with inhibitory anti-GPVI antibody JAQ1 also suppresses thrombus 
formation in these arteries
23
. We therefore conclude that, in this model, the thrombotic 
process is regulated by both coagulation activation by exposed tissue factor/factor VII(a) 
and interaction of collagen with platelets. Interestingly, the role of tissue factor in this 
process was similar in arterial and venous thrombus formation. 
Stronger inhibition of thrombin is required to affect thrombus formation in veins 
To investigate how thrombin generation and coagulation drive the thrombotic 
process in arteries and veins, wildtype mice were injected with a moderate or higher 
dose of melagatran (0.175 or 0.5 µg/g bw, respectively). Ex vivo analysis indicated that 
these doses gave 3-fold and higher prolongation in clotting times (see also below). In 
comparison to control mice, injected with saline vehicle, injection of 0.175 µg/g bw 
melagatran did not influence the lag-time to thrombus formation in arteries (Figure 3A), 
but thrombus height was significantly reduced (Figure 3B). After administration of the 
higher melagatran dose (0.5 µg/g bw), the arterial lag-time to thrombus formation was 
prolonged to 514 ± 86 s (mean ± SEM, n=7, Figure 3A), while thrombus build-up was 
again greatly reduced (Figure 3B). Strikingly, venous thrombus formation was inhibited 
only by the higher dose of melagatran (Figure 3A, B). None of the veins occluded within 
10 min with the moderate or high dose of melagatran. Similar observations were made 
after injection of 0.05 U/g bw unfractionated heparin, an indirect thrombin inhibitor. This 
only inhibited thrombus formation in arteries (p<0.05), but not significantly in veins (not 
shown). 
Plasma samples were obtained from blood collected after 30 min of melagatran 
administration. The thrombogram method was used to determine the activity of 
melagatran in ex vivo mouse plasma and indicated that thrombin peak height was 
diminished to 18% and 4% of control, respectively (Figure 3C). 
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Figure 3 Complementary roles of thrombin and platelet activation in FeCl3-induced thrombus 
formation in arteries and veins. Mice were injected with saline vehicle (control), melagatran (0.175-
0.500 µg/g bw) and/or prostaglandin E1 (PGE1, 0.4 mg/g bw). Mesenteric vessels were damaged by 
topical application of FeCl3 as in Figure 1. (A) Lag-time to thrombus formation after FeCl3 application. 
(B) Thrombus height measured at indicated times after FeCl3 application (% of vessel diameter). Data 
are means ± SEM (n=4-9). *p<0.05; 
+ 
p<0.07 compared to control. (C) Effect of in vivo injection of 
melagatran (0.175-0.5 µg/g bw) on thrombin generation. After in vivo experimentation, blood was 
collected, and PPP was prepared and supplemented with 4.0 µM phospholipid vesicles. Thrombin 
generation was triggered with tissue factor/CaCl2. (D) Effect of in vitro added inhibitors on thrombin 
generation. Mouse PRP (1.5×10
8
 platelets/ml) was pre-incubated with melagatran (0.1-10 µM) and/or 
PGE1 (10 µM), and thrombin generation was triggered with tissue factor/CaCl2. Data show effects on 
peak height relative to control condition; means ± SEM (n=3-5); *p<0.05 compared to control. 
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Similarly, when added to PRP in vitro, melagatran (Figure 3D) or heparin (not 
shown) dose-dependently reduced tissue factor-triggered thrombin generation; the IC50 
for melagatran was about 0.5 µM. Together, these data stress the importance of 
thrombin generation and coagulation in this mouse thrombosis model, and, furthermore 
show that stronger inhibition of the thrombin-generating process is required to affect 
venous compared to arterial thrombus formation. 
Additive effect of platelet and thrombin inhibition on venous thrombus formation 
To inhibit platelet activation, the cAMP-elevating agent prostaglandin E1 (PGE1) 
was used. In isolated mouse PRP, 10 µM PGE1 substantially reduced platelet 
aggregation (not shown) and platelet-dependent thrombin generation (Figure 3D, peak 
 
Figure 4 Normal FeCl3-induced thrombus formation in arteries and veins of factor V Leiden 
mice. Mesenteric vessels of homozygous factor V Leiden (Fv
Q/Q
) and wildtype (Fv
+/+
) mice were 
subjected to FeCl3-induced thrombus formation. (A) Lag-time to thrombus formation after FeCl3 
application. (B) Thrombus height at indicated times after FeCl3 application (% of vessel diameter). 
Data are means ± SEM (n=8-13). 
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height reduced to 73 ± 5%, p=0.003). This corresponds to results obtained with human 
PRP
6,27
. In vivo treatment of mice with 0.4 mg/g bw PGE1 (giving a plasma concentration 
of about 10 µM) significantly delayed and reduced thrombus formation in arteries, but not 
in veins (Figure 3A, B). Ex vivo measurements demonstrated that the injected PGE1 
caused a 40% reduction in thrombin formation. 
Combined administration of PGE1 (0.4 mg/g bw) and the lower dose of 
melagatran (0.175 µg/g bw) resulted in significant retardation and reduction of the 
thrombotic process, not only in arteries, but also in veins (Figure 3A, B). Thus, in veins, 
the combined administration was much more effective than that of PGE1 or moderate 
melagatran alone. Or stated otherwise, platelet inhibition by PGE1 or moderate thrombin 
inhibition by melagatran alone was sufficient to inhibit arterial thrombus formation, but 
the combined action was needed for reducing venous thrombosis. 
Unchanged thrombus formation in arteries and veins of factor V Leiden mice 
To investigate the involvement of anticoagulant activity in the thrombus-forming 
process, we used transgenic mice carrying the factor V Leiden mutation (homozygous 
FV
Q/Q
), which renders factor Va relatively resistant to inactivation by activated protein C 
and hence enhances thrombin generation
21,30
. When compared to wildtype controls 
(FV
+/+
), in FV
Q/Q
 mice neither the lag-time to thrombus formation (Figure 4A) nor the 
extent of thrombus formation (Figure 4B) was altered in arteries or veins. However, the 
time to arterial occlusion of FV
Q/Q
 mice was significantly shorter than that of FV
+/+
 mice 
(462 ± 62 vs. 531 ± 41 s, n=8, p<0.05). Apparently, in spite of the key role of thrombin in 
this process, resistance of factor Va to inactivation by activated protein C, as in FV
Q/Q
 
mice, did not have a major effect on arterial and venous thrombus formation. 
Procoagulant platelets control thrombus formation in arteries and veins 
To investigate the role of procoagulant platelets in the thrombus-forming 
process, FeCl3 was applied to induce thrombus formation, and mice were subsequently 
injected with a tracer amount of FITC-labeled annexin A5 (0.16 µg/g bw), which detects 
cell surface-exposed PS. Overlays of transmission and fluorescence images indicated 
that the thrombi in both arteries and veins incorporated labeled annexin A5 (Figure 5A), 
pointing to the presence of PS-exposing platelets. During the experiments no staining 
with FITC-annexin A5 was observed inside the vessel wall or in vessels without thrombi 
(not shown). 
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Figure 5 Role of platelet procoagulant activity in arterial and venous thrombus formation in 
vivo. (A) Vessel wall damage was induced by topical FeCl3 application, directly after which FITC-
annexin A5 (0.16 µg/g) was infused intravenously. Trans-illumination images were taken at 
baseline; fluorescence images were taken at 5 and 10 minutes after FeCl3 application. Dotted lines 
indicate vessel wall, arrows indicate direction of flow; bar represents 50 µm. (B) Mice were infused 
with a high dose of 7.7 µg/g bw annexin A5 or mutated M1234-annexin A5, resulting in plasma 
concentration of 70 µg/ml. Mesenteric vessels were damaged by topical application of FeCl3. (B) 
Lag-time to thrombus formation after FeCl3 application. (C) Thrombus height measured at indicated 
time points after FeCl3 application (% of vessel diameter). Data are means ± SEM (n=6-7); *p<0.05 
compared to control. Note that M1234-annexin A5 infusion led to a similar thrombus build-up in 
arteries and veins as vehicle (control) infusion (p=0.179). (D) In vitro effect of annexin A5 on 
thrombin generation in PRP. Thrombin generation was measured in PRP, treated with a moderate 
dose (10 µg/ml) mutated M1234-annexin A5 or wildtype annexin A5. Values are thrombin peak 
heights as % of control (means ± SEM, n=3-4). 
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The importance of PS exposure was further investigated by injecting mice with 
a saturating dose (7.7 µg/g bw) of unlabeled annexin A5. Quadruple-mutated annexin A5 
(M1234-annexin A5, 7.7 µg/g bw) was used as a negative control. The M1234-annexin 
A5 has single amino acid mutations in each of the four Ca
2+
 binding sites that greatly 
reduces its affinity for binding to PS
31
. Whereas injection of M1234-annexin did not 
influence thrombus formation as compared to vehicle control (p≥0.18), wildtype annexin 
A5 almost completely inhibited this process in both arteries and veins (Figure 5B, C). In 
fact, in none of the 7 damaged arterioles more than little platelet deposition was detected 
within the 10-min time frame, while in 3 out of 6 venules only very small thrombi 
assembled. 
Thrombin generation experiments in vitro showed that addition of 10 µg/ml 
annexin A5 to PRP was sufficient to reduce the thrombin peak to 11 ± 1.6% (n=3) of 
control, while M1234-annexin A5 was without effect (Figure 5D). In plasma collected 
from mice injected with annexin A5 (7.7 µg/g bw), thrombin generation was reduced to 
17 ± 4% (n=4) of control plasma. Thus, in either vessel type, thrombus formation 
appears to rely on PS exposure and ensuing thrombin generation by (activated) 
platelets. Similarly, in in vitro flow experiments (see Figure 1), addition of annexin A5 
reduced PS exposure by platelets and clot formation (not shown). 
Discussion 
In this paper, we investigated the interaction mechanisms of platelets and 
coagulation in thrombus formation under in vivo conditions, using an established murine 
thrombosis model of vascular damage induced by FeCl3. In both arteries and veins, we 
detected substantial externalized PS on platelets trapped into thrombi, using 
fluorescently labeled annexin A5. This probe has previously also been used for in vivo 
monitoring of PS-exposing, apoptotic cardiomyocytes in a mouse model of 
ischemia/reperfusion of the heart
32
. A major finding was that injection of a high dose of 
annexin A5, sufficient to suppress PS-dependent thrombin generation in plasma, results 
in a profound delay in initiation and in an almost complete suppression of arterial and 
venous thrombus formation. In contrast, a mutated non-binding annexin A5, was without 
any effect. These in vivo data are in good agreement with results from in vitro flow 
experiments, where PS-exposing platelets were found to accumulate under conditions of 
high thrombin generation and clot formation. Together, this is first evidence for a key role 
of PS exposure and platelet-dependent coagulation in the thrombotic process in vivo, in 
both arteries and veins. This work thereby significantly extends knowledge from 
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experiments in test tubes that PS-exposing platelets promote prothrombin cleavage
9,13
. 
Indirect evidence for the clinical importance of this process comes from the finding that 
Scott patients, whose platelets are deficient in PS exposure upon activation, are 
characterized by a mild bleeding defect
33
. 
Strikingly, in this FeCl3-induced microvascular model the same initiating factors 
appear to be involved in the thrombus-forming process in arteries and veins. 
Accordingly, in both vessel types blocking of tissue factor with a monoclonal antibody or 
injection of inactivated factor VIIa (both of which interventions block the tissue factor 
pathway of coagulation) delayed and suppressed thrombus formation. Others have 
shown that tissue factor, platelets and fibrin gradually accumulate into developing murine 
thrombi, produced in microvascular arterioles
2
. For the current model, we cannot answer 
the question whether
34
 or not
35
 blood-borne tissue factor is involved in the thrombotic 
process. However, the data do support the proposal that tissue factor is a promising 
target for new antithrombotic treatment
36
. 
Another similarity between arteries and veins we found in this model, is that the 
absence of FcRγ-chain and GPVI delays and reduces thrombus formation in both vessel 
types. The arterial results agree with those of others, who found diminished arterial 
thrombus formation in mice lacking the FcRγ-chain, using a similar model
3,37
. This also 
holds for high shear flow studies showing impaired thrombus formation with blocked or 
absent GPVI signaling in vitro, regardless of the presence of coagulation
23,25
. In contrast, 
laser-induced thrombosis is not diminished in arteries of FcRγ-chain deficient mice, likely 
to due a high generation of thrombin after this type of injury
3,4
. 
Furthermore, our results show that, in arteries as well as veins, thrombin is an 
important mediator of the thrombotic process. In both vessel types, thrombus formation 
is abrogated by infusion of the thrombin inhibitor melagatran at an established fully 
effective concentration. Interestingly, however, while in arteries also a lower, partly active 
melagatran concentration is inhibiting, in veins this concentration is without effect, except 
when given in combination with platelet-inhibiting PGE1. For arterial thrombus formation 
induced by FeCl3, laser or mechanical damage, significant contribution of thrombin is 
also noted by others
1,4,5,18
. 
The importance of anticoagulation was investigated using FV
Q/Q
 mice carrying 
the factor V Leiden mutation, rendering factor Va relatively resistant to inactivation by 
activated protein C
21
. It has been proposed that factor Va inactivation is controlled by 
binding to the platelet surface
12
, implicating that thrombus formation is potentially 
regulated by factor Va-platelet binding. Here, we found that FV
Q/Q
 vessels had no more 
than a small increase in arterial or venous thrombus formation; significant effects, i.e. on 
Chapter 6 
130 
 
arterial occlusion, were only present at a late stage of thrombus formation. Thus, 
although in the present model arterial and venous thrombosis is controlled by 
coagulation factor activation (thrombin), factor Va inactivation only appears to play a 
significant role at later stages of the process. Therefore, our results do not support the 
observation that the factor V Leiden mutation enhances arterial thrombosis in mice
38
. 
Taken together, the present data indicate that the thrombotic process in arteries 
as well as veins involves: (i) platelet-collagen interaction via GPVI/FcRγ-chain, (ii) tissue 
factor-induced initiation of thrombin generation, (iii) platelet activation and aggregation, 
and (iv) development of platelet procoagulant activity, i.e. PS exposure, to potentiate 
thrombin generation and clot formation. Apparently, in both arteries and veins the 
thrombotic process is driven by sequential loops of thrombin generation, platelet 
activation and PS exposure. 
While the mechanisms of arterial and venous thrombus formation are strikingly 
similar, the present data also point to typical quantitative differences. Thrombus 
formation in veins was faster in onset than in arteries. Such differences between arteries 
and veins were also found in other, non-FeCl3 thrombosis models
39
. In the present 
model, one of the reasons of the faster onset of venous thrombosis may be a quicker 
penetration of FeCl3 through the relatively thin venous vessel wall. Another possible 
explanation is the slower dilution in veins of locally formed prothrombotic substances 
(factor VII, ADP, thrombin). Support for the latter comes from the observation that 
stronger inhibition of thrombin, or combined inhibition of thrombin and platelets, is 
required to suppress thrombus formation in veins in comparison to arteries. This points 
to a relatively high accumulation of thrombin in the slowly flowing venous blood. A third 
possibility is that more thrombin is formed in damaged veins, for instance because they 
may express more tissue factor, which is known to be distributed through the vascular 
system in a non-uniform way
40
. 
In conclusion, the present study provides new insights into similarities and 
differences in the dynamic process of arterial and venous thrombus formation. In this 
murine model, platelet PS exposure appears to be an important regulatory process in 
either vessel type, integrating platelet activation and thrombin generation. This in vivo 
study thus indicates that platelet procoagulant activity may be a clinically relevant target 
for antithrombotic therapy. 
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Abstract 
Platelets play a dual role in thrombosis by forming aggregates and stimulating 
coagulation. We investigated the commitment of platelets to these separate functions 
during thrombus formation in vitro and in vivo. Flow of human or mouse blood over 
collagen under coagulant conditions in vitro results in fibrin-rich thrombi with platelets 
exposing phosphatidylserine (PS). Two-photon microscopy reveals these thrombi to be 
heterogeneous in composition. They partly consist of microdomains of aggregated, 
fibrin(ogen)-binding platelets with activated αIIbβ3 integrins. These are segregated from 
strings of PS-exposing platelets, low in αIIbβ3 activation but displaying increased binding 
of all components of the prothrombinase complex (factor Va, factor Xa and prothrombin). 
Typically, “coated” platelets, binding factor Va, overlap both types of microdomains. In 
vivo, damage of the murine carotid artery leads to production of thrombi with a similar, 
patch-like composition. A key regulatory event in the appearance of PS-exposing 
platelets is the secondary down-regulation of active αIIbβ3, which is mediated by 
increased tyrosine kinase activity. Together, these results point to a local segregation 
within thrombi of aggregated and coagulation-active platelets, whereby tyrosine kinases 
trigger to integrin inactivation, thus reducing the aggregatory properties of procoagulant 
platelets. 
Introduction 
Activated platelets have a dual role in hemostasis and thrombosis. They form 
the building blocks of a thrombus and provide the membrane surface for coagulation 
factor activation, which results in thrombin and fibrin formation
1,2
. Once formed, thrombin 
greatly enhances the activation and aggregation of platelets. Given this strong 
interdependency of thrombin generation and platelet activation, it is intuitively assumed 
that the platelets that participate in aggregate formation are also involved in coagulation. 
The mechanism(s) by which platelets contribute to the coagulation process are 
still incompletely identified. Kinetic evidence shows that collagen/thrombin-activated 
platelets expose phosphatidylserine (PS) at their outer surface and then bind Gla 
domain-containing coagulation factors, mediating factor Xa and thrombin generation
3
. 
However, even after activation with strong Ca
2+
-mobilizing agonists, not all platelets 
expose PS
4-6
. Conversely, there is evidence that PS exposure alone is insufficient to fully 
explain the procoagulant effect of platelets
7,8
. Another point of debate is whether 
subfractions of activated platelets have specific functions in the coagulation process. 
Several reports indicate that only part of the PS-exposing platelets are capable to bind 
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one or more of the coagulation factors Va, VIIIa, IXa and Xa
9-11
. One study identifies a 
subpopulation of activated platelets with so-called SCIP morphology (for sustained 
calcium-induced platelet), which are targets for factor XIIIa or other transglutaminases 
and partly express PS
12
. Some authors describe a subpopulation of collagen- and 
thrombin-activated (COAT or ‘coated’) platelets, which express serotonin binding sites at 
their outer surface that function in the assembly of sheets of fibrinogen, von Willebrand 
factor (vWF) and factor Va
13-15
. However, others conclude that factor XIIIa is not required 
for generation of the coated platelet phenotype
16
. Thus, there is substantial evidence that 
individual platelets respond in a different way to collagen/thrombin activation by binding 
to coagulation factors. However, the mechanism of origin and the function of these 
differences are still unclear. Moreover, the relevance of this for the thrombus forming 
process is completely unknown. 
Recently, we and others have shown that platelets which adhere to collagen 
under high shear flow conditions are heterogeneous with respect to Ca
2+
 signaling and 
PS exposure
12,17
. Here, we aimed to extend this work by hypothesizing that differences 
in intracellular signaling properties determine the ‘fate’ of a platelet to become either 
procoagulant or proaggregatory. Our results show that, both in flow chambers in vitro 
and in arterial thrombosis models in vivo, platelets in a thrombus appear to segregate 
into distinct microdomains with aggregatory or procoagulant functions. A key 
discriminatory event in the segregation process is the activation and subsequent 
inactivation of integrin αIIbβ3. 
Materials and methods 
Materials  
Convulxin was purified to homogeneity from the venom of Crotalus durissus 
terrificus (Latoxan, France)
4
. Annexin A5 labeled with Oregon Green (OG)-488, Alexa 
Fluor-568 (AF568) or AF647 was from Molecular Probes (Leiden, The Netherlands), as 
were OG488-conjugated human fibrinogen, Syto-44 and AF532-labeled streptavidin. 
Fluorescein isothiocyanate (FITC)-labeled monoclonal antibody against human P-
selectin (α-CD62 mAb) was from WAK Chemie (Steinbach, Germany); FITC-labeled 
PAC1 antibody from BD Biosciences (San Jose, CA); (FITC-labeled) anti-
phosphotyrosine mAb 4G10 from Upstate Biotechnology (Dundee, UK); anti-actin mAb 
AC-40 from Sigma (St. Louis, MO). Lotrafiban was a gift from GlaxoSmithKline 
(Middlesex, UK). Biotin-pentylamine-succinylated bovine serum albumin (BPA-sBSA), 
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prepared by reacting succinylated BSA with biotin-pentylamine, was kindly provided by 
dr. G. Dale (Dept. of Medicine, Health Science Center, Oklahoma). BPA-sBSA 
recognizes serotonin binding sites on coated platelets and is less sensitive to oxidation 
than the parent compound, biotin-BSA-(5HT)n
14
. Biotin was detected with AF488- or 
AF532-labeled streptavidin. Other materials were from sources described earlier
17
. 
Fluorescent coagulation factors  
Active site OG-labeled, human factor Xa was prepared by inactivation of native 
factor Xa with N
α
-[(acetylthio)acetyl]-(D-Phe)-Pro-Arg-CH2Cl, and covalent modification 
with OG488-iodoacetamide following mild NH2OH treatment, as described
18
. OG-
prothrombin was labeled at the active site by a similar method, following formation of the 
catalytic site on the prothrombin zymogen by the use of a staphylocoagulase fragment
19
. 
Stoichiometries of OG incorporation into factor Xa and prothrombin were 0.8 and 0.9 mol 
probe per mol protein, respectively. OG-prothrombin had 0.1% residual native 
prothrombin, determined as described
19
. Bovine factor V, purified as described
20
, was 
suspended in phosphate-buffered saline and labeled with AF488 protein labeling kit 
using a PD-10 column (Molecular Probes). The AF-488 labeled factor V contained 15 
mol probe per mol protein. After activation with thrombin, the labeled factor Va had 
retained its cofactor function in enhancing factor Xa activity. SDS-gelelectrophoretic 
analysis under reducing conditions showed that both the heavy and light chains of factor 
Va were labeled. Concentrations of labeled coagulation factors were confirmed by 
protein assay. 
Collection of human and mouse blood  
Blood was obtained from healthy volunteers with full informed consent. For 
experiments in the absence of coagulation, blood was collected into 40 µM D-Phe-Pro-
Arg-chloromethyl ketone (PPACK) in 10% saline, and supplemented hourly with 
additional 20 µM PPACK. For experiments involving coagulation, blood was collected in 
10% 0.129 M trisodium citrate. 
Wildtype 12-week-old C57Bl/6 mice of either sex (20-25 g) were obtained from 
Charles River (Maastricht, The Netherlands). Blood was collected under anesthesia with 
ketamine and xylazine (Eurovet, Bladel, The Netherlands) by orbital puncture. For 
experiments in the absence of coagulation, blood was collected in PPACK/heparin
21
; for 
experiments involving coagulation, blood was collected into 0.129 M trisodium citrate. 
Experiments were approved by the local animal
 
care and use committees. 
Formation of procoagulant microdomains in thrombi 
 
 
139 
Two-photon laser scanning microscopy (TPLSM) and confocal microscopy  
TPLSM was performed with a BioRad 2100 multiphoton system. Excitation was 
with a Spectra Physics Tsunami Ti:Sapphire laser, tuned and mode-locked at 800 nm, 
producing pulses of 100 fs wide (repetition rate 82 MHz), which was connected to an 
upright Nikon E600FN fluorescence microscope
22
. Two photomultipliers with separate 
pinholes detected fluorescence, selected by optical filters, at 508-523 nm and 570-620 
nm. A third photomultiplier detected fluorescence above 660 nm from a parallel-placed 
red diode laser, exciting at 647 nm. This system was used for confocal scanning of 
thrombi in flow chambers during or after perfusion, and for deep scanning of intact 
carotid arteries, mounted in a home-build perfusion chamber. Thrombi were double or 
triple labeled to detect fluorescence from the probes OG488 (color-coded green), AF568 
or Syto-44 (color-coded blue), and AF647 (color-coded red). Optical sections were 
scanned in Kalman filtering mode without further image processing. Single-photon, two-
color confocal laser scanning microscopy, using a Leica confocal microscope (DM, IRE2; 
Leica, Milton Keynes, UK), was performed as described
23
. Analysis of all confocal 
images (gray level bit maps) and 3D reconstruction of images were with 
ImagePro/LaserPix software (Media Cybernetics, Silver Spring, MD). Degree of co-
localization of two fluorophores was evaluated using the Pearson’s correlation coefficient 
(Rr), which describes the overlap between two colored patterns, and is independent upon 
pixel intensity values. The overlap coefficient (R) and the sub-coefficients k1 and k2, 
which vary with differences in color intensities, were also calculated. 
Thrombus formation on collagen under flow  
Human or murine blood was perfused at shear rate of 150-1000 s
-1
 over a 
collagen surface, as described
24
. Briefly, glass coverslips were coated with fibrillar Horm 
type-I collagen, blocked with Hepes buffer pH 7.45 (5 mM Hepes, 136 mM NaCl, 2.7 mM 
KCl, 0.42 mM NaH2PO4 and 1% BSA), and then placed in a parallel plate flow chamber 
(slit depth of 50 µm). Blood pre-incubated for 15 minutes with inhibitors and/or probes, 
was perfused for up to 4 minutes over the collagen. Thereafter, the flow chamber was 
post-perfused for a further 4 minutes with Hepes buffer, pH 7.45 containing 2 mM CaCl2 
and 1 U/mL heparin. For coagulation experiments, citrate-anticoagulated blood was co-
perfused with 10 vol% of Hepes buffer, pH 7.45 containing 20 pM tissue factor and 200 
mM CaCl2 upon entry into the flow chamber
24
. 
Bright-field phase-contrast and fluorescence images of adherent platelets were 
also recorded using a non-confocal two camera system
25
. Surface coverage with 
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platelets was analyzed using ImagePro software. Data from >10 different fields of view 
were averaged per experiment without image processing. 
Thrombus formation in vivo  
Twelve-week-old mice were anesthetized by subcutaneous injection of 
ketamine and xylazine, followed by continuous infusion of ketamine. Fluorescently 
labeled compounds were administered intravenously through a PE-10 catheter in the tail 
vein
26
. Carotid arteries were dissected free and ligated vigorously for 5 minutes to induce 
vascular injury. In other animals, the adventitial surface of the carotid artery was 
damaged by local application of a filter paper (0.5×1.0 mm) with 1 M FeCl3 for 5 minutes. 
With either method, thrombus formation was allowed to proceed for 10 minutes, after 
which fluorescence in the still intact vessel was monitored by TPLSM. For ex vivo 
evaluation, 5 mm of the artery was carefully removed, mounted between two 
micropipettes in a perfusion chamber, and subjected to 1.0 atmosphere pressure
22
. 
Mounted arteries were post-labeled for 30 minutes with Syto-44 (2 µM in phosphate-
buffered saline), to stain for nuclei. 
Flow cytometry 
Diluted PRP or washed platelets (1×10
8
 platelets/mL) were activated with 50 
ng/mL convulxin and 4 nM thrombin in the presence of 2 mM CaCl2 for 5-30 minutes. 
Samples were incubated with fluorescent labels and/or antibodies, as described in the 
text. For double labeling experiments, probes exciting at 488 and 647 nm were added 
simultaneously at saturating concentrations. Detection of fluorescence was with a 
FACScan flow cytometer, equipped with an argon and a red diode laser (Becton-
Dickinson, Franklin Lakes, NJ). For analysis, platelets were gated based on their forward 
scatter/side scatter (FSC/SSC) characteristics. A minimum of 10,000 events was 
counted per assay. Control measurements were performed with unlabeled/stimulated 
and labeled/unstimulated platelets. List-mode data were analyzed using WinMDI 2.8 
software (http://facs.scripps.edu). 
Protein tyrosine phosphorylation in adherent platelets  
After flow experiments, adherent platelets on collagen-coated coverslips were 
stained with AF647-annexin A5, and then fixed for staining with FITC-4G10 anti-
phosphotyrosine mAb. Alternatively, platelets on coverslips were carefully lysed with ice-
cold NP-40-based lysis buffer pH 7.4 (300 mM NaCl, 20 mM Tris-HCl, 2 mM EGTA, 2 
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mM EDTA, 2 mM Na3VO4, 1 mM 4-(2-aminoethyl)-bezenesulfonylfluoride, 10 µg/ml 
leupeptin, 10 µg/ml aprotinin, 1 µg/ml pepstatin, 2% NP-40). Protein was quantified in the 
lysates with a BioRad DC protein kit. Lysates with calculated equal protein amounts were 
resolved on 10% SDS-PAGE gels, then transferred to blotting membranes by semi-dry 
transfer. Membranes were immuno-blotted using an ECL system (Amersham 
Biosciences, Bucks, UK) with 4G10 mAb followed by stripping of the membranes and re-
probing with AC-40 anti-actin mAb to verify equivalent loading
27
. 
Statistics  
Differences were tested on significance with the Mann-Whitney U test using the 
statistical package for social sciences (SPSS 11.0, Chicago, IL). Results are given as 
mean values ± SD, unless otherwise indicated. 
Results 
Microdomains of aggregated and procoagulant platelets in thrombi formed under 
flow  
In the absence of coagulation, flow of human or murine blood over collagen 
leads to GPVI-dependent formation of thrombi containing PS-exposing platelets
21,25,26
. 
We studied how the tissue factor coagulation pathway contributed to this thrombus 
formation, by flowing human blood over collagen under high shear conditions in the 
presence of different fluorescent labels. Using PPACK-treated blood, OG-labeled 
fibrinogen (0.2 mg/mL) slowly, but steadily incorporated into platelet aggregates that 
were formed on collagen (Figure 1A). The probe OG-annexin A5 (0.5 µg/mL), which 
labels exposed PS
4
, only started to accumulate after a delay of 200 seconds (Figure 1B). 
When coagulation was triggered by co-perfusion of citrate blood together with tissue 
factor/CaCl2, the formation of platelet aggregates and fibrin fibers was followed by that of 
larger clots containing erythrocytes. The incorporation of OG-fibrinogen was increased in 
this condition, and it further enhanced at the time point (~170 seconds) of clot formation 
(Figure 1A). The addition of OG-annexin A5, which is an anticoagulant
28
, typically 
delayed the clotting time to 200 seconds. After this time point, annexin A5 labeling 
greatly increased (Figure 1B, see also below). 
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Multicolor TPLSM with high optical resolution and high penetration power was 
used to better localize the bound OG-fibrin(ogen) and AF647-annexin A5 within human 
and murine thrombi formed on collagen. These labels were simultaneously or 
sequentially added to the blood, either during or after flow, with essentially the same 
results (data not shown). Comparison of bright-field contrast images and two-color 
fluorescent images indicated that OG-fibrinogen was only present on aggregated 
platelets, whilst AF647-annexin A5 bound a distinct population of single platelets (Figure 
2, upper and middle rows). Triggering of coagulation with tissue factor/CaCl2 did not 
influence the labeling of OG-fibrin(ogen), still binding to aggregated platelets. Again, 
AF647-annexin A5 labeled a different population of platelets around the clots. The same 
 
Figure 1 Time-dependent accumulation of labeled fibrin(ogen) and annexin A5 in thrombi 
formed in the absence or presence of coagulation. Human blood containing 0.2 mg/mL OG-
fibrinogen (A) or 0.5 µg/mL OG-annexin A5 (B) was perfused over collagen at a shear rate of 1000 
s
-1
, and fluorescent images were captured from the collagen surface. PPACK-anticoagulated blood 
was used (open diamonds) or, alternatively, citrate-anticoagulated blood that was co-perfused with 
2 pM tissue factor and 2 mM free CaCl2 (final concentrations) to reach physiological Ca
2+
/Mg
2+
 
concentrations (filled squares). Surface area coverage with fluorescence of a representative 
experiment out of 4 performed is shown; arrows indicate appearance of microscopic clots. Images 
(150×150 µm) shown are examples of experiments in which coagulation occurred (150-250 s). 
 
Formation of procoagulant microdomains in thrombi 
 
 
143 
staining patterns were obtained with both human and murine blood (Figure 2), including 
when any one of the two labels was omitted (data not shown). Thus, the heterogeneous 
labeling pattern was not due to competition between labels for the same binding sites on 
platelets. 
‘Coated’ platelets are recognized by their property to bind multi-amine, 
serotonin-like compounds such as BPA-sBSA, and may participate in coagulation
13,14
. To 
detect the formation of coated platelets under flow, we allowed thrombi to form on 
collagen in the presence of labeled BPA-sBSA. Simultaneously, AF647-annexin A5 was 
present in this experiment to detect PS-exposing platelets. Surprisingly, the BPA-sBSA 
labeling pattern was markedly different from that of annexin A5 in both human and 
 
Figure 2 Heterogeneity in human and murine thrombi formed on collagen. Flow experiments 
were performed with human (A) or murine (B) blood in the absence of tissue factor (-TF) using 
PPACK-anticoagulated blood (left columns); or with citrate blood that was perfused together with 
tissue factor (+TF, 2 pM, f.c.) and CaCl2 (2 mM free Ca
2+
, f.c.) to allow coagulation (right columns). 
Standard perfusion time was 4 minutes at a shear rate of 1000 s
-1
. Blood was preincubated with 0.2 
mg/mL OG-fibrinogen. Alternatively, preincubation was with 50 µg/mL BPA-sBSA and post-labeling 
with 1 µg/mL AF532-labeled streptavidin. In both cases, AF647-annexin A5 was also present. 
Upper panels: bright-field phase-contrast images after perfusion. Middle panels: TPLSM images of 
OG-fibrinogen and AF647-annexin A5 fluorescence. Lower panels: TPLSM images of BPA-sBSA 
and AF647-annexin A5 staining. Images are representative of 4-8 experiments; bars indicate 20 
µm. 
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mouse blood, with many of the fluorescent BPS-sBSA corresponding to platelets in 
aggregates (Figure 2, lower row). Clot (thrombin) formation affected the labeling pattern 
only slightly, although some of the label coincided with annexin A5. Control experiments 
indicated that BPS-sBSA labeling was not affected by the presence of annexin A5 (not 
shown). This pointed to a clear difference between coated and PS-exposing platelets. 
The biphasic increase in annexin A5 labeling under coagulant conditions 
suggested that platelets expose PS after interaction with either collagen or clot material 
(e.g. fibrin). This was indeed visible in high magnification images (Figure 3). In the 
absence of clots, or prior to their formation, only isolated, collagen-bound platelets with a 
bleb-shaped appearance bound annexin A5. A few minutes after coagulation, strings or 
patches of annexin A5-positive, bleb-shaped platelets appeared around the clots. 
Interestingly, the majority of aggregated platelets did not form blebs nor stained 
positively for annexin A5. Thus, microdomains of PS-exposing platelets are clearly 
separated from the microdomains of aggregated platelets. 
Heterogeneity of integrin activation and PS exposure upon stimulation of collagen 
and thrombin receptors  
To search for the mechanism responsible for the heterogeneity, other dual 
labeling flow studies were performed under coagulant conditions in the presence of 
FITC-PAC1 mAb (detecting activated αIIbβ3) and AF647-annexin A5 (for PS exposure). 
 
Figure 3 Bleb-shaped annexin A5-binding platelets on fibrin-containing aggregates. Human 
thrombi were formed on collagen during perfusion with tissue factor, and stained as described for 
Figure 2. Representative high-resolution phase-contrast and fluorescence images are shown after 
5 (left) and 15 minutes (right) of perfusion. Bars indicate 20 µm. 
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TPLSM showed that platelets assembled into aggregates and clots expressed activated 
 αIIbβ3 (Figure 4A). These platelets were well separated from the annexin A5-binding 
platelets (which did not bind PAC1), e.g. around clots. Again the same labeling patterns 
were obtained, when the experiments were performed with either probe alone (not 
shown). Control experiments indicated that the aggregated and bleb-shaped platelets 
both bound mAb, directed against activation-independent epitopes of  αIIbβ3, indicating 
that integrins were still present on the PS-exposing platelets. 
To validate these findings, also platelets in suspension were stimulated with a 
GPVI agonist, convulxin, alone or in combination with thrombin. Two-color flow cytometry 
showed that populations of FITC-PAC1 positive and negative platelets were well 
separated in the FL1 channel, while those of AF647-annexin A5 positive and negative 
cells were separated in the FL4 channel (Figure 4B). Time curves indicated that shortly 
after stimulation, most of the platelets bound FITC-PAC1, but were negative for AF647-
annexin A5 (Figure 4B,C). After 10-15 minutes, PAC1 binding was down-regulated in the 
 
Figure 4 Temporary integrin activation state in procoagulant platelets. (A) Human thrombi were 
formed on collagen during tissue factor-induced coagulation, as described for Figure 2. Stains were 
0.6 µg/mL FITC-PAC1 and 0.5 µg/mL AF647-annexin A5. Representative two-photon images are 
shown of FITC and AF647 fluorescence at lower and higher magnifications. Bars indicate 20 µm. (B, 
C) Washed platelets were stimulated in the presence of 2 mM CaCl2 with 50 ng/mL convulxin alone or 
with 4 nM thrombin, for 5-30 minutes. (B) Representative dot plots are given of FL1 (FITC) versus FL4 
(AF647) after 5 minutes of stimulation with convulxin. (C) Two-color flow cytometry after co-staining at 
indicated times with FITC-PAC1 and AF647-annexin A5, showing transient appearance of PAC1 
binding sites and persistent PS exposure. Data are percentages of platelets staining with FITC-PAC1 
(grey bars) or OG-annexin A5 (black bars). Mean ± SD (n=4), *p<0.05 compared to t=5 minutes. 
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majority of the platelets, which now bound annexin A5. Pretreatment of platelets with the 
transglutaminase inhibitor, mono-dansyl cadaverine (MDC), or the calpain inhibitor, 
calpeptin, left annexin A5 binding unchanged, but caused a 30% or 3% decrease in 
PAC1 binding, respectively. Apparently, transglutaminase and calpain are not major 
factors in regulating the inactivation of integrins and the heterogeneity in PS exposure. 
Further characterization of microdomains of PS-exposing platelets in thrombi  
It was shown earlier that PS-exposing membranes function as assembly sites 
for the prothrombinase complex, to form thrombin
29
. To investigate this further, flow 
studies were performed with blood containing labeled factors of this complex, i.e. AF488-
factor Va, OG-factor Xa or OG-prothrombin, always in the simultaneous presence of 
AF647-annexin A5. Without coagulation, weak staining was visible at the aggregated 
platelets (not shown). In the presence of tissue factor and coagulation, the labeling of 
thrombi with these factors increased, e.g. AF488-factor Va fluorescence per pixel 
increased by 2.3 fold (n=4). High-magnification images showed that particularly patches 
of (bleb-formed) platelets were double-stained with annexin A5 and the coagulation 
factors (Figure 5A). The PS-exposing platelets also stained positively for CD62. Further 
evidence that especially the PS-exposing platelets may have a function in coagulation 
 
 
Figure 5 Partial overlap of coagulation factor and annexin A5 binding to stimulated platelets. 
Human thrombi were generated on collagen under coagulant conditions in the presence of AF647-
annexin A5 (see Figure 2) in combination with either 20 nM AF488-factor Va, 200 nM OG-prothrombin, 
100 nM OG-factor Xa or 1.25 µg/mL FITC-α-CD62 mAb. (A) Representative TPLSM fluorescence 
images are shown of AF647-annexin A5 and indicated coagulation factor or antibody. Bars indicate 20 
µm. (B) Pattern overlap analysis of TPLSM images with annexin A5 and indicated factor or antibody. 
Pearson’s correlation coefficients (Rr) of corresponding green and red bit maps are given. Data are 
from at least 4 experiments. 
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came from quantitative overlap analysis of the various sets of two-colored fluorescence 
images. The Pearson’s correlation coefficient (Rr) was calculated to determine the 
pattern overlap of complementary images of red annexin A5 and green probe. Strikingly, 
this coefficient was low for green fibrinogen, PAC1 or BPA-sBSA, but much higher for 
green factor Va, factor Xa, prothrombin or anti-CD62 mAb (Figure 5B). Quite similar 
results were obtained when the overlap coefficient (R) was calculated for the same 
image sets (not shown), although it is sensitive for color intensity variation. 
Two-color flow cytometric analysis was performed, following platelet stimulation 
with convulxin and thrombin, to confirm the separation of platelets into groups with 
different properties. On average, the population of stimulated, annexin A5-negative 
platelets relatively weakly bound the fluorescent-labeled factor Va, factor Xa and 
 
Figure 6 Heterogeneity in binding properties of PS-exposing platelets. Platelets in suspension 
were either unstimulated or stimulated with 50 ng/mL convulxin, 4 nM thrombin and 2 mM CaCl2 for 10 
minutes. Two-color flow cytometry was performed after staining with AF647-annexin A5 in combination 
with either 20 nM AF488-factor Va, 100 nM OG-factor Xa, 200 nM OG-prothrombin or 1.25 µg/mL 
FITC-α-CD62 mAb. (A) Shown are dot plots of FL1 (AF488, OG) versus FL4 (AF647), representative 
of at least 4 experiments. (B) Characterization of the annexin A5 positive and annexin A5 negative 
fractions of platelets after 10 minutes of activation. Data are percentages of platelets staining positively 
(upside bars) or negatively (downside bars) with indicated probe: FITC-PAC1, AF532-streptavidin 
BPA-sBSA, AF488-factor Va, OG-factor Xa, or FITC-α-CD62. Data are representative for 4 
independent experiments. 
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prothrombin, whereas the annexin A5-positive platelets showed increased binding of 
these coagulation factors by 2.7, 3.1 and 2.0 fold, respectively (Figure 6A). In contrast, 
both populations of activated platelets were similarly high in CD62 expression. 
For further analysis of these populations of AF647-annexin A5 positive and 
negative platelets, threshold levels of green fluorescence were set to indicate activation-
induced binding of labeled antibodies and coagulation factors (Figure 6B). Comparison 
showed that hardly any of the PS-exposing (annexin A5-positive) platelets bound PAC1, 
while only a minority bound BPA-sBSA (probing coated platelets). In contrast, a large 
fraction of the PS-exposing platelets had increased binding of factor Va, factor Xa and 
anti-CD62 mAb. On the other hand, the PS-negative platelets preferentially bound PAC1, 
anti-CD62, and to a moderate extent PBA-sBSA, but they were low in factor Va and 
factor Xa binding. Taken together, these data provide strong indications that platelets in 
a thrombus are segregated into aggregates that bind fibrin(ogen), PAC1 and BPA-sBSA 
and, at the other hand, patches of PS-exposing platelets with increased binding of all 
components of the prothrombinase complex (factor Va, factor Xa, and prothrombin) at 
the expense of integrin activation. 
Tyrosine phosphorylation state regulates platelet heterogeneity  
The observation that in platelets stimulated by convulxin and thrombin, αIIbβ3 
inactivation is linked to PS exposure may point to the involvement of a common signaling 
 
Figure 7 Modulation of protein tyrosine phosphorylation alters integrin activation and PS 
exposure. Human washed platelets were stimulated with 50 ng/mL convulxin and 4 nM thrombin in 
the presence of 2 mM CaCl2. The cells were pre-incubated for 10 minutes, as indicated, with vehicle, 
200 µM phenylarsine oxide (PAO), 100 µM genistein, 20 µM PP2, or 10 µM lotrafiban. Co-labeling was 
with a mixture of FITC-PAC1 and AF647-annexin A5. Data are expressed as percentages of platelets 
staining with FITC-PAC1 (grey bars) or OG-annexin A5 (black bars). Mean ± SD (n=4), *p<0.05 
compared to stimulation in the presence of vehicle. 
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factor.  
To investigate this further, platelets in suspension were pretreated with the 
αIIbβ3 blocker, lotrafiban
17
, prior to stimulation with convulxin/thrombin. Lotrafiban 
treatment abolished PAC1 binding, while annexin A5 binding remained high (Figure 7), 
suggesting that integrin activation does not regulate PS exposure. Because both 
collagen and thrombin receptors activate platelet tyrosine kinases, we then investigated 
the effects of modulation of the tyrosine phosphorylation state. Pretreatment of platelets 
with the protein tyrosine phosphatase inhibitor, phenylarsine oxide (PAO), resulted in 
increased tyrosine phosphorylation (not shown), which was accompanied by 
substantially reduced PAC1 binding and unchanged PS exposure (Figure 7). By 
contrast, platelet pre-incubation with the general protein tyrosine kinase inhibitor 
genistein or the Src-kinase inhibitor PP2 left PAC1 binding virtually unchanged, while 
 
Figure 8 Role of integrin αIIbβ3 in tyrosine phosphorylation of collagen-adherent platelets. 
Human blood pre-treated with vehicle (control) or 10 µM lotrafiban was flowed over collagen for 4 
minutes at a shear rate of 1000 s
-1
, and stained with OG488-annexin A5. Numbers below images 
indicate mean surface area coverage ± SD. (A) Representative phase-contrast (120×120 µm) and 
fluorescence (150×150 µm) images. (B) Flow chambers were perfused with lysis buffer to remove 
adherent platelets and lysates (equalized as far as possible for protein quantity) were run on a SDS-
PAGE gel, transferred to PVDF and blotted for phosphotyrosine using mAb 4G10, (C) then stripped 
and re-probed for actin using mAb AC-40. Representative data of 2-4 experiments. Note the low 
actin staining for the lotrafiban lane, indicating the increased phosphorylation of 7, 38, 72 and 105 
kDa proteins is underestimated for this gel. 
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these compounds reduced the number of PS-exposing cells. Yet, in all conditions, the 
majority of the platelets that bound PAC1 did not bind annexin A5, and vice versa. 
Together, this indicated that a prolonged high tyrosine phosphorylation state (e.g., by Src 
kinase activity) reduced integrin activation, but stimulated PS exposure. 
The importance of protein tyrosine phosphorylation was further examined in 
flow studies (in the absence of coagulation). Pre-incubation of blood with lotrafiban 
increased the number of PS-exposing platelets, but reduced the total number of 
adherent platelets, because aggregation was abolished (Figure 8). Gel electrophoresis of 
the platelet proteins, followed by immunoblotting with anti-phosphotyrosine 4G10 mAb, 
 
Figure 9 Heterogeneity in arterial thrombi induced by carotid ligation or by FeCl3 
application. Mice were infused with OG-fibrinogen and AF568-annexin A5 (200 µg each). Left 
panels: undamaged control carotid artery. Middle panels: One carotid artery was damaged by tight 
ligation at the bifurcation for 5 minutes to induce vascular damage. Right panels: in another animal, 
the carotid artery was damaged by local application of saturated FeCl3. Thrombus formation 
proceeded for 10 minutes, after which fluorescence inside the arteries was recorded by TPLSM. 
(A) Upper row: images of fibrin(ogen) and annexin A5  fluorescence taken on the luminal side of 
the vessel wall. Note distinct patches of green and red fluorescence. Second row: images of Syto-
44 fluorescence at cross section through the vessel wall. Arrow heads indicate absence of cell 
nuclei at sites of damage. (B) Three-dimensional reconstructions of fibrin(ogen) and annexin A5 
fluorescence in the ligated artery: side view through vessel wall, turned view, and view from inside 
of vessel lumen. Images are 206×206 µm. 
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indicated that lotrafiban treatment specifically increased the tyrosine phosphorylation 
levels of proteins of about 7, 38, 72 and 105 kDa (Figure 8). More direct evidence for an 
increased tyrosine phosphorylation in PS-exposing platelets was obtained by staining the 
collagen-bound platelets on coverslips with FITC-4G10 mAb. Comparison of brightfield 
and confocal fluorescent images indicated that, typically, the single (AF647-annexin A5 
positive) platelets were more fluorescent than adjacent platelets in aggregates. 
Quantitative analysis showed that fluorescence levels per pixel of the single cells were 
2.4 ± 0.8 (n=7) fold higher, in comparison to pixels with aggregated platelets. Lotrafiban 
treatment maintained this high FITC-4G10 staining. Accordingly, high tyrosine 
phosphorylation levels accompany PS exposure, but not integrin activation. 
Heterogeneity in fibrin(ogen) binding and PS exposure of thrombi formed in vivo  
A key question is how the platelet heterogeneity as observed in thrombi formed 
in vitro relates to the in vivo situation. To investigate this, anesthetized mice were co-
infused with fluorescently labeled OG-fibrinogen and AF568-annexin A5. Thereafter 
damage to the carotid arteries was provoked using two different techniques. In the first 
method, the artery was ligated, which results in mechanical exposure of subendothelial 
collagen
30
. Alternatively, FeCl3 was applied locally to the vessel, which causes 
endothelial denudation by free radical formation
26,31
. After in vivo thrombus formation for 
10 minutes, the injured and control (undamaged) vessels of the animals were scanned 
using the high penetration power of TPLSM. Typically, fluorescence from both probes 
was detected only at sites of ligation or FeCl3 application, and was absent in control 
arteries. Optical cross-sections showed local spots of OG-fibrin(ogen) at the wall-lumen 
interface, which to a small extent overlapped with spots of AF568-annexin A5 (Figure 9A, 
first row). Three-dimensional reconstruction of the images at thrombotic sites showed 
distinct patches of fluorescent fibrin(ogen) and annexin A5, again only at the damaged 
vascular lumen (Figure 9B). After scanning, the still intact arteries were post-stained for 
vessel wall cells with the nuclear stain Syto-44, and then rescanned. Optical cross-
sectioning demonstrated absence of Syto-44 fluorescence at the sites of ligation or FeCl3 
application, thus confirming the local damaging effect of the prothrombotic interventions 
(Figure 9A, second row). Together, these data show that fibrin(ogen)-rich and annexin 
A5-binding domains appear at adjacent but distinct locations during in vivo thrombus 
formation. 
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Discussion 
The present data indicate that during the thrombus-forming process different 
clusters of platelets contribute to aggregate formation and to coagulant activity, which 
points to a clear spatial separation of these two key functions of platelets. In shear-
dependent thrombus formation triggered by collagen (GPVI) and thrombin receptors, we 
distinguish at least two, and likely even three microdomains of activated platelets: (i) 
platelets packed in fibrin-containing aggregates (clots) with activated αIIbβ3 integrin at 
their surface; (ii) strings of non-aggregated platelets which are low in activated αIIbβ3, 
but expose PS and efficiently bind the components of the prothrombinase complex; (iii) 
platelets binding serotonin probes in addition to factor Va, which partly overlap with the 
aggregated platelets. 
The microdomains of aggregated platelets, rich in fibrin(ogen) under condition 
of thrombin generation, were most readily distinguished by high binding of PAC1 mAb, 
which stains activated αIIbβ3 integrins. Part of these platelets expressed CD62 at their 
surface, indicating secretion. Typically, as long as aggregated, these platelets did not 
bind annexin A5 and, thus, did not expose procoagulant PS. In both confocal microscopy 
and flow cytometry, the annexin A5 negative platelets showed low binding to coagulation 
factors Va and Xa and prothrombin. 
The second type of microdomain consists of mostly bleb-shaped platelets, 
which often appear as strings at the edge of clots. Visual inspection and also overlap 
analysis of two-color fluorescence images pointed to a clear separation of the annexin 
A5-binding platelets, exposing PS, from the fibrinogen- and PAC1-binding platelets in 
aggregates or clots. The round morphology and lack of pseudopods is well compatible 
with the low integrin activation state and thus diminished adhesion. Likely, these platelets 
play an important role in thrombotic thrombin generation, given the increased binding of 
factor Va, factor Xa and prothrombin. For these studies, we used fluorescent labeled 
factor Va, which had fully kept its co-factor function in prothrombinase activity; and active 
site-labeled factor Xa and prothrombin, with proven unaltered binding characteristics
19
. 
The appearance of single, bleb-shaped, PS-exposing platelets upon interaction 
of platelets with collagen via GPVI was already reported earlier
24,25
. However, a novel 
finding is that this platelet response becomes much more frequent during perfusion of 
blood in the presence of thrombin generation and coagulation. In this case, strings of 
platelets often located around clots jointly transform into PS-exposing cells. The result is 
that thrombi develop into a patched structure with microdomains of platelet/fibrin 
aggregates, alternated with loose clusters of PS-exposing platelets. It is tempting to 
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suggest that the collagen-bound platelets in the first phase of PS exposure contribute to 
initial phases of thrombin generation, while the procoagulant platelets around clots help 
to propagate thrombin production. A similar patched structure of fibrin(ogen)- and 
annexin A5-binding cells is observed by TPLSM imaging of the thrombi inside murine 
arteries, generated following two different models of vascular damage in vivo. Thus, we 
hypothesize that the microdomain organization with separate aggregated/clotted and 
coagulation-active platelets is functionally relevant to arterial thrombosis in humans. 
The experiments distinguish a third subpopulation of platelets, but with less 
characteristic binding properties. Using BPA-sBSA as a probe that specifically detects 
serotonin binding sites, we observed appreciable labeling of platelet aggregates and to a 
smaller extent to single, PS-exposing platelets. In fact, the Pearson correlation 
coefficient Rr of BPA-sBSA versus fibrinogen staining is 0.54, i.e. higher than the Rr of 
BPA-sBSA versus annexin A5 labeling of 0.21. The fact that aggregates were labeled 
with BPA-sBSA is not surprising, because the initial description of ‘coated’ (or COAT) 
platelets referred to platelets that are covered with serotonin-derivatized proteins such as 
fibrin(ogen) and thrombospondin in association with the granular proteins vWF, factor V, 
and fibronectin
14
, all of which are present on platelet aggregates formed on a collagen 
surface
26,32,33
. On the other hand, current literature is inconsistent in the description of 
coated platelets - e.g. as formed by convulxin/thrombin stimulation -, which may coincide 
with PS-exposing platelets
15
, or with fibrin(ogen)-binding platelets
16
. The present data 
can resolve this discrepancy by showing that BPA-sBSA binds aggregates (in thrombi) 
with a certain preference, but also to some extent PS-exposing platelets (in 
suspensions). 
Recent studies have suggested that platelet-secreted proteases are involved in 
the formation of subpopulations of coagulation-active platelets. One proposal is that 
extracellular transglutaminases like factor XIIIa contribute to this platelet response by 
cross-linking membrane surface proteins with secretion factors, e.g. via serotonin 
conjugation to form coated platelets
12,13
. Also, extracellular or intracellular calpain activity 
may contribute to development of the procoagulant platelet phenotype
4,12
. In our hands, 
inhibition of transglutaminases (MDC) or calpain (calpeptin) had only little effect on PS 
exposure, while only MDC had a small inhibitory effect on integrin inactivation in 
convulxin/thrombin-stimulated platelets. This indicated that transglutaminases did not 
play a major role in the regulation of platelet procoagulant activity, which is in line with a 
recent report that the binding of secretory proteins and annexin A5 to platelets on 
collagen requires GPVI/FcR γ-chain activity, but not factor XIIIa
16
. 
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Therefore, we investigated the possibility that an intracellular signaling pathway 
rather than an extracellular mechanism is responsible for platelet heterogeneity in 
thrombus formation. Reason for this is the knowledge that GPVI alone or in combination 
with thrombin receptor stimulation causes a potent Ca
2+
 response, which is a 
prerequisite for PS exposure in both human and murine platelets
4,12,24,34
. The current 
data provide evidence that protein tyrosine kinase activity is stimulatory to PS exposure 
(likely via stimulation of the GPVI - phospholipase C-γ2 pathway), but inhibitory to 
persistent integrin αIIbβ3 activation. This is concluded from the relatively high tyrosine 
phosphorylation state of PS-exposing, PAC1-negative platelets on collagen as probed 
with fluorescent 4G10 mAb, and also from the reducing effect of tyrosine phosphatase 
inhibition on PAC1 binding with unchanged PS exposure. Further support came from 
perfusion experiments in the presence of an αIIbβ3 antagonist, which increased the 
tyrosine phosphorylation of several platelet proteins along with the number of PS-
exposing platelets on collagen. 
In summary, we conclude that in collagen- and thrombin-induced thrombus 
formation, differences in intracellular signaling state controlled by αIIbβ3 activation 
accomplish the separation of microdomains of aggregated and PS-exposing platelets. 
Typically, in PS-exposing platelets, down-regulation of integrin binding is accompanied 
by up-regulation of coagulation factor binding. These results point to a balance, in which 
coagulant activity suppresses integrin activation, while conversely, aggregate formation 
reduces the procoagulant activity of platelets. 
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The majority of cardiovascular diseases involve undesired thrombus formation 
and embolisation following vascular damage or plaque rupture. The thromboembolic 
process is known to be driven by platelet activation and the coagulation system. As 
these processes are of major importance in both arterial and venous thrombosis, clear 
understanding of the interactions between these two processes will be important for a 
successful fight of cardiovascular diseases. The overall goal of the studies presented in 
this thesis is to identify and study the interaction between platelet activation and 
coagulation at different levels of complexity. Part of the investigations considers sub-
cellular and cellular aspects of the signaling pathways of platelets that contribute to the 
generation of their procoagulant activity. Other experiments focus on the intercellular 
processes defining the formation of multi-platelet thrombi formed in vitro under conditions 
of blood flow and coagulation. Furthermore, in vivo mouse models of experimental 
intravascular thrombosis have been developed and used to assess the role of 
procoagulant platelets in coagulation and the differences among platelets in a thrombus. 
The signaling receptor for collagen, glycoprotein VI, appears to play a key role in this 
platelet response. 
Signaling pathways of glycoprotein VI to procoagulant activity 
Knowing that platelet-collagen interaction via glycoprotein VI (GPVI) can induce 
procoagulant activity, we were interested to determine which processes operating 
alongside and downstream of GPVI contribute to the procoagulant response under 
physiologically relevant conditions. Chapter 4 discusses the important question how the 
other collagen receptor, integrin α2β1, contributes to the procoagulant function of GPVI 
in human blood flowing at arterial shear rate. Using a newly generated single-chain 
phage antibody fragment, 10B12, we were able to demonstrate that GPVI is the 
exclusive receptor implicated in all collagen-induced activation responses, such as Ca
2+
 
signaling, aggregate formation and phosphatidylserine (PS) exposure. Inhibition of α2β1 
with specific peptides or antibodies reveals that this integrin does contribute to the 
regulation of Ca
2+
 signaling, platelet aggregation and PS exposure, but only by 
enforcement of the responses evoked by GPVI. Inhibitory experiments also show that 
blocking of another adhesive receptor, the GPIb-V-IX complex which binds von 
Willebrand factor (vWF), has only little effect on PS exposure. These results thus 
indicate that only two of the three human platelet receptors for vWF/collagen are 
involved in the procoagulant response. However, in mice GPIb interaction with vWF was 
found to enhance GPVI-induced PS exposure, along with stimulation of the rise in 
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[Ca
2+
]i
1
. The reason for this discrepancy is unclear. However, in the human system we 
have not investigated the contribution of GPIb to procoagulant activity at shear rates 
higher than 1000 s
-1
, at which more prominent GPIb effects are expected
1
. 
During the progress of this work, several other studies with human and mouse 
blood with different anti-GPVI antibodies and GPVI-deficient mouse models indicated 
that GPVI plays a key role in collagen-induced thrombus formation under flow; GPVI thus 
appears to be the principal collagen receptor causing Ca
2+
 signaling, secretion, integrin 
activation and procoagulant activity
2-4
. In the present context it is of interest that the data 
of chapter 4, and also those of other papers, demonstrate a direct relation between the 
GPVI-evoked rises in intracellular Ca
2+ 
levels and the extent of phosphatidylserine (PS) 
exposure by platelets. Together, this supports the early suggestion that the PS-exposing 
mechanism (‘scramblase’) is directly or indirectly regulated by a strong elevation in 
intracellular Ca
2+ 
concentration
5
. 
The murine studies described in chapter 5, are of particular interest for the 
signal transduction route by which GPVI is capable to induce PS exposure in the process 
of thrombus formation. Using mice deficient in FcR γ-chain, the adaptor protein LAT or 
phospholipase Cγ2 (PLCγ2), we show that these signaling proteins, which are 
downstream of GPVI, are all required for PS exposure. In addition, the essential role of 
Src-family kinases, likely Lyn, in this process was examined by using the specific 
inhibitor PD173952. It is known that the GPVI/Lyn/LAT signaling pathway is the most 
important mechanism for tyrosine phosphorylation and activation of PLCγ2 via protein 
assembly in the so-called LAT signallosome
6,7
. The same research indicated that Syk is 
the principal tyrosine kinase mediating phosphorylation of both LAT and PLCγ2
6,7
. It was 
also known that genistein, which is an inhibitor of Syk kinase, suppresses collagen-
induced PS exposure
8
, which thus makes it quite likely that also Syk is an essential 
component of the signaling route from GPVI to PS exposure. However, as Syk deficient 
mice are not viable
9
, we have not been able to demonstrate this unequivocally. 
Interestingly, recent data using vital Syk -/- chimeras pointed to a novel signaling 
pathway of GPVI in supporting thrombin-induced activation, which operates 
independently of Src and Syk kinases
10
. In view of the current results, it is unlikely that 
this GPVI pathway is involved in procoagulant activity. 
A number of other members of the LAT signallosome have been identified, 
which all act downstream of GPVI and Syk kinase, including the tyrosine kinases Btk and 
Tec, the G-protein-stimulating factors Vav1/3, and the adaptor proteins SLP-76 and 
Gads
7
. Although we have not investigated involvement of these components, we predict 
that they will only play a role in PS exposure as far as operating upstream of PLCγ2. 
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Together, our data show that the role of GPVI in PS exposure is mediated via a relatively 
simple signaling pathway, consisting of Src kinase (Lyn), Syk and LAT, and resulting in 
activation of PLCγ2 as a key intermediate step (Figure 1). This work thereby emphasizes 
the importance of PLCγ2 in platelet activation
7
. 
Activation of PLCγ2 leads to production of inositol 1,4,5-trisphosphate (InsP3) 
and subsequent Ca
2+
 release from intracellular stores. In cell types other than platelets, 
the PH domain-containing PLCγ isoforms bind to and are activated by 
phosphatidylinositol 3,4,5-trisphosphate (PIP3), which is formed in the plasma membrane 
by phosphoinositide 3-kinase (PI3K) activity
11
. Therefore, the membrane-bound PLCγ 
has easier access to its substrate, PIP2. Especially members of the class 1A/B PI3K 
isoforms appear to be responsible for PIP3 formation
12
. Earlier work with platelets 
showed that GPVI activation is accompanied by incorporation of the class 1A regulatory 
subunit p85α into the LAT signallosome
13
. We therefore investigated whether the GPVI 
pathway to PLCγ2 activation, Ca
2+
 signaling and PS exposure involves activity of one or 
 
 
Figure 1 Overview of intracellular platelet signaling leading to procoagulant activity. The 
indicated GPVI pathway to PLCγ2 activation is recognized as the key signaling mechanism for 
Ca
2+
-dependent PS exposure and procoagulant activity. Several signaling proteins cluster together 
in the LAT signallosome (grey box). The PI3Kα and β isoforms support in this platelet response, by 
enhancing Ca
2+
 mobilisation and subsequent store-mediated Ca
2+
 entry. 
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more PI3K isozymes. Platelets contain various class IA (α, β and δ) and class IB (γ) PI3K 
isoforms
14,15
. However, some authors report that the expression of the p110δ catalytic 
subunit is only limited
16-18
. For the study presented in chapter 3, we used several newly 
developed inhibitors interacting with the catalytic subunits of the various PI3Ks, as well 
as mice lacking the p85α regulatory subunit (for class 1A PI3Ks) and animals lacking the 
p110γ catalytic subunit (class 1B PI3Kγ). The overall results indicate that both the p85α 
regulatory subunit and the catalytic p110β activity contribute significantly to Ca
2+
 
signaling and PS exposure elicited by GPVI ligands. This contribution occurs via the 
classical Ca
2+
 pathway, i.e. by enhancing Ca
2+
 mobilization and subsequent store-
mediated Ca
2+
 entry (Figure 1). In our hands, the class 1A PI3Kδ and the class 1B PI3Kγ 
do not seem to have a prominent role in this process. 
For platelets it is known that deletion of the murine p85α regulatory subunit 
does not influence the expression of other type IA regulatory subunits (p55α, p50α and 
p85β); however, it leads to a major reduction in the level of the p110α catalytic subunit, 
along with greatly reduced p110β and δ expression
16,19,20
. Recent experiments with 
PI3Kδ-deficient mice pointed to only a minor but detectable role for the δ isoform in 
mediating platelet activation by collagen
21
. Furthermore, both PI3Kβ and γ isoforms were 
found to control ADP-dependent platelet activation processes
12,17,22
. Together with the 
present results, this indicates that in mouse as well as human platelets particularly the 
PI3Kα and β isoforms, acting via p85α, are involved in GPVI-induced activation, while 
the β and γ isoforms rather act downstream of ADP receptors. 
GPVI-induced PLCγ2 activation produces InsP3, which opens the InsP3 receptor 
Ca
2+
 channels to release Ca
2+
 from intracellular stores. It is recognised that intracellular 
Ca
2+
 mobilisation, by itself, is insufficient for full platelet activation. The process of store-
operated Ca
2+
 entry, which causes Ca
2+
 influx from the extracellular medium, is required 
to reach the high cytosolic Ca
2+
 concentration needed for PS exposure
5,8,23
. One 
research group provided evidence that the store-operated Ca
2+
 entry is impaired in a 
French Scott patient and, thereby, suppresses surface exposure of PS on activated 
platelets and other blood cells
24,25
. Chapter 2 describes the unexpected observation that 
the Ca
2+
 responses in both platelets and immortalized B-cells from two different Scott 
patients (including the propositus patient) are unaltered in comparison to cells from 
control subjects. On the other hand, PS exposure in response to GPVI is strongly 
reduced in cells from these patients. These results indicate that the impaired lipid 
scrambling in the Scott cells can not be ascribed to alterations in Ca
2+
 release from 
intracellular stores or subsequent Ca
2+
 entry. Unfortunately, we have not been able to 
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make a direct comparison with cells derived from the French Scott patient. Although the 
reason for the discrepancy with the literature is unclear, it is noteworthy that the 
diminished Ca
2+
 influx in the cells from the French patient was only detected with specific 
time-dependent protocols to measure Ca
2+
 influx
24
 and, therefore, could be due to subtle 
signaling changes distantly from the Ca
2+
 influx channels. Alternatively, the differences 
might reflect variants of the Scott syndrome, which is still not genetically characterised. 
Platelets from (our) Scott patients are interesting, because these are so far the 
only platelet types, in which high Ca
2+
 does not automatically lead to PS exposure. This 
implies that the defect in these patients should lay downstream of Ca
2+ 
signal generation 
and, moreover, that Ca
2+
 entry channels themselves are not determinants for PS 
exposure. This was confirmed by the finding that the expression pattern of Trpc 
channels, which are strong candidates of the channels responsible for store-regulated 
Ca
2+
 entry, is similar in the cells from Scott patients and control subjects (I. Munnix, 
unpublished results). A major drawback in the field is that the molecular identity of the 
components (enzymes, channels?) that are responsible for the lipid scrambling 
implicated in PS exposure is unknown. After many efforts, a phospholipid scramblase 
has been identified
26
, but this enzyme does not mediate PS exposure in platelets
27
. It is 
shown that in addition to Ca
2+
 channels, also Gardos-type of K
+
 channels play a role in 
PS exposure
28
. Other, newly identified proteins involved in store-regulated Ca
2+
 entry are 
the ORAI channels
29
 and STIM1, which is a calcium sensor for Ca
2+
 channels and 
couples Ca
2+
 stores to the plasma membrane
30
. STIM1 is also expressed on platelets
31
. 
However, it is unlikely that ORAI or STIM1 is changed in the Scott syndrome, since 
platelets from at least two patients show normal Ca
2+
 responses. 
Multiple contributions of glycoprotein VI to thrombus formation 
under flow 
Whereas the function of platelet GPVI in collagen-induced intracellular Ca
2+
 
rises and PS exposure under flow has not been questioned, the precise role of GPVI in 
platelet adhesion and thrombus formation is less clear. Concerning adhesion, the relative 
contribution of the two collagen receptors, GPVI and α2β1, was the subject of 
considerable discussion in the past decades. According to the original two-site two-step 
adhesion model, high affinity interaction with collagen through α2β1 would slow down a 
platelet, and allow low affinity binding of GPVI
32,33
. However, studies with GPVI- or α2β1-
deficient mice demonstrated that GPVI had a critical role in initial platelet adhesion and 
subsequent aggregation on collagen
34
. The same work showed that α2β1 was not 
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required for these events. However, several later studies re-established that mouse α2β1 
can facilitate the role of GPVI in platelet adhesion to collagen
2,35
. 
Since for human platelets, the contribution of the two collagen receptors had 
remained unclear, we have studied this in chapter 4. We observed that under high-shear 
flow conditions, GPVI does stimulate, but is not essential for primary platelet adhesion to 
collagen. Furthermore, we detected redundancy in the roles of α2β1 and GPIb-V-IX for 
platelet adhesion. Inhibiting GPIb or α2β1 on its own, but not GPVI, only partially 
reduced the number of collagen-adherent platelets. Combined inhibition of GPIb or α2β1 
had a greater effect on platelet deposition, but still a significant number of aggregates 
were observed. That GPVI is in interplay with both other receptors is concluded from the 
observation that adhesion was completely abolished using a combined blockade of GPIb 
and GPVI or α2β1 and GPVI. This indicates that all three receptors play a role in 
adhesion, in contrast to procoagulant activity where only two receptors are involved. 
These results clearly deviate from those obtained using GPVI-deficient mice, which 
showed total abolition of platelet-collagen adhesion
34
. This issue of possible differences 
between human and mouse platelets was addressed by Auger et al.
36
, who directly 
compared adhesion, activation and aggregation in either species. Two mechanisms of 
stable platelet adhesion and activation on collagen were shown to co-exist. In some 
platelets, adhesion involving α2β1 appears to be followed by GPVI-mediated increases 
in Ca
2+
 concentration, while in other platelets it precedes the Ca
2+
 response. This 
heterogeneity in responses is preserved in mouse and human platelets, and can explain 
apparent differences in the literature. 
A number of studies have demonstrated that even minute amounts of GPVI 
signaling are sufficient to bring integrin α2β1 in a higher-affinity state, which permits this 
receptor to play a prominent role in adhesion
37-39
. Together with the present work, this 
has led to the recognition that platelet collagen responses are in a game of molecular 
ping-pong between different collagen receptors, in which GPVI is the first player to 
serve
40
. With respect to platelet aggregation under flow, our data in chapter 4 and 5 are 
in full agreement with other studies with mouse and human blood that GPVI plays a key 
role in collagen-induced thrombus formation
2,34,36,41
. The GPVI signaling pathway 
underlying shear-dependent platelet aggregation involves the FcR γ-chain, Src-family 
kinases, Syk, LAT and PLCγ2 (chapter 5). These are the same signaling components 
that have been shown to be involved in the GPVI-dependent aggregation response of 
suspensions of human and mouse platelets
6,42,43
. Our results with LAT, however, are 
remarkable, since with suspended LAT-deficient platelets aggregation was only reduced 
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in the presence of low doses of collagen or collagen-related peptide, and became 
normalized at higher agonist doses
44
. This suggests that, the LAT pathway can be 
bypassed in collagen-induced suspension measurements, but not in (more physiological) 
flow measurements on collagen. 
As shown by others, aggregate formation on a collagen surface is the result of 
several platelet responses, including activation of the fibrinogen-binding αIIbβ3 integrin 
and release of the paracrine agents thromboxane A2 and ADP (Figure 2)
38,45,46
. 
Particularly the release and the formation of thromboxane A2 and the secretion of ADP 
are Ca
2+
-dependent responses, thus likely to be controlled by PLCγ2 activation. The 
results presented in chapter 4 show that also human platelet aggregation under flow – 
similarly as discussed for PS exposure – occurs through the concerted action of GPVI in 
cross-talk with α2β1. Accordingly, as indicated in Table 1, the same or similar sets of 
proteins and signaling mechanisms are implicated in aggregation and PS exposure 
during the thrombus-forming process.  
In chapter 5, we further investigated the thrombus-forming process under 
conditions where the coagulation was triggered with tissue factor and the platelet 
aggregates accumulated massive amounts of fibrin. Although in the absence of GPVI 
activity, still trace amounts of fibrin could be detected (indicative of non-zero thrombin 
 
 
Figure 2 Overview of the roles of glycoprotein VI in thrombus formation. This thesis describes 
that platelet adhesion to collagen/vWF is mediated by GPVI in combination with α2β1 and GPIb. GPVI 
subsequently plays a key role in several platelet activation processes, including rise in intracellular 
Ca
2+
 concentration, secretion, integrin αIIbβ3 activation and PS exposure. In the thrombus-forming 
process, this results in two populations of platelets either clustered into aggregates or with 
procoagulant activity. Both populations are embedded in a network of fibrin, formed as a result of the 
coagulation. 
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formation), aggregated and PS-exposing platelets were hardly detected under this 
condition, 
indicating that platelet activation by GPVI, most likely via PS exposure, is of key 
importance for full coagulant activity under the present flow conditions. Thus, GPVI-
induced platelet activation can act as a driving force of the coagulation process in these 
flow chamber experiments. Interestingly, in the presence of GPVI activity, the number of 
PS-exposing platelets increased under conditions of coagulation (chapter 7). The most 
obvious explanation is that the processes of collagen-induced PS exposure and thrombin 
generation are interrelated and influence each other, likely through a positive feed 
forward loop, in a similar way as was previously suggested for platelet interaction with 
fibrin
47
. Only few comparable studies with coagulation have been reported, but these 
particularly concerned ex vivo flow chamber experiments where effects of thromboxane 
A2 and ADP blockade were investigated instead of GPVI
48
. 
In summary, we have shown that the GPVI receptor, acting via a relatively 
simple signaling pathway, is a principal mediator of aggregation and PS exposure, as 
well as platelet-dependent thrombin generation and fibrin formation (Figure 2). 
Composition and structure of a thrombus 
As shown in Table 1, a quite similar set of signaling proteins downstream of 
GPVI  appears to be involved in two different platelet responses, i.e. PS exposure and 
aggregate formation. In chapters 5 and 6, we show that these two responses are 
generated by quite different populations of platelets. In addition, during blood flow over 
collagen, we find that the aggregated and PS-exposing platelets tend to cluster in 
separate micro-domains within thrombi. The aggregated platelets bind fibrin(ogen), have 
Table 1 Contribution of platelet receptor and signaling proteins to thrombus formation on 
collagen  
 
 Adhesion Ca
2+
 signaling PS exposure Secretion Aggregation 
GPVI +
* 
++ ++ ++ ++ 
α2β1 + + + + 0 
FcRγ + ++ ++ ++ ++ 
LAT + ++ ++ ++ ++ 
PI3Kα/β 0 + + + + 
PI3Kγ + 0 0 0 + 
PLCγ2 + ++ ++ ++ ++ 
*
0, no contribution; +, potentiating; ++, required. 
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activated αIIbβ3 integrins and express P-selectin at their surface, which is a strong 
indicator of secretion. Separately, the thrombi contain patches of single PS-exposing 
platelets, which bind annexin A5 and have a bleb-forming morphology. The latter 
platelets are reduced in adhesion, do not tend to bind fibrin(ogen), but display increased 
binding for prothrombin, factor Va and factor Xa, which properties are all compatible with 
a role in coagulation. While it is clear that the Gla-domain-containing factors Xa and 
prothrombin bind to PS-exposing membranes, we have not further examined the 
coagulation factor binding sites on platelets. 
Previously, others have characterised a population of so-called coated platelets 
that express serotonin binding sites and attract factor Va, fibrinogen, vWF, fibronectin 
and thrombospondin
49
. However, in our studies with labelled fibrinogen and coagulation 
factors, the platelets that express serotonin binding sites could not be distinguished as a 
separate population of cells, but partially overlapped with the two other platelet 
populations. Given these results it can be questioned whether the coated platelets 
described by others in fact represent a unique platelet population. 
An important question is how one and the same signaling pathway, starting 
from GPVI and leading to PLCγ2 activation, can result in so different platelet responses 
within a single thrombus. In chapter 7, a first clue observation that can explain the 
platelet heterogeneity came from flow cytometry experiments. These showed that all 
GPVI-activated platelets at first express activated forms of integrin αIIbβ3, while at a later 
stage secondary inactivation of the integrins on PS-exposing platelets occurs. This 
suggests that initially all platelets are well equipped to incorporate into aggregates, but 
that later only the PS negative platelets have retained this property. This is in agreement 
with the observation that, under flow conditions, platelets in aggregates fail to expose 
PS. It can be speculated that platelets in aggregates are protected from PS exposure, 
but we do not have evidence to support this hypothesis. Earlier data indicate that 
platelets with a prolonged and high Ca
2+
 signal tend to expose PS and become 
procoagulant
50,51
. In combination with the present findings, this suggests that a 
prolonged Ca
2+
 increase not only causes phospholipid scrambling, but also leads to 
αIIbβ3 inactivation (Figure 3).  
A second novel observation is that blocking of protein tyrosine phosphatases 
enhances the secondary integrin inactivation in GPVI-stimulated platelets. Since tyrosine 
kinases can act Ca
2+
-dependently, it is likely that prolonged elevation in Ca
2+
 leads to 
both PS exposure and tyrosine kinase-dependent integrin inactivation. Measurement of 
Ca
2+
 fluctuations in platelets under flow conditions indeed showed considerable 
heterogeneity between platelets. Considering that the height of the Ca
2+
 response is a 
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critical determinant of PS exposure and is coupled to this integrin inactivation, there are 
several possible explanations for the response heterogeneity. 
It can be caused by variation in the expression levels of one or more platelet 
receptors or signaling proteins, e.g. by allelic differences in the GPVI gene
52
. Also the 
platelet’s age may play a role, since older platelets may loose or gain surface expression 
of functional glycoprotein receptors. For instance, GPIb-V-IX and GPVI have been 
shown to be sensitive for clustering and protease-mediated cleavage during storage
53-55
. 
Following this reasoning, GPIb clustering may make older platelets more susceptible for 
tethering on (collagen-bound) vWF or for aggregation mediated via GPIb-vWF 
interaction. Another possibility is that micro-environmental diversities upon platelet 
adhesion cause later response heterogeneity. All together, this leads to the idea that 
restricted GPVI activity and/or signaling leads to a proaggregatory response, while high 
stimulation of the GPVI pathway enhances procoagulant activity. This hypothesis is 
supported by a recent study, in which protein kinase C was identified as a signaling 
protein to enhance platelet aggregation but suppresses Ca
2+
 and procoagulant 
responses during thrombus formation on collagen
56
. 
Some authors have proposed that extracellular transglutaminases like factor 
XIIIa contribute to the formation of coagulation-active platelets by cross-linking surface-
membrane proteins to secretion factors, e.g. via serotonin conjugation to form coated 
platelets
51,57
. However, we were not able to confirm this result, since in our hands 
inhibition of transglutaminases had no effect on PS exposure by GPVI-stimulated 
platelets. Our findings are, however, in line with a recent report in which it was shown 
 
 
Figure 3 New model of transient integrin αIIbβ3 activation. Inside-out signaling is known to lead to 
αIIbβ3 activation, exposing fibrinogen-binding epitopes on the integrin. We provided evidence that this 
activated conformation is a transient state, as prolonged Ca
2+
 elevation and tyrosine phosphorylation 
events lead to secondary inactivation of the integrins on PS-exposing platelets. Typically, these 
procoagulant platelets are single, non-adherent with a blebbing morphology. For further explanations, 
see text. 
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that the binding of secretory proteins and annexin A5 to platelets on collagen requires 
GPVI/FcR γ-chain activity, but not factor XIIIa
58
. It was also proposed that intracellular or 
extracellular calpain activity contributes to the development of procoagulant platelets 
51,59
. In agreement with earlier results, however, we find no major role for calpain in the 
regulation of platelet procoagulant activity, although calpain is involved in gaining the 
bleb-shaped morphology of the cells
50
. 
A novel finding in chapter 7 is that, while heterogeneity is maintained during 
perfusion of blood under conditions of thrombin generation and coagulation, the 
frequency of procoagulant, PS-exposing platelets becomes higher in this case. 
Furthermore, it appears that the PS-exposing platelets bind all components of the 
prothrombinase complex. Taken together, these results indicate that collagen provides 
an adhesive substrate, at which the processes of platelet aggregation and coagulation 
are integrated but also separated over different micro-domains. 
Roles of collagen and glycoprotein VI in thrombus formation in vivo 
In the studies presented in chapters 5 and 7, an established FeCl3 
microvascular thrombosis model was used to study the importance of collagen and GPVI 
in the thrombotic process in vivo. Upon application to adjacent arteries and veins, the 
free radical-generating compound FeCl3 caused endothelial denudation and subsequent 
exposure of the collagen-containing extracellular matrix
60
. We used several approaches 
to show that arterial thrombus formation relies on collagen-GPVI interaction and 
subsequent signaling. Thus, in mesenteric arteries from mice lacking the FcR γ-chain, no 
thrombi were formed after FeCl3 application. Also, in mice where GPVI on the platelet 
surface was down-regulated by long-term injection with anti-GPVI JAQ1 mAb, thrombus 
formation in arteries was delayed and reduced. In the damaged arteries of wild-type 
control mice, we were able to visualize externalized PS on platelets that were trapped in 
thrombi, using fluorescently labeled annexin A5. However, in vessels from mice pre-
injected with JAQ1 mAb, only small spots of labeled fibrin were present and labeled 
annexin A5 was not detectable at all. Accordingly, both GPVI-induced responses, 
aggregation and PS exposure, observed in vitro, were also present in thrombi formed in 
vivo. That murine GPVI has a function in arterial thrombus formation in vivo was also 
proven in other mouse studies using the same FeCl3 method
61,62
. Yet, with mild FeCl3-
induced injury, thrombus formation in FcR γ-chain deficient mice appeared to be normal, 
probably due to minimal exposure of collagen
62
. Confusing results were obtained when 
thrombus formation was induced by superficial or severe laser injury. Here, GPVI/PLCγ2 
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effects were only detected after the superficial laser injury
63,64
. Furthermore, also in large 
arteries, ligation models demonstrate a role for GPVI in thrombus formation
61
. 
We used the method of FeCl3-induced injury to study the role of procoagulant 
platelets and thrombin in arterial thrombosis in vivo (chapter 7). Infusion of annexin A5 
completely inhibited thrombus formation in the mesenteric arteries. Moderate thrombin 
inhibition with melagatran or platelet inhibition with prostaglandin E1 completely blocked 
arterial thrombus formation. Thus, besides GPVI, procoagulant platelets mediating 
thrombin generation and coagulation play a key role in this microvascular thrombosis 
model. In agreement with the present findings, others also describe that thrombin
60
 and 
platelet thrombin receptors
65,66
 contribute to FeCl3-induced thrombus formation in small 
arteries. In this context, it should be noted that a drawback of many in vivo thrombosis 
models is the lack of information on the precise type of vascular damage and the extent 
of collagen exposure. 
Some of the experiments in this thesis are focussed on perfusion of blood at 
intermediate shear over a glass surface coated with fibrillar collagen. It is important to 
know whether this flow-chamber system provides a physiological model for the events of 
thrombus formation in vivo. Interestingly, comparison of the in vitro flow studies with the 
in vivo mice data shows great similarity between the two methods used (chapters 5-7). 
Both in vitro and in vivo we detect a key role of GPVI in the thrombus formation and 
procoagulant activity, and similarly, in the heterogeneous composition of the formed 
thrombi. Therefore, the in vitro flow model seems to mimic the conditions of in vivo 
thrombus formation, although obviously no vessel is present. There are, however, clearly 
limitations of the flow-chamber model, one being that type I collagen is used in the 
present work, while other types of collagen (type IV) are also abundantly present in the 
vascular extracellular matrix, and can support platelet activation. In addition, the 
contribution of other matrix proteins, e.g. laminin, to platelet adhesion and thrombus 
formation can not be ruled out
67
. It is therefore of interest to extend the present model to 
the study of additional collagen types and other matrix proteins, either in isolation or in 
combination. 
Role of thrombin in arterial and venous thrombosis 
An important question is to which extent platelets and coagulation contribute to 
arterial and venous thrombosis. Using the FeCl3 method, a number of characteristic 
differences between thrombus formation in mesenteric arteries and veins are described 
in chapter 6. In this model, platelet inhibition by prostaglandin E1 or moderate thrombin 
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inhibition by melagatran was insufficient to affect venous thrombus formation, although 
arterial thrombosis was greatly inhibited. The combined action of both agents or a higher 
dose of melagatran was needed to reduce the thrombotic process in the veins. An 
attractive explanation for this difference is that thrombin generation is locally higher in 
veins than in arteries, for instance due to a slower flow-mediated dilution of thrombin and 
other coagulation factors
68
. Alternatively, since endothelial cells of arteries and veins can 
have different antithrombotic properties
69
, increased suppression of the coagulation 
process in the mesenteric arteries may explain their relatively high responsiveness to 
thrombin inhibition. More speculative is the hypothesis that FeCl3-induced damage of the 
mesenteric veins results in the exposure of more coagulation-stimulating vascular 
material, such as tissue factor. Indeed, the expression of tissue factor does not appear to 
be uniform throughout the vascular tree
70
. An interesting parallel is seen in a model of 
laser-induced arterial thrombus formation, where suppressed platelet activation (using 
FcR γ-chain deficient mice) only affected thrombus formation, when thrombin was 
simultaneously inhibited
63
. These data suggests that, also in arterial thrombosis, high 
thrombin formation can overrule the contribution of specific platelet-activating pathways. 
In prospective 
The studies in this thesis shed new light on the importance of coagulation and 
platelet activation for thrombus formation under arterial and venous flow conditions. A 
relevant finding is the observation that absence or inhibition of the collagen receptor, 
GPVI, can significantly suppress thrombus formation and platelet procoagulant activity 
both in small and large arteries. This makes GPVI a new interesting target for future 
antithrombotic treatment. Another relevant finding is the relatively high accumulation of 
thrombin in vivo in veins, and in vitro at venous shear rates. It is thus important to realize 
that the suggested antithrombotic effect of GPVI can be bypassed by high thrombin 
generation and coagulation under conditions of low shear. This also explains why 
patients lacking GPVI suffer from no more than a mild bleeding diathesis. Similarly, in 
mice, GPVI deficiency is not accompanied by prolonged bleeding times. Together, this 
suggests that anti-GPVI treatment may be most effective in case of arterial thrombosis 
(low thrombin), rather than in case of venous thrombosis (high thrombin). In addition, it 
provides more information on the structural organization of such thrombi. Currently, 
several clinical trials are started to validate the antithrombotic effect of GPVI. 
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Intravascular thrombosis is classified as venous thrombosis (e.g., in deep veins) 
or arterial thrombosis (as in myocardial infarction and ischemic stroke). Irrespective of 
other factors (vessel wall, circulation and blood cell composition), venous thrombosis is 
commonly associated with high coagulation activity, which can cause undesired fibrin 
clot deposition. On the other hand, arterial thrombosis is often linked to high platelet 
activation, which leads to the formation of platelet-rich thrombi. Although nowadays there 
are good examples of favorable combination therapy with anticoagulant and antiplatelet 
drugs, anticoagulants are still preferred in reducing venous thromboembolism while 
antiplatelet agents are mostly used in the prevention of arterial thrombosis. Irrespective 
of this, laboratory investigations indicate that the processes of platelet activation and 
coagulation are strongly mutually dependent. The crucial coagulation product, thrombin, 
is one of the most potent platelet agonists known. Conversely, activated platelets are 
essential in providing the procoagulant surface at which thrombin generation occurs. 
This is in apparent contrast with the supposed differential roles of thrombin and activated 
platelets in venous and arterial thrombosis, respectively. Hence, the main goal of this 
thesis is to investigate the diversity in interaction mechanisms between platelet activation 
and coagulation in different situations and on different levels of complexity. 
Platelets can be activated by complex cascades of signaling pathways. Current 
knowledge of a number of these pathways is described in chapter 1. Emphasised is how 
the ADP receptor, P2Y12, the thrombin receptors, PAR1 and PAR4, and the collagen 
receptor, glycoprotein (GP)VI, activate the phosphoinositide 3-kinase (PI3K) pathway by 
producing phosphoinositide 3,4,5-trisphosphate. Particularly, PI3K that is activated 
downstream of GPVI plays a role in recruiting phospholipase C-γ2 (PLCγ2) to the plasma 
membrane. Activation of PLCγ2 leads to Ca
2+
 elevation by mobilisation of Ca
2+
 from 
internal stores, and subsequent secretion and exposure of phosphatidylserine (PS) at 
the platelet surface. Earlier literature is cited that PS-exposing platelets are active in 
thrombin generation and coagulation, by providing a surface at which coagulation factors 
assemble. Separately, P2Y12 and PAR receptor stimulation activates the so-called 
Rap1b, PI3K and Akt pathway, which leads to integrin αIIbβ3 activation and hence 
platelet aggregation. 
The rare Scott syndrome is a bleeding disorder, characterized by impaired 
surface exposure of procoagulant PS on activated platelets and other blood cells. Since 
store-mediated Ca
2+
 entry is essential for the procoagulant response of platelets, we 
investigated in chapter 2 whether the Ca
2+
 entry process is impaired in blood cells from 
Scott patients. Measurements of Ca
2+
 fluxes and PS exposure were performed in 
isolated platelets and in immortalized B-cell lymphoblasts from two different patients. The 
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responses of platelets and B-cells from the Scott patients appeared to be unaltered in 
comparison to cells from control subjects. On the other hand, the extent of PS exposure 
in response to GPVI stimulation was strongly reduced in patient platelets. These results 
thus indicate that impaired phospholipid scrambling in Scott cells can not be ascribed to 
alterations in Ca
2+
 signaling, e.g. of diminished Ca
2+
 entry. 
Inositol phospholipids, especially those produced by PI3K, play key roles in 
Ca
2+
 signaling in platelets. Chapter 3 describes a study on the role of various platelet 
PI3K isoforms in the regulation of Ca
2+
 signaling, following platelet activation by collagen 
or thrombin. Mice lacking the p85α regulatory subunit (class 1A PI3K) or the p110γ 
catalytic subunit (class 1B PI3Kγ) were used, as well as several newly developed 
inhibitors interacting with the catalytic subunits of the various PI3Ks present in platelets. 
The results indicate that both the p85α regulatory subunit and the catalytic p110β activity 
contribute significantly to Ca
2+
 signaling and subsequent PS exposure elicited by 
collagen receptor activation. This contribution occurs via the classical Ca
2+
 pathway, i.e. 
by enhancing the PLC-dependent Ca
2+
 mobilisation and subsequent store-mediated 
Ca
2+
 entry. The class 1A PI3Kδ and the class 1B PI3Kγ isoforms do not seem to have a 
prominent role in this process. 
In the in vitro flow studies reported in chapter 4, the interacting roles of the 
platelet adhesive receptors for von Willebrand factor (vWF), i.e. GPIb-V-IX and integrin 
αIIbβ3, and for collagen, i.e. GPVI and integrin α2β1, were examined. Studies were 
performed to measure thrombus formation and procoagulant activity during high-shear 
perfusion of human whole blood over a collagen surface. Novel antibodies and peptides 
directed against the two collagen receptors were used to specifically unravel the function 
of each receptor molecule. GPVI was found to be crucial for platelet aggregate 
formation, Ca
2+
 signaling and PS exposure, but not for primary adhesion to 
collagen/vWF. Inhibition of α2β1 revealed that this integrin had a modulating role in Ca
2+
 
signaling, PS exposure and aggregate size, since it enforced the responses evoked by 
GPVI. Interestingly, both GPIb-V-IX and α2β1 contributed to primary adhesion, and 
showed a partly overlapping function. Co-inhibition studies revealed synergism of distinct 
platelet receptors in thrombus formation. Co-inhibition of ADP with collagen receptors 
resulted in greatly decreased adhesion and aggregation. Co-inhibition of GPVI with 
either GPIbα or α2β1 was required to cause complete eradication of thrombus formation. 
It was concluded that platelet deposition on collagen depends on the concerted interplay 
of several receptors, GPIb-V-IX in synergy with integrin α2β1 mediating primary 
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adhesion, reinforced by platelet activation through GPVI, which in turn regulates 
thrombus formation. 
Coagulation activation with tissue factor may contribute to collagen-induced 
thrombus formation. Chapter 5 introduces an assay to trigger thrombin generation and 
coagulation in flow-adhesion experiments on collagen. Investigated was by which 
signaling pathway collagen-induced platelet activation interacts with tissue factor-
triggered coagulation both in vitro and in vivo. In murine blood flowing over collagen, 
platelet exposure of PS and procoagulant activity, but not adhesion, completely relied on 
each of the following signaling modules: GPVI, the FcR γ-chain, Src kinases, the adaptor 
protein LAT, and PLCγ2. Upon flow in the presence of tissue factor, these signaling 
components were essential for platelet aggregation and greatly enhanced the formation 
of fibrin clots. The physiological importance of this GPVI pathway was shown in a FeCl3-
induced in vivo murine thrombosis model. In both venules and arterioles, the presence 
and activity of GPVI, FcR γ-chain and Src kinases resulted in an enhanced formation of 
PS-exposing and fibrin-rich thrombi. These findings demonstrate that the GPVI-PLCγ2 
activation pathway can regulate collagen-dependent coagulation in venous and arterial 
thrombus formation. 
In chapter 6, the mutually stimulatory processes of platelet activation and 
thrombin generation in arterial and venous thrombus formation in vivo were investigated 
in more detail. In the murine FeCl3 model, the thrombus-forming process appeared to be 
triggered by both collagen exposure and complex formation of tissue factor and factor 
VII(a). Interestingly, mild thrombin inhibition or platelet inhibition suppressed arterial 
thrombus formation, while strong thrombin inhibition or mild thrombin inhibition in 
combination with platelet inhibition was necessary to suppress venous thrombosis. 
Thrombus formation in both vessel types was characterized by the presence of PS-
exposing platelets, as detected with fluorescently labeled annexin A5. Shielding of 
exposed PS by injection of a surplus of unlabelled annexin A5 abolished the formation of 
both arterial and venous thrombi, while a mutant M1234-annexin A5 was ineffective. 
Surprisingly, decreased anticoagulant activity in mice carrying the factor V Leiden 
mutation had no more than little effect. Together, these findings demonstrated that the 
propagation of thrombin generation by PS-exposing platelets is a key regulatory process 
in both veins and arteries. Since platelet-dependent thrombin generation is most active in 
venous thrombus formation, this process may be a clinically relevant target for 
antithrombotic therapy. 
As indicated, platelets play a dual role in thrombus formation by assembling into 
aggregates and by stimulating the coagulation. In chapter 7 we investigated the 
Summary 
 
 
179 
commitment of platelets to either of these functions both in vitro and in vivo. High-
resolution two-photon fluorescence microscopy revealed that during thrombus formation 
under flow, fibrin(ogen)-binding platelets assembled into separated aggregates, after 
which distinct patches formed of non-aggregated platelets, exposing PS. The latter 
platelet population had inactivated αIIbβ3 integrins and displayed increased binding of 
coagulation factors. Coated platelets, expressing serotonin binding sites, were not 
identified as a separate population. Thrombin generation (coagulation) favored the 
integrin inactivation and the transformation into PS-exposing platelets with reduced 
adhesion. Prolonged tyrosine phosphorylation in vitro resulted in secondary down-
regulation of active αIIbβ3. Together, these results lead to a new, spatial model of 
thrombus formation, in which aggregated platelets ensure thrombus stability, while 
distinct patches of non-aggregated platelets effectuate procoagulant activity and 
generate thrombin and fibrin. Herein, the haemostatic activity of a developing thrombus 
seems to be determined by a balance in formation of proaggregatory and procoagulant 
platelets. This balance likely influences the efficacy of antiplatelet or anticoagulant 
medication. 
The significance of the findings described in this thesis is discussed in chapter 
8, particularly in the light of relevant, recent literature. In summary, the data recognize 
the GPVI pathway to PLCγ2 activation as a key signaling mechanism for Ca
2+
-dependent 
PS exposure and procoagulant activity. Signaling proteins that cluster together in the 
LAT signallosome, including the PI3Kα and β isoforms support this pathway. Yet, only 
the population of platelets with prolonged Ca
2+
 elevation and tyrosine phosphorylation 
shows this procoagulant activity. Altogether, the key role of GPVI in the thrombus-
forming process makes this platelet receptor as a promising new antithrombotic tool. 
However, the data also suggest that anti-GPVI treatment may be most effective in case 
of arterial thrombosis (low thrombin), rather than in case of venous thrombosis (high 
thrombin), since high thrombin formation can overrule the antithrombotic effect of anti-
GPVI treatment. This knowledge may help to develop improved treatment strategies of 
the still numerous patients who suffer from cardiovascular thrombotic diseases. 
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Trombose, dat wil zeggen verstopping van de bloedvaten is nog steeds een van 
de meest voorkomende aandoeningen in onze samenleving. De medische wereld maakt 
daarbij onderscheid tussen veneuze trombose (zoals bijvoorbeeld een trombosebeen) 
en arteriële trombose (zoals bij een hart- of herseninfarct). Veneuze trombose is het 
gevolg van ongewenste bloedstolling, waarbij een fibrineprop gevormd wordt in de aders 
of venen. Arteriële trombose daarentegen is veelal het gevolg van schade van de 
bloedvatwand en daaropvolgende activering van de bloedplaatjes, die daarbij 
samenklonteren tot een plaatjesprop of plaatjesaggregaat. Veelal wordt veneuze 
trombose tegengegaan door stollingsremmers (‘bloedverdunners’), terwijl arteriële 
trombose eerder onderdrukt wordt door medicatie die de plaatjesactivering remt 
(bijvoorbeeld aspirine). De laatste jaren is echter ook nagegaan, in hoeverre 
combinatietherapie met stollings- en plaatjesremmers effectief is ter preventie van 
trombose. Onderzoek met geïsoleerd bloed, met name in Nederland uitgevoerd, heeft 
laten zien dat de processen van stolling en plaatjesactivering heel nauw met elkaar 
verweven zijn. Trombine, dat een belangrijk product is van de stolling, is tevens een van 
de meest krachtige activatoren van plaatjes. Anderzijds zorgen geactiveerde plaatjes 
voor een oppervlak, waarop stollingsreacties kunnen plaatsvinden. Dit lijkt echter 
tegengesteld aan de verschillende functies van stolling (trombine) en geactiveerde 
plaatjes bij veneuze en arteriële trombose. Het doel van het onderzoek beschreven in dit 
proefschrift is daarom na te gaan hoe de interacties tussen trombinevorming en 
plaatjesactivering afhankelijk zijn van de condities zoals die naar verwachting optreden 
tijdens veneuze en arteriële trombose. 
Bloedplaatjes worden geactiveerd door een aantal ingewikkelde, trapsgewijs 
werkende signaleringsroutes, waarbij vele eiwitten betrokken zijn. Een algemeen 
overzicht van de routes, die relevant zijn voor dit proefschrift, is gegeven in hoofdstuk 1. 
Hier wordt het werkingsmechanisme uitgelegd van de receptor voor ADP, P2Y12, de 
trombinereceptoren PAR1 en PAR4, en de collageenreceptor glycoproteïne (GP)VI. Al 
deze receptoren activeren de zogenaamde fosfoinositide 3-kinase (PI3K) route, die zorgt 
voor de vorming van het signaleringslipide fosfoinositide-3,4,5-trifosfaat. Activering van 
PI3K door GPVI speelt een rol bij de rekrutering en activering van fosfolipase C-γ2 
(PLCγ2) naar de plasmamembraan. Deze activering van PLCγ2 leidt tot een verhoging 
van het intracellulaire calcium, dat gemobiliseerd wordt vanuit interne opslagplaatsen. 
Een daaropvolgende stap is de calcium-afhankelijke expositie van het stollingsactieve 
fosfatidylserine (PS) op het plaatjesoppervlak. Gememoreerd wordt dat PS-exposerende 
plaatjes actief zijn in de generatie van trombine en het stimuleren van de 
stollingsactivieit, doordat zij als bindingsplaats dienen van stollingsfactoren. Stimulering 
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van de plaatjes via de P2Y12 en PAR receptoren leidt daarnaast tot activering van de 
Rap1b - PI3K - Akt route, die zorgt voor plaatjesaggregatie via activering van het 
integrine αIIbβ3. 
Het zeer zeldzame syndroom van Scott is een milde bloedingsziekte, die 
gekenmerkt wordt door een verminderde expositie van stollingsactief PS op 
geactiveerde plaatjes en andere bloedcellen. De literatuur bevatte aanwijzingen dat de 
calciuminstroom als gevolg van interne calciummobilisatie verstoord is in plaatjes van 
Scott-patiënten. Aangezien dit een verklarende factor zou kunnen zijn voor de 
verminderde procoagulante respons van deze plaatjes, is in hoofdstuk 2 onderzocht in 
hoeverre deze calciuminstroom daadwerkelijk veranderd is. In geïsoleerde plaatjes en 
geïmmortaliseerde B-cel lymfoblasten van twee verschillende Scott-patiënten zijn 
daarom metingen verricht aan zowel de calciuminstroom als de PS expositie. Er werden 
echter geen verschillen waargenomen tussen de cellen van Scott-patiënten en 
overeenkomstige cellen van controlepersonen. Wèl was in Scott plaatjes de mate van 
PS expositie na GPVI stimulatie sterk gereduceerd. Deze resultaten weerleggen 
daarmee de veronderstelling dat een deficiëntie in calcium-signaaltransductie ten 
grondslag ligt aan het Scott syndroom. 
Inositol-bevattende fosfolipiden, die voornamelijk geproduceerd worden door 
PI3K, spelen een rol bij de activering van plaatjes. Welke rol is nog niet helemaal 
duidelijk. Hoofdstuk 3 beschrijft onderzoek naar de functie van verschillende PI3K 
isovormen in plaatjes na activering met collageen of trombine. Voor dit onderzoek werd 
gebruik gemaakt van muizen, die deficiënt waren in ofwel de p85α regulerende subunit 
(klasse IA PI3K) ofwel de p110γ katalytische subunit (klasse 1B PI3K), en verder van 
enkele nieuw ontwikkelde remmers van specifieke katalytische subunits. Wij konden 
aantonen dat zowel de p85α als de katalytische p110β subunit bijdraagt aan de 
calciumsignalering en daaropvolgende PS expositie. In plaatjes gestimuleerd met 
collageen verloopt deze bijdrage via de klassieke calciumsignaleringsroute, dat wil 
zeggen door verhoging van PLC-afhankelijke calciummobilisatie en daarop volgende 
opslag-gemedieerde calciuminstroom. In tegenstelling tot de isovormen PI3Kα en PI3Kβ 
(beide klasse 1A), blijken de isovormen PI3Kδ en PI3Kγ een minder belangrijke rol te 
hebben in dit proces. 
Middels in vitro perfusieproeven, beschreven in hoofdstuk 4, is de rol van 
verschillende plaatjesreceptoren voor adhesieve eiwitten, namelijk het glycoproteïne Ib 
(GPIb) en integrine αIIbβ3 als receptoren voor von Willebrand factor (vWF), en GPVI en 
integrine α2β1 als receptoren voor collageen, onderzocht bij de trombusvorming. Het 
Samenvatting 
184 
 
trombusvormende proces en de procoagulante activiteit zijn daarbij gemeten tijdens de 
stroming van humaan bloed over een collageenoppervlak onder een hoge 
afschuifsnelheid (shear rate). Gebruik werd gemaakt van nieuw ontwikkelde 
antilichamen en peptiden gericht tegen collageenreceptoren, teneinde de specifieke 
functie van elke receptor te ontrafelen. Gebleken is dat GPVI essentieel is voor de 
vorming van plaatjesaggregaten, de calciumsignalering en de PS expositie. Anderszins 
speelt GPVI geen rol in de primaire adhesie van plaatjes aan het collageen/vWF 
oppervlak. Integrine α2β1 heeft slechts een modulerende rol in de calciumsignalering, 
plaatjesaggregatie en PS expositie, doordat het de werking van GPVI versterkt. De 
glycoproteïnen GPIb en α2β1 overlappen elkaar gedeeltelijk in primaire adhesie. Co-
inhibitie van ADP- en collageenreceptoren geeft een sterk verminderde adhesie en 
aggregatie. Om complete remming van de trombusvorming te krijgen moet echter zowel 
GPVI als GPIb of α2β1 geblokkeerd worden. Op basis van deze resultaten konden wij 
concluderen, dat de plaatjesadhesie en -aggregatie op collageen bepaald worden door 
onderlinge samenwerking van de verschillende adhesieve receptoren: GPIb in synergie 
met α2β1 voor de primaire adhesie, welk in een proces dat versterkt wordt door GPVI 
leidt tot trombusvorming. 
Op grond van de literatuur werd aangenomen dat activering van de stolling 
middels weefselfactor betrokken is bij de collageen-afhankelijke trombusvorming. 
Hoofdstuk 5 beschrijft een nieuwe methode om trombinegeneratie en stolling op te 
wekken, door bloed onder stromingscondities over collageen te leiden. Deze methode is 
gebruikt om de vraag te beantwoorden via welk signaleringspad de plaatjesactivering 
door collageen bijdraagt aan de stolling onder invloed van weefselfactor. In muizenbloed 
dat geperfundeerd werd over collageen bleek de expositie van PS, maar niet de 
plaatjesadhesie, volledig afhankelijk van de volgende signaleringmodules: GPVI, de FcR 
γ-keten, Src kinases, het adaptor eiwit LAT en PLCγ2. In aanwezigheid van weefselfactor 
waren deze signaleringcomponenten essentieel voor de plaatjesaggregatie en droegen 
zij bij aan de vorming van fibrinestolsels. De fysiologische betekenis van dit GPVI 
signaleringspad werd onderzocht in een in vivo trombosemodel in muizen. Hierbij werd 
trombose opgewekt na vasculaire beschadiging met behulp van ijzertrichloride (FeCl3). 
In de microscopische arteriën en venen van het darmvlies resulteerde de afwezigheid 
van actief GPVI, FcRγ-keten of Src kinases in een sterk verlaagde vorming van PS-
exposerende en fibrinerijke trombi. Deze bevindingen geven aan dat de activeringsroute 
van GPVI naar PLCγ2 van belang is voor het trombusvormende proces, inclusief stolling 
en fibrinevorming onder arteriële en veneuze stromingscondities. 
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De interactie tussen plaatjesactivering en trombinegeneratie in arteriële en 
veneuze trombusvorming in vivo is onderzocht in hoofdstuk 6. In hetzelfde FeCl3 
trombosemodel bleek dat de trombusvorming op gang werd gebracht door vasculaire 
blootstelling van zowel collageen als weefselfactor. De trombusvorming in arteriën kon 
worden onderdrukt door plaatjesremming of door lage dosering van een 
trombineremmer. Echter in venen kon de trombusvorming alleen onderdrukt worden 
door een combinatie van beide remmers, of door een hoge dosis van de 
trombineremmer. De procoagulante respons van bloedplaatjes verdween na infusie van 
annexine A5, een eiwit dat bindt aan PS. Wanneer annexine A5 vooraf aan muizen 
toegediend werd, resulteerde dit in een complete remming van de trombusvorming in 
beide typen bloedvaten. Dat er inderdaad procoagulante bloedplaatjes aanwezig zijn in 
de arteriële en veneuze trombi werd bevestigd door deze in vivo aan te kleuren met 
fluorescerend annexine A5. Verrassend genoeg had verlaagde antistollingsactiviteit in 
muizen met een factor V Leiden-mutatie slechts een klein effect op het tromboseproces. 
Samen laten deze resultaten zien dat de versterking van trombinegeneratie door PS-
exposerende plaatjes van belang is voor het trombotische proces in venen en arteriën. 
Aangezien PS-afhankelijke trombinegeneratie het meest actief lijkt bij de veneuze 
trombusvorming, kan deze plaatjesreactie een doelwit zijn voor nieuwe antitrombotische 
therapie. 
Zoals eerder aangegeven hebben plaatjes een tweeledige rol in het proces van 
trombusvorming, namelijk door vorming van aggregaten en door stimulering van de 
bloedstolling. In hoofdstuk 7 onderzochten wij welke van deze twee functies plaatjes 
vertonen na activering onder in vitro of in vivo condities. Hoge resolutie tweefoton 
fluorescentie-microscopie liet zien dat tijdens de trombusvorming een groot aantal 
fibrinogeen-bindende plaatjes clusterde tot aggregaten, terwijl een andere groep van 
niet-aggregerende plaatjes PS exposeerde. Deze laatste plaatjespopulatie bleek in 
versterkte mate stollingsfactoren te binden, terwijl hun αIIbβ3 integrines in een niet-
actieve conformatie waren. Zogenaamde ‘coated’ plaatjes, die gekarakteriseerd zijn door 
een expressie van serotonine bindingsplaatsen, vormden geen aparte populatie. 
Interessant is dat de vorming van trombine (stolling) de inactivering van integrines 
bevorderde en ook zorgde voor een verhoogde transformatie van plaatjes tot losse, PS-
exposerende cellen. De secundaire inactivering van αIIbβ3 integrines kon herleid worden 
tot een verlengde fosforylering van tyrosines middels protein tyrosinekinasen. 
Samengevat resulteren deze resultaten in een nieuw, ruimtelijk model van 
trombusvorming, waarbij clusters van geaggregeerde plaatjes zorgen voor 
trombusstabiliteit, terwijl andere, niet-aggregerende plaatjes zorgen voor de 
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procoagulante activiteit en de vorming van trombine en fibrine. Verondersteld wordt dat 
de hemostatische activiteit van een zich ontwikkelende trombus een resultante is van de 
balans in vorming van proaggregerende en procoagulante plaatjes. Deze balans is 
waarschijnlijk van belang voor de werkzaamheid van antiplaatjes- en antistollings-
medicatie. 
Hoofdstuk 8 beschrijft het belang van de bevindingen van dit proefschrift in het 
licht van relevante, recente literatuur. Aangegeven is dat de GPVI route naar PLCγ2 
activering van groot belang is voor calcium-afhankelijke PS expositie en de 
procoagulante activiteit van plaatjes. Diverse signaleringseiwitten die samenklonteren in 
het LAT signalosoom zijn betrokken bij het ontstaan van deze procoagulante activiteit, 
inclusief de PI3Kα en β isovormen. De cruciale rol van het GPVI signaleringpad in het 
trombusvormende proces maakt de GPVI receptor tot een veelbelovend doeleiwit voor 
nieuwe antitrombotische middelen. Het is daarbij te verwachten dat anti-GPVI 
behandeling het meest effectief zal zijn bij de preventie van arteriële trombose (laag 
trombine) en minder effectief bij de veneuze trombose (hoog trombine). Immers een 
hoge trombinevorming zal het antitrombotische effect van een anti-GPVI behandeling 
ongedaan kunnen maken. De in dit proefschrift beschreven kennis zal hopelijk bijdragen 
tot de ontwikkeling van nieuwe behandelingsmethoden voor de nog zeer vele 
trombosepatiënten. 
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